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Dissolution testing is a tool towards prediction of dosage form behaviour under 
physiologically relevant conditions. The use of simple aqueous media dictated by the 
pharmacopoeias cannot predict the drug’s in vivo response as their physicochemical properties 
differ significantly from the complex environment of the gastrointestinal tract. To improve the 
predictive potential of drug dissolution, the development of more “biorelevant” media is 
essential. In particular, simulating drug dissolution in the gastric environment after 
administration of a meal still remains a challenge. Furthermore, except for the optimisation of 
the medium composition, the analysis of these usually complex heterogeneous media has also 
been challenging, due to the lack of a unified guideline for the selection of medium and 
analytical assay. The principal aim of the thesis was the development of a simple and robust 
analytical methodology, optimised on the basis of the drug’s physicochemical properties, 
interaction with excipients in a formulation and fat partitioning behaviour. The potential use of 
sample clean-up techniques including protein precipitation (PP) and solid phase extraction 
(SPE) was investigated. Optimised clean-up protocols were successfully used for extraction 
and quantification of drugs of a wide range of lipophilicity in milk-based fed biorelevant media. 
It was demonstrated that prior knowledge of the active ingredient’s physicochemical 
properties, such as log P, aqueous solubility, ionisation and protein binding can be used towards 
the selection of optimum extraction conditions. Moreover, the presence of certain excipients, 
when mixed with the APIs can significantly affect the methods’ efficiency and must therefore 
be taken into consideration during analytical method development. Interactions between active 
ingredients and lipid part of the fed gastric content were also investigated, via development of 
biphasic “drug partition to fat” in vitro setups. The rate of drug partition to fat was successfully 
predicted based on the drug’s physicochemical properties and in vivo food effect. Finally, a 
simpler medium, alternative to Fed State Simulated Gastric Fluid (FeSSGF) was developed, 
requiring a less laborious extraction protocol. Overall, this thesis has provided useful insight 
on the critical aspects of fed gastric medium and analytical methodology development. It 
provides a point of reference for future work on better understanding on drug solubilisation in 





Aims and Objectives 
The experimental work of the thesis is divided in three main parts. The first part will 
assess critical aspects in the analysis of APIs in biorelevant milk-based fed gastric media, in 
the presence and absence of excipients, with an intend to provide a unified guideline, applicable 
for wide range of drugs of different physicochemical properties. The second part will focus on 
the interactions between the model compounds and the lipid portion of the biorelevant media 
developed in vitro, and will try to correlate the partition and release to and from fat with drug 
food effect observed in vivo with and with drug’s physicochemical characteristics. Finally, the 
last part will propose an alternative medium of similar physicochemical properties with the 
widely used FeSSGF, as a first step towards the development of a gastric fed medium requiring 
less laborious sample clean-up techniques prior to drug analysis.  
The overall aim of the thesis is to design, develop and validate a universal analytical 
method for the quantification of drugs in fed state gastric media including sample clean-up, 
extraction and evaluation of drug distribution in the aqueous and lipid parts of the medium, 
when the gastric environment affects the drug’s behaviour. More specifically the objectives of 
each chapter of the current study are:  
For Chapter 1: The description of the information available on standard meals used in 
in vivo food effect studies and the biorelevant media developed in vitro for the simulation of 
the gastric fed state. The study aims to give an insight on their in vitro characterization and 
understanding of the parameters affecting the drug and formulation’s pharmacokinetic 
behaviour. The analytical techniques of the above media and the challenges in overcoming the 
time and complexity of such techniques are being discussed, setting the background and 
experimental challenges of the PhD project. 
For Chapter 2: The development of a roadmap, which will serve as a guide for the 
analysis of APIs in milk-based fed state gastric media. More specifically, the study aims to 
provide a guideline for sample cleanup of drugs of a wide range of lipophilicity (from 
extremely hydrophilic to extremely lipophilic) and evaluate use of drug physicochemical 
characteristics as critical selection variables.  
For Chapter 3: Evaluation of the effect of commonly used excipients in suitability of 
the sample treatment, as developed in the extraction of APIs in fed state media. The objective 




in drug-excipient mixtures and evaluate possible changes in the effect of drug physicochemical 
properties compared to the ones determined in Chapter 2, and integrate the modifications in 
the API extraction guideline. 
For Chapter 4: Assessment of the interactions developed between drug and lipid part 
of the fed medium. More specifically, the aim of this part of the study is to elucidate the rate 
of drug partition to the lipid portion of the gastric content in the fed state, and correlate this 
type of behaviour with drug’s physicochemical properties and/or food effect observed when 
administered with food in human in vivo studies. The study aims to develop a discriminating 
in vitro test able to determine the differences in partition rates to fat of drugs of different 
physicochemical characteristics which could potentially be used towards the prediction of drug 
food effect in vivo. 
For Chapter 5: Development and physicochemical characterization of a novel fed 
gastric medium, simulating FeSSGF, which would require a less laborious extraction 
technique. The aim of the study is to develop and fully characterize the medium and also mimic 
the main drug solubilisation mechanisms of FeSSGF in drugs of a range of lipophilicity. The 
long-term aim of the study is to set the bases towards the development of a simpler fed gastric 





Chapter 1: Fed-state gastric media and drug analysis techniques: 
Current status and points to consider 
Abstract 
Gastric fed state conditions can have a significant effect on drug dissolution and absorption. In 
vitro dissolution tests with simple aqueous media cannot usually predict drugs’ in vivo 
response, as several factors such as the meal content, the gastric emptying and possible 
interactions between food and drug formulations can affect drug’s pharmacokinetics. Good 
understanding of the effect of the in vivo fed gastric conditions on the drug is essential for the 
development of biorelevant dissolution media simulating the gastric environment after the 
administration of the standard high fat meal proposed by the FDA and the EMA in 
bioavailability/bioequivalence (BA/BE) studies. The analysis of drugs in fed state media can 
be quite challenging as most analytical protocols currently employed are time consuming and 
labour intensive. In this review, an overview of the in vivo gastric conditions and the 
biorelevant media used for their in vitro simulation are described. Furthermore, an analysis of 
the physicochemical properties of the drugs and the formulations related to food effect is given. 
In terms of drug analysis, the protocols currently used for the fed state media sample treatment 
and analysis and the analytical challenges and needs emerging for more efficient and time 
saving techniques for a broad spectrum of compounds are being discussed. 







In vitro dissolution studies are an integral part of quality control and drug development 
processes. During drug development, they are used as a tool for the selection of the appropriate 
excipients and the most suitable formulation type [1] and also as an in vitro surrogate for in 
vivo performance [2]. In quality control, they are used to ensure the batch-to-batch consistency 
[3–5]. Dissolution tests, as dictated by the Pharmacopoeias, cannot always provide information 
about the in vivo behaviour of the drugs, even though there are cases in which these tests can 
provide good in vitro–in vivo correlations (IVIVC). The dissolution media described in 
Pharmacopoeia monographs are mainly used for quality control purposes, and are not often 
able to predict the in vivo behaviour of poorly soluble drugs for which the fat content and the 
bile salt concentration in the gastrointestinal environment will affect their solubility and 
dissolution rate [6, 7]. Due to the limited ability of the simple aqueous media suggested by the 
Pharmacopoeias to simulate the characteristics of the gastrointestinal (GI) tract, the need for 
media simulating the GI physiological environment in the fasted and fed states (usually called 
biorelevant media) arose; in these media the physicochemical properties of the GI contents 
(pH, osmolality, surface tension, buffer capacity) are taken into account and physiological 
components such as bile salts and lecithin are incorporated [2]. Use of biorelevant media during 
the drug development process enables the assessment of drug’s biopharmaceutic characteristics 
and the prediction of in vivo performance [2, 8]. 
While the fasted state gastric environment has been well studied, the more complex 
conditions of the fed state stomach have made the prediction of food effect a challenging task. 
For further information on the gastric fasted gastric state properties, the reader may refer to 
Vertzoni et al. [4]. In summary, pH values of approximately 1.5-1.9, pepsin output of a 
maximum value of 0.8 mg/mL and gastric lipase concentration of 0.1 mg/mL have been 
reported. Average values of bile salts have been found at a range of 80 to 275 µΜ, while 28-
51 mN/m and 200 mOsm/kg values have been reported for surface tension and osmolality 
respectively. Several in vitro biorelevant gastric media have been used for the simulation of 
the gastric fed state environment and as far as the sample treatment is concerned, there is no 
specific protocol available and sample treatment and drug analysis are developed on a case by 
case basis. A good understanding of the in vivo conditions of the fed state stomach could lead 
towards the development of a suitable medium being able to simulate the gastric content and 
ideally overcoming the extensive treatment before the analysis that is needed with the current 




role of the fat content in the solubilisation of drugs, the gastric emptying rate and the interaction 
with certain formulations [11] as well as the binding of drugs with metal ions and meal 
components are some of the parameters which have rendered the in vitro prediction of food 
effect extremely complicated. 
In the current review, initially we describe the available information for the 
characterisation of the in vivo gastric fed state conditions after the administration of standard 
meals with an aim to provide an understanding of the effect of drug’s physicochemical 
parameters on its in vivo behaviour. Then, the standard meals and the gastric biorelevant media 
currently being used and their interaction with drugs of different physicochemical properties 
are presented. In the last part, the analytical techniques used in vitro for sample treatment and 
quantification of the drug along with their challenges are discussed. 
1.2. In vivo gastric conditions in the fed state 
Gastric conditions in fasted state have been characterised in terms of pH, osmolality, 
surface tension, buffer capacity and protein content [12–14]. In the fed state, the determination 
of absolute values is more complicated than in the fasted state. The food type is an additional 
factor on top of other parameters responsible for the interindividual variation of the above 
properties such as the individual’s age [15] and administered medication [16]. The role of 
several physicochemical parameters of the contents of the fed state stomach on drug’s 
dissolution and absorption is reviewed. 
1.2.1. Gastric secretions in the fed state 
The main components of the gastric juice are hydrochloric acid (HCl), pepsinogens, 
mucus and water; pepsinogen is the inactive form of pepsin, activated by the presence of HCl 
[17]. Pepsin content is higher in the fed state stomach than in the fasted state (fasted state values 
= 0.11-0.22 mg/mL). Samples of gastric antrum content of twenty healthy volunteers after 
administration of Ensure Plus®, demonstrated pepsin values within a range from 0.26 to 0.58 
mg/mL in a time period from 30 to 210 min after administration of the liquid meal [13]. Gastric 
lipase is also present in the stomach. It is the enzyme responsible for the digestion of fat in the 
upper gastrointestinal tract. Its role involves the hydrolysis of exogenously administered 
triglycerides to di-glycerides and fatty acids [18]. Gastric lipase has been reported to account 
from 10 to 30% of the total hydrolysis of triglycerides contained in a meal [19, 20] with the 




of a liquid meal was 22.6 ± 8.1 mg (concentration 16.7 ± 0.7 µg/mL) after administration of a 
liquid meal in human subjects [19]. 
1.2.2.  Bile salts in gastric contents in the fed state 
Bile salts can increase the dissolution of poorly soluble drugs by decreasing the energy 
barrier between the drug and the medium, by increasing the active surface area, or via micellar 
solubilisation [22]. Bile salt concentration in the stomach is much smaller than in the small 
intestine, where the bile salts are released by the gall bladder, with their concentration in the 
intestinal environment in the fasted state demonstrating an approximate four-fold decreased 
value in comparison with the fed state (1-4 mM and 10-20 mM, respectively) [23, 24]. In the 
gastric fed state, (after administration of 500 mL Ensure Plus®) only traces of bile salts have 
been reported (60 µM) [13]. Similar bile salt concentration (51 µM) was measured in the fed 
state stomach of healthy subjects after a standard lunch (13.5 g protein, 18 g corn oil, and 53 g 
carbohydrate in 300 mL water) [25]. 
1.2.3. Proteins, lipids and carbohydrates in gastric contents in the fed state 
The protein, lipid and carbohydrate content in the fed state stomach is dependent on the 
type of meal consumed before the administration of the drug; therefore, their concentration is 
highly variable and cannot be expressed solely by the results of a single study. Indicatively, the 
concentrations of proteins and carbohydrates after administration of 500 mL Ensure Plus® to 
healthy subjects were found to be 23.3 mg/mL and 152.1 mg/mL at 30 min respectively, 
decreasing to 11.2 mg/mL and 49.1 mg/mL at 210 min after the liquid meal’s administration 
[13]. 
1.2.4. pH of gastric contents in the fed state 
The pH affects dissolution and absorption of both actively and passively absorbed 
drugs. The non-ionised fraction of the drug is more efficiently absorbed during passive 
absorption, while the affinity of the drug carrier for the ionised or non-ionised fraction defines 
the rate of active absorption [26, 27]. The pH of the stomach in the fed state is significantly 
higher than in fasted state (pH ≈ 1.7) [13, 28] with a wide range of values between 3 and 7 [1]. 
The pH increases up to approximately a value of 6.5 after a meal and decreases exponentially 
reaching a value of 2-2.7, similar to the pH value measured in the fasted state after 3-4 h. In 
case of patients suffering from hypochlorhydria/achlorhydria due to pathological conditions 




antagonists or Proton-Pump Inhibitors), initial fasted pH values are elevated compared to the 
values mentioned above, reducing the dissolution rate of basic drugs [29, 30]. Thirty minutes 
after administration of 500 mL of a nutrient drink (Ensure Plus®), Kalantzi et al. reported a pH 
value of 6.4 in the gastric aspirates of twenty human subjects (Figure 1.1) and a decrease in the 
gastric pH to a value close to the fasted state three and a half hours after the liquid meal’s 
administration [13]. The gradual decrease in gastric pH values is attributed to the induction of 
secretion of gastric acid after the administration of a meal and to the meal’s buffering properties 
[22]. Another in vivo study [21] showed that after administration of a liquid standard meal 
containing 65% fat, 29.5% carbohydrate and 5% protein, the pH reaches a maximum of 4. A 
study by Yamaguchi et al. [31], which monitored the gastric pH of human subjects using a 
Bravo® pH monitoring system, with the aid of a capsule placed on the gastric wall, confirmed 
also the immediate burst and gradual decrease to the fasted state level pH, with it returning to 
its initial value 2 h after the administration of a meal. The subjects of the above study were 
monitored for 48 h and did not follow any restriction in their dietary routine. The absolute 
values of these two studies cannot be compared though, as the subjects of the latter did not 
follow a specific diet. The time needed for the gastric pH levels to return to the initial values 
and the pH “peak” value of the fed state are dependent upon the type of standard meal 
administered during each in vivo study, the age of the subject and the experimental protocol 
followed [32]. For instance, the pH decreases to the fasted state value faster after the 
administration of a liquid meal than after a solid meal. Gastric pH mostly affects the dissolution 
of drugs with a pKa value close to the physiological pH values, as when ionised behave as 
week electrolytes with their solubility being increased in comparison with their un-ionised form 
[27]. Therefore, changes in gastric pH mostly affect weak acids and weak bases with the 
increased values in the fed state enhancing the dissolution of acids and reducing the dissolution 
of bases. Gastric pH can also affect drug release. Coatings with pH-dependent disintegration 
properties, such as enteric coatings which dissolve rapidly in pH values of 4.5–8 [21] may 





Figure 1.1. Mean pH values from aspirates of patients after administration of 500 mL Ensure 
Plus® containing 10 mg/mL PEG 4000. Data extracted from [13]. 
1.2.5. Osmolality of gastric contents in the fed state 
Osmolality can affect drug’s dissolution rate by inducing changes in the swelling 
behaviour of the formulation. Osmolality is linked with water penetration in the formulation; 
when the difference in osmotic pressure between the inner and outer (GI environment) part of 
the formulation decreases, water penetration decreases as well, affecting negatively drug 
release [33]. The gastric fluids in the fed state are slightly hyperosmotic 30 min after 
administration of Ensure Plus® (559 mOsm kg−1), and their osmolality is decreased to 217 
mOsm kg−1 3.5 h after the administration [13], revealing that the osmolality of the gastric 
contents returns to the fasted state value during this time period (191 ± 36 mOsm kg−1 based 
on measurements of 24 healthy subjects) [12]. 
1.2.6. Surface tension of gastric contents in the fed state 
The surface tension of the fed gastric fluids is lower than the one of an aqueous solution 
due to the presence of surface tension lowering compounds, such as bile salts entering the 
stomach through duodenal reflux and acting as surfactants, pepsin and food components [34]. 
Pepsin is an enzyme produced in the mucosal lining of the stomach and acts as a digestive 
protein in the gastric environment. Since the lowest surface tension values acquired after the 
addition of biorelevant concentrations (0.003–0.195 mg/mL) of the enzyme (fasted state) in an 
acidic solution (pH 1.6, HCl solution with 2 g/L NaCl) were 57 mN/m, it can be assumed that 
other surfactants are present as well in both fasted and fed state gastric fluids, as their surface 
tension value was significantly lower with a value of about 30–31 mN/m in the fed state and 




1.2.7.  Buffer capacity of gastric contents in the fed state 
The buffer capacity of the medium can have a great effect on drug’s dissolution in 
combination with its pH, as change in pH can affect the ionisation percentage and consequently 
the solubility of ionisable drugs and excipients. In the fasted state, bicarbonate is the buffer 
mainly present in the stomach [37]. In the fed state, the buffer capacity is dependent mainly on 
the meal contents than on the stomach’s mucosa, making this chemical property highly meal-
dependent [37]. Buffer capacity at gastric fed state conditions after administration of Ensure 
Plus® is around 14–28 mmol/L·DpH based on in vivo measurements [13]. Table 1.1 
summarises the physicochemical properties of the contents of the gastric fed state environment, 





Table 1.1. Physicochemical properties of the contents of the fed state stomach based on in 
vivo measurements. 
pH 
Value Technique employed Meal Sample Reference 
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1.3. Drug properties that relate to potential food effect 
Food effects can be induced via the direct interaction of drugs, due to their unique 
physicochemical properties, with food components [38]. Such interactions include formation 
of insoluble complexes (i.e. tetracyclines and calcium ions) [39], binding to proteins (i.e. 
phenytoin) [40], or interaction/exchange of drugs with anionic or cationic sites of dietary fibres 
(i.e. metformin) [41]. In this section the drug properties that can affect drug dissolution and 
absorption leading to a potential food effect are described. 
1.3.1. Ionisation (pKa) 
The pKa determines the percentage of a drug’s charged/uncharged form under certain 
pH conditions and affects the solubility of drugs at differing media pH. Solubility and 
dissolution of weekly acidic drugs are low at the pH of the fasted stomach as they are mostly 
in their unionised form. At fed state conditions, where the pH is higher, their gastric solubility 
and dissolution increase with a subsequent effect on their pharmacokinetics [6]. The uncharged 
state of the drug has a positive effect on membrane permeability, as the fraction of the unionised 
form of a drug is proportional to its lipophilicity [42]. As far as weekly basic drugs are 
concerned, their gastric solubility and dissolution are lower due to the higher pH of the stomach 
in the fed state in comparison with the fasted state. For compounds that are non-ionisable in 
the gastric environment a gastric fed state dissolution test is essential [6], as the type of meal 
consumed affects the surface tension of the gastric contents and thus, the active surface area 
that is available for drug solubility and dissolution [43]. 
1.3.2. Lipophilicity (log P, log D) 
Partition coefficient, log P, is indicative of the lipophilicity of a compound and 
determines the partition of a compound in a system of n-octanol/water. For an ionisable 
molecule the apparent partition coefficient (log D) is the value which expresses the partition in 
the aqueous and organic phase in a more accurate way as it takes into consideration its 
ionised/unionised percentage and therefore log D values vary according to the pH of the 
environment. Log P values are related to drug’s affinity for biological membranes and target 
sites affecting its biological activity [42]. Ideally, the drug should have such a hydrophilic-
lipophilic balance so that it can be dissolved in the biological fluids, where the site of absorption 
is, and also be able to permeate the membranes of the site of action. Drug’s lipophilicity is 




dissolution of lipophilic drugs in the fed stomach are performed through their partitioning in 
the lipid fraction of the meal during its breaking into particles throughout digestion before 
reaching the small intestine [6]. 
1.3.3. Solubility 
Solubility is a key drug property for its potential oral absorption. Due to the prolonged 
residence of the drug in the gastric environment during the fed state, the solubility in the gastric 
contents will affect drug’s dissolution and subsequent absorption. The wetting and 
solubilisation of drugs co-administered with food can be increased by the digestion products 
of lipolysis products in the gastrointestinal tract (Figure 1.2) [22]. The gastric compartment is 
the part of the gastrointestinal tract where the dietary lipids are emulsified at first place. 
Facilitated by gastric lipase, gastric agitation and emptying, protein and polysaccharide 
contents along with lypolytic triglyceride products stabilize the interface between lipid and 
aqueous phase [18]. Therefore, the presence of gastric lipase in the fed stomach is important 
when biorelevance needs to be achieved for in vitro assays. Aqueous media usually give an 
underestimation of the drugs’ solubility in the gastric environment. An underestimation of 
solubility was also observed for undigested milk, suggesting that apart from having the same 
pH, buffer capacity, protein content and osmolality, the presence of enzymes should be 
considered for a good prediction of drug’s solubility in the gastric environment [44]. If not 
adequately soluble in the gastrointestinal fluids, drugs orally administered can have a solubility 
limited dissolution and nonlinear dose responses due to inadequate drug in solution in the site 







Figure 1.2. Schematic representation demonstrating the lipid digestion, formation of micelles 
and drug absorption in the small intestine after administration of a meal; processes taking place 
in the stomach in the highlighted rectangle. Modified from [22]. 
1.3.4. Biopharmaceutics Classification System (BCS) and food effect 
Amidon and co-workers [45] defined drug aqueous solubility and permeability as 
determining parameters which control a drug’s systemic in vivo absorption and introduced the 
Biopharmaceutics Classification System (BCS) which categorises the drugs in four classes 
according to their aqueous solubility and permeability: 
BCS I compounds: high solubility-high permeability 
BCS II compounds: low solubility-high permeability 
BCS III compounds: high solubility-low permeability 
BCS IV compounds: low solubility-low permeability 
Fleischer et al. [46] proposed a food effect predictive model for the drugs’ absorption 
according to their drugs’ BCS class (delayed/no effect for BCS class I, increased with fat 
content for BCS class II, decreased for BCS class III, low and non-predictable for fed/fasted 
states for BCS class IV); this model is only a general guideline as many drugs do not follow 




BCS classes have a wide range of properties and consequently different rate limiting steps for 
drug absorption. For example, a low solubility compound with absorption just under 90% is 
classified as a class IV compound, but it is unlikely that its permeability would be the rate 
limiting step for its absorption [47]. Based on the BCS classification, Wu and Bennet [48], 
correlated the interactions of the different BCS class drugs with intestinal efflux and influx 
transporters. It was suggested that for BCS class II compounds, the relative magnitude of the 
inhibition between efflux and influx transporters with additional solubilisation in the intestinal 
environment and gastric emptying are the two parameters affecting the drugs’ absorption, with 
the latter process being the determinant one. Inhibition of uptake transporters was suggested as 
a possible reason for negative food effect for most BCS class III compounds, while BCS class 
IV compounds combine all the above mechanisms for BCS classes II and III drugs (Table 1.2) 





Table 1.2. Biopharmaceutics classification system, predictability of food effect and transporter 













Transporter effect by 







Minimal No effect 








Efflux transporters inhibition, 
intestinal drug solubilisation 
(drug passively absorbed) 
Inhibition of both absorptive 
and efflux transporters. Food 
effect according to relative 
inhibition (drugs actively 
absorbed) 








Inhibition of absorptive 
transporters in the intestine 
IV -/- 












All effects mentioned above 






1.4. Standard meals used in BA/BE studies 
Homogenised standard meals have been used as an attempt to simulate gastric fed state 
conditions. In order to determine the effect of food on drug absorption, both the Food and Drug 
Administration (FDA) and the European Medicines Agency (EMA) recommend the use of a 
high-fat meal for the determination of drug’s pharmacokinetic parameters in the fed state as 
the worst-case scenario [50]. Meals that are of a high caloric and fat content are recommended 
in BA/BE studies as these are more likely to affect gastric physiology and have a more 
pronounced effect on drugs [51]. As a high-fat and high-calorie meal FDA suggests a meal of 
800–1000 caloric content with ∼	50% of the calories deriving from its fat content with 150, 
250 and 500–600 kcal being obtained by protein, carbohydrate and fat, respectively [51]. An 
example of a typical high fat standard breakfast as proposed by the FDA used in a 
bioequivalence study for Cicloral® and Neoral® (100 mg cyclosporine A formulations) [52] is 
as follows: “2 eggs fried in butter, 2 strips of fat bacon, 120 g hash brown potatoes, 250 mL 
whole milk, and 1 croissant”. For food effect studies, EMA suggests a similar standardised 
high fat meal (800–1000 kcal caloric content, 500–600 and 250 of which derive from fat and 
carbohydrates, respectively) and a moderate meal of ∼	400–500 kcal with ∼	150 kcal deriving 
from fat [50]. As far as the dosage strength to be tested in fed state studies is concerned, FDA 
recommends the testing of the highest dose to be marketed and lower doses if the testing of the 
former is not possible for safety reasons [51]. According to EMA, the highest and lowest doses 
in the drug therapeutic range have to be tested when the drug follows nonlinear 
pharmacokinetics [50]. 
Apart from the meals described previously, other types of meals can also be used in the 
investigation of the effect of food in drug’s pharmacokinetics in cases of a specific food effect 
mechanism. For example, a high-protein meal (80 g protein, 52 g carbohydrate, 9 g fat) was 
used in the investigation of the pharmacokinetics of gabapentin, an anticonvulsant, whose 
transport through the biological membranes is controlled by System-L, the l-amino acid 
transport system [53]. Klein et al. [43] characterised two standard meals (GSK high fat-(62%) 
standard meal and FDA intermediate fat (37%) standard meal), constituted by homogenised 
eggs, bacon, butter, milk and other ingredients indicative of a median diet (Table 1.3). The 
purpose of the study was the comparison of their physicochemical properties with those of the 
meals, such as milk and nutrient drinks currently being used for the simulation of fed-state 




Table 1.3. Examples of meals used for the determination of drug-food interactions in vivo. 




standard meal  
2 slices of toasted white bread 
with butter, 2 eggs fried in 
butter, 2 slices of bacon, 2 oz of 
hash browned (fried shredded) 
potatoes, 8 oz of whole milk 
67 g (603 kcal, 
62% of total 
calories) 
33 g (132 kcal, 
14% of total 
calories) 
58 g (232 kcal, 





2 eggs fried in butter, 2 strips of 
bacon, 2 slices of toast with 
butter, 4 oz of hash brown 
potatoes, 8 oz of whole milk 
(800–1000 kcal) 
500–600 kcal 150 kcal 250 kcal [51] 
FDA intermediate-
fat standard meal 
1 English muffin with butter, 1 
fried egg, 1 slice of cheese, 1 
slice Canadian bacon, 1 serving 
of hash browned (fried 
shredded potatoes), 6 oz of 
orange juice, 8 oz of whole 
milk 
27 g, 
(240 kcal, 37% 
of total 
calories) 
29 g (116 kcal, 
18% of total 
calories) 
73 g (292 kcal, 





Not specified (+100 mL of 
black coffee) 
26 g 28 g 51 g [121] 
Standardised high-
carbohydrate meal 
Not specified (1000 kcal) Not specified Not specified 600 kcal [122] 
Low-fat meal 1 slice of white spread bread 
with jelly, 6 oz of orange juice, 
8 oz of skim milk (250 kcal) 

















Fat: 31% w/w long chain 
triglycerides Proteins: whey, 





36% of total 
calories 
16% of total 
calories 





Fat: 80% w/w medium chain 
triglycerides (C6-C12) Proteins: 





36% of total 
calories 
16% of total 
calories 
48% of total 
calories 
[123] 
High-protein meal 2% low fat milk, Carnation 
Instant Breakfast® and Pro 
Pac® Plus (protein supplement) 
9 g 80 g 52 g [53] 
High-protein meal Not specified (439.5 kcal) 17.1 g 30.5 g 43.5 g [124] 




1.5. In vitro simulation of gastric conditions in the fed state (biorelevant 
dissolution media) 
Even though actual homogenised meals are able to simulate gastric state conditions the 
best, problems in the analysis of the drugs led to the development of alternative approaches 
[37, 54]. A range of dissolution media have been developed in order to simulate the in vivo 
conditions of the fed state stomach (Table 1.4). These media were developed with the aim of 
having the same physicochemical properties with the standard meal recommended by FDA for 




Table 1.4. Physicochemical properties of gastric fed state biorelevant media used in vitro. 
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a 25 °C. 
b 37 °C. 
c Calories derived from fat.
Nutrison®    5.4  420   [5] 
FSGES    5     [125] 
Intralipid® 




1.5.1. Milk-based media 
1.5.1.1. Milk 
Milk started being used as a dissolution medium for gastric fed state simulation about 
twenty years ago. Macheras et al. successfully used low fat milk (0.75% fat) with a flow 
injection serial dynamic dialysis technique (FISDD) as a food simulation medium for drug 
dissolution, for four drugs of different physicochemical properties: salicylamide, 
acetaminophen, propantheline and nitrofurantoin. Milk was selected as a dissolution medium 
in this study due to its potential as substrate of the gastric fed conditions and also due to its use 
as a vehicle in drug delivery systems [55]. Furthermore, its energy content is similar to that of 
a standard meal administered to the subjects participating in bioavailability/bioequivalence 
studies [56]. Despite its similarities with the gastric environment in the fed state, the use of 
milk does not always simulate the gastric fed state ideally. The issues of the use of milk as a 
dissolution medium relate to its lower values in osmolality (285 ± 2.7 mOsm kg−1) and buffer 
capacity (13.9 ± 0.2 mEq pH−1 L−1) at 37 °C compared to the standard high-fat breakfast 
proposed by the FDA (771 ± 10 mOsm kg−1 and 30.1 ± 1.8 pH−1 L−1, respectively) [43]. Other 
issues relate to its higher pH value (pH ≈ 6.5) than the equivalent pH of gastric media after a 
meal (5.8 ± 0.2 after 50% of gastric emptying after liquid meal administration) [57], and the 
possible need of supplementary enzyme addition due to the digestion of milk’s lipids and 
proteins taking place in vivo [6]. 
In 1998, Galia et al. [58], assessed the suitability of full fat milk as a biorelevant gastric 
fed state medium for the evaluation of the dissolution behaviour of one BCS class I drug 
(acetaminophen) and two BCS class II drugs (danazol and mefenamic acid). The results of this 
study demonstrated that for BCS class I drugs there is a strong dependence between the 
absorption and the type of formulation, with the interaction between the fed matrix and 
excipients controlling the absorption rate. Milk’s high content in lipids enhances the solubility 
and dissolution of lipophilic drugs; for instance, release of danazol, a BCS class II drug, in 
milk, was substantially higher than in water. Furthermore, the pH of milk (pH ≈ 6.5) favours 
the dissolution of weak acids, such as mefenamic acid [58]. Diakidou and co-workers showed 
that despite milk’s similarity in pH and protein contents with human aspirates after 
administration of a liquid meal, the solubility values of two BCS class II weak bases 




and 3.6 times lower in milk (after the addition of pepsin and lipase from Rhizopus niveus) than 
in the gastric fed-state aspirates, respectively [44]. 
1.5.1.2. Digested milk 
After administration of a meal in vivo, digestion takes place. In vitro digestion milk 
models have been used for simulation of the in vivo digestion of gastric contents. These in vitro 
milk based models, take into consideration the role, amount and activity of the physiologically 
existing gastric enzymes in the fed state. 
In a milk based medium, HCl, lipase and pepsin have been added [44, 59, 60]. Two models 
using bovine milk were considered for the simulation of gastric environment. In the first model 
the dissolution of l-sulpiride, a hydrophilic weak base was studied in milk digested with pepsin 
and HCl [60], with 4.4 mg of pepsin from hog stomach dissolved in HCl being added every 15 
min for a 90-min time period. The dissolution assay was performed in USP Apparatus 2 (100 
rpm, 500 mL volume). The second model used milk digested with pepsin/HCl/lipase from 
Rhizopus niveus aiming to simulate the fed gastric environment after food intake [44, 59]. In 
solubility studies of two lipophilic bases, dipyridamole and ketoconazole, it was shown that 
milk digested with the HCl solution of pepsin gave a good prediction of the ketoconazole’s 
solubility in human gastric aspirates after administration of 500 mL of Ensure Plus® while a 
solubility overestimation was observed for dipyridamole. When milk digested with 
pepsin/HCl/lipase was used the prediction of the drug’s solubility in the gastric aspirates was 
dependent on the time that the in vivo sample was collected [44]. The biorelevance of the 
addition of lipase in the milk in terms of pH and protein content was shown in a release study 
of felodipine from an extended release matrix. Gastric pH decreased slower and protein content 
faster than an identical medium in the absence of lipase, giving pH and protein content values 
closer to the ones observed in vivo [13]. 
1.5.1.3. Fed State Simulated Gastric Fluid (FeSSGF) 
As an effort to improve the biorelevance of milk as dissolution medium and simulate 
the postprandial conditions of the gastric tube, a medium called Fed State Simulated Gastric 
Fluid (FeSSGF) was developed. This medium was developed by Jantratid and his co-workers 
[37] and is comprised of 3.5% fat milk diluted with acetate buffer. In order to mimic the three 
phases of gastric digestion with the pH value being 6.4, 5.0 and 3.0 for the early, middle and 
late phases, respectively, a FeSSGF for each phase was prepared (Table 1.4) [37]. The pH was 




medium reflects in a satisfactory manner the sum of the physiological gastric conditions during 
meal ingestion. Accepting this compromise, FeSSGF could potentially be used as a universal 
medium potential for fed-state gastric dissolution [37]. It should be noted though that this 
medium does not contain any enzymes, so the presence of the gastric pepsin and lipase is not 
taken into account. As milk in the absence of enzymes can only simulate the gastric fed state 
condition in its early phase [8], the use of the three “snapshot” media can simulate the 
intraluminal changes in pH, osmolality and protein contents accurately. 
1.5.2. Nutrient drinks/emulsions 
The use of various nutrient drinks and emulsions for parenteral administration has been 
employed to studies as an attempt to mimic the gastric stomach conditions in the fed-state, as 
they have similar composition (Table 1.5) to the standardised meals used in drug food effect 
studies [6]. 
Table 1.5. Composition of nutrient drinks/parenteral emulsions used as fed state gastric media 
in vitro. 
Nutrient drink Composition (per Litre)a 
Scandishake® Mix 598 kcal, 30.4 g fat, 11.7 g protein, 69.5 g carbohydrateb 
Ensure® 930 kcal, 25 g fat, 38 g protein, 135 g carbohydrate 
Ensure Plus® 1500 kcal, 46 g fat, 55 g protein, 210 g carbohydrate 
Nutrison® 1000 kcal, 39 g fat, 40 g protein, 123 g carbohydrate 
Intralipid® 30 3000 kcal, 300 g fat 
a According to the manufacturer [63] (Ensure® and Ensure Plus® vanilla flavour). 
b 85 g powder in 240 mL whole milk. 
 
Scandishake® Mix is a nutrient drink used for the simulation of gastric environment in 
the fed state. It was used in the form of powder mixed with whole milk with simulated gastric 
secretions containing lipase and pepsin in a dynamic in vitro system (TNO TIM-1), simulating 
the stomach and small and large intestines’ environment. Scandishake® Mix was used for the 
simulation of a high-fat meal in the development of a dissolution model for fosamprenavir 
(prodrug of the antiretroviral amprenavir) [61]. Food-induced disintegration of 
fosamprenavir’s tablets was assessed using Magnetic Resonance Imaging (MRI). The stomach 
compartment in the dynamic system was comprised of two units separated by a silicon wall 
with the surface between the outer and inner tubes being thermostated (37 °C). The simulated 




“contractions” and “relaxations” per minute. Simulated gastric lipase and pepsin were pumped 
to the compartment at a flow of 0.5 mL/min. The nutrient drink, compared with simulated 
gastric fluid (SGF) which was used for the gastric fasted state simulation, predicted the 
formulations’ postprandial delay in disintegration observed in vivo. This effect on the tablet’s 
disintegration can be attributed to the competition of the nutrient drink with the water 
molecules for the interaction with the matrix and the formation of a layer of increased viscosity 
around the tablet [61]. 
The nutrient drinks Ensure® [62] and Ensure Plus® [13] have been used in several 
studies as biorelevant fed–state gastric media. According to the manufacturer [63], both 
emulsions contain water, corn maltodextrin, sugar, milk protein concentrate, canola oil and 
corn oil (Ensure Plus®) or soy oil and sucromalt (Ensure®). Intralipid®, an emulsion of similar 
fat content with Ensure® and Ensure Plus®, has also been used for the simulation of gastric fed 
state conditions after the administration of a high-fat breakfast [10]. Ensure® contains fat 
(3.7%), protein (3.7%) and carbohydrate (14.5%), while Intralipid® is available in 10, 20 and 
30% fat concentrations (soya oil), with the emulsion also containing egg lecithin protein (12 
g/1000 mL) and glycerol (22, 22 and 16.7 g/1000 mL for 10, 20 and 30% fat, respectively). 
Ensure® and Intralipid® 10% were used at a 1:6 dilution with universal buffer (pH 2.5 and 5.6) 
in dissolution (USP Apparatus 2, 100 rpm) and microcalorimetry studies of aminophylline 
controlled release tablets comprised of an aliphatic alcohol and hydroxyalkylcellulose [64]. 
Each dissolution profile was the expression of two distinct processes: dissolution of the alcohol 
and diffusion of the drug through the cellulose derivative. The profile was comprised of two 
first order rates separated by a mixed rate. The composition of the biorelevant medium mainly 
affected the rate of the initial first-order process and also the onset time of the second apparent 
first order, indicating that differences in the medium can affect the drug release mechanism. 
The similarities of the physicochemical properties (pH, osmolality, buffer, capacity, 
viscosity and surface tension) between standard meals used in in vivo studies and gastric fed 
state media used in vitro have been assessed [43]. Ensure Plus® demonstrated better 
resemblance to the gastric conditions after the administration of a homogenised standard 
breakfast than milk and Ensure® but had significantly different viscosity, an issue resolved after 
addition of 0.45% w/v pectin, a water soluble polysaccharide. In vitro dissolution studies 
performed with Ensure® (USP Apparatus 2) [62] and Ensure Plus® [64] (USP Apparatus 3) 
demonstrated that dissolution behaviour is greatly affected by interaction between medium 




to a formation of a hydrophobic layer around the formulation (HPMC matrix) decreasing water 
ingress in the tablet [64], or by granting a more effective hydration of a matrix component [62]. 
Another nutrient drink, Nutrison®, was used for the simulation of gastric fed state 
conditions in dissolution studies (USP Apparatus 2, 100 rpm) for the study of possible food-
drug interactions between food components and metoprolol tartrate IR tablets [5]. The nutrient 
drink contains 6 g/100 mL protein, 6 g/100 mL vegetable oil fat, 18 g/100 mL carbohydrate, 
vitamins and minerals. For its use as a biorelevant medium it was diluted to 60% with a solution 
containing HCl, NaCl, KCl and sucrose, giving values of pH (pH = 5.4) and osmolality (420 
mOsm kg−1) similar to the in vivo fed state conditions. A potential excipient dependent 
mechanism of delay in tablet disintegration was indicated through the formation of a protein 
film from the medium’s components around the tablets (visual observation) attributed to 
electrostatic or hydrophobic interactions between the proteins and the excipient confirmed by 
scanning electron microscopy (SEM). The dependence of the formation of this layer on certain 
tablet excipients was confirmed by preparation of single excipient-medium mixtures and 
observation of a precipitation layer in the vessel for each mixture. The effect of meal type was 
further evaluated by comparing tablet disintegration times in media containing a single 
(protein, fat or carbohydrate) or mixtures of the mentioned components present in the fed state 
medium. The presence of proteins increased the tablet disintegration time the most, with a more 
profound effect when proteins were combined with fat, carbohydrates or both. 
Even though the composition of nutrient drinks such as Ensure Plus® is more similar to 
the high-fat meals administered in BA/BE studies, milk based media can simulate the fed 
gastric content taking the presence of secretions into consideration [65]. Moreover, with the 
two approaches mentioned before (gradual digestion and “snapshot” media), the changes in the 
fed gastric environment during time can be more closely simulated. 
Another version of the FeSSGF “snapshot” media has been recently proposed replacing 
milk with Lipofundin® MCT 20 [66], an emulsion containing medium chain triglycerides, 
which administered parenterally to patients, provides essential fatty acids. The emulsion:buffer 
ratios were different to those of the milk based FeSSGF “snapshot” media (17.5, 8.75 and 
4.375% v/v content for early, middle and late media, respectively compared to 100, 50 and 
25% for the milk-based media). Lipofundin® does not contain any proteins, which facilitates 




1.6. Drug and formulation-related food effect 
Under fed state conditions, tablet disintegration is generally delayed. For example, as 
mentioned previously, a nutritional drink used both in in vivo (canine) and in in vitro studies 
delayed disintegration and dissolution of metoprolol tartrate tablets by creating the formation 
of a food-induced thin layer around the tablet which did prevent not only the water penetration 
in the tablet but also the drug particles from leaving the matrix [5]. 
Food can have a significant effect on the absorption of drugs. This can be affected by 
differences in the interaction of the active pharmaceutical ingredient and/or the formulation 
with the fasted and fed state environments. Examples of two drugs (itraconazole and 
nifedipine) demonstrating drug-related and formulation-related gastric food effect, 
respectively, are discussed below. 
Itraconazole, an antifungal agent, is a well-studied drug in terms of its food effect. The 
positive effect of food on itraconazole’s absorption has been verified by both in vivo and in 
vitro studies. An in vivo study on itraconazole capsules (2 × 100 mg capsules administered) 
containing sugar coated pellets in healthy subjects was performed with the use of the FDA 
standard breakfast for the determination of the drug’s food effect [68]. The study showed a 
significant increase for both Cmax and AUC0→∞ values [(Cmax(fasted) = 0.59 Cmax(fed), AUC0→∞ 
(fasted) = 0.61 AUC0→∞ (fed)] (Figure 1.3) with the increase in the drug’s absorption being 
attributed to the drug’s increased solubility in the food components. A similar study by 
Zimmermann et al. [69] (one 100 mg capsule administered with a standard breakfast) 
demonstrated similar results, with the relative bioavailability in the fasted state being 0.54 times 
the one observed after meal administration. The differences were attributed to the high fat 
content of the meal and also to the longer gastric retention time in the fed state. 
	
Figure 1.3. Pharmacokinetic parameters after administration of two 100 mg itraconazole 
capsules under fasted and fed (standard breakfast) state conditions. ∗ denotes a statistically 




In vitro studies were in agreement with the fact that the drug’s bioavailability could be 
significantly affected by food [70]. An in vitro study used milk of different fat concentrations 
mixed with simulated gastric fluid (SGF) (pH adjusted to 3) as fed state biorelevant dissolution 
media and demonstrated that except for fat, other food components may be responsible for the 
food effect observed with itraconazole in vitro. Despite a pronounced difference between 
dissolution rates in the fasted (SGF pH 3) and the fed state simulated media, the fat content did 
not lead to statistically significant dissolution rates among the milk-based media. The presence 
of different carbohydrates (1% w/v glucose, lactose and starch in SGF) increased the 
dissolution rate at a small extend, possibly by formation of hydrogen bonds between the drug 
and the carbohydrates’ hydroxyl functional groups. On the contrary, increased protein content, 
appeared to have a positive effect on drug dissolution. Drug dissolution rates in media 
containing albumin (0.5–4% w/v) concentration in SGF, increased by increasing the protein 
content. One possible mechanism could be through protein-drug binding possibly by the 
development of electrostatic and lipophilic interactions between the drug and albumin. 
Nifedipine is a calcium channel blocker with a complicated formulation-related food 
effect [5]. Immediate release tablets, prolonged (modified) release tablets, capsules and soft 
capsules of nifedipine (5–60 mg) are commercially available [71]. Significant differences in 
the bioavailability of nifedipine modified – release formulations after oral administration have 
been observed in vivo between fasted and fed state conditions [72, 73]. The bioavailability of 
the brand formulation, Adalat® OROS (Osmotic-Release Oral System), has not been 
significantly affected by the presence of food [72, 74, 75]. Dose dumping and unusually long 
lag times, possibly due to lack of robustness of the mechanism of drug release in the fed state 
or due to prolonged stay of the formulation in the stomach, have been observed after 
administration of generic nifedipine formulations. During the gastric residence of nifedipine, 
the rate of absorption is limited, which led to rapid and high absorption when it reached the 
small intestine, altering the formulation’s controlled release mechanism characteristics of some 
generic formulations [76, 77]. Nifedipine Sandoz® retard 30 mg (eroding matrix system) [74], 
Nifedicron® 60 mg, (capsule with mini-tablets, Pharmatec International, Milano, Italy) [75], 
Slofedipine® XL 60 mg (eroding matrix system) [72] and Nifedipine ER 90 mg test tablet 
(hydrophilic matrix, pilot formulation, Astra AB, Sweden) [78] demonstrated a formulation 
induced food effect after co-administration with a high-fat standard breakfast. Nifedipine 
Sandoz® retard demonstrated significant differences in its pharmacokinetic behaviour between 




controlled way, with the exact mechanism not having been experimentally proven [76]. Dose 
dumping and a threefold increase of the Cmax were observed for Nifedicron® under the fed state 
conditions compared to the fasted state [75]. Slofedipine® XL’s profiles between the fasted and 
the fed state (high-fat breakfast) were also significantly different. Nevertheless, even though 
the geometric AUC0→24 mean in the fed state was approximately half the one in the fasted state 
for Slofedipine® XL, the AUC0→tn values were identical [72]. Similar behaviour was observed 
with Nifedipine ER tablets (90 mg), which demonstrated a higher absorption rate than 
Procardia® XL (90 mg) (osmotic pull-push system tablet), which was used as a reference 
product. The effect was attributed to the increased erosion rate as a result of the gastric motility 
and alterations in the gastric content after meal administration [78]. 
It is worth mentioning that in several of the above studies, differences in the fed state-
pharmacokinetic behaviour between the brand and generic formulations have also been 
observed. In the case of nifedipine Sandoz® retard, great inter-patient variability often 
accompanied with fast, uncontrolled drug release was observed in plasma concentration vs time 
profiles, demonstrating failure of the controlled release behaviour of the formulation under fed 
conditions [74]. In case of Slofedipine® XL [72], the authors concluded that the differences 
between the test (Slofedipine® XL) and the reference (Adalat® OROS) formulations in the fed 
state could be attributed to the prolonged transit time of the former. Slofedipine® XL had a 
significant delay on the onset of its therapeutic action in 15 out of 24 patients of the study (15 
h lag time), which resulted in 29% decreased AUC0→tn compared to Adalat®. Slofedipine® XL’s 
lag time was attributed to the fact that undissolved particles of the formulation of a diameter 
above 10 mm were not able to pass through the pylorus, until the onset of phase III of the 
migrating motor complex (MMC; the cylindrical series of gastric electrical activity, taking 
place between meals) [79]. In the same study, in vitro dissolution studies in acetate buffer pH 
4.5 demonstrated that at pH values similar to the fed state, the generic formulation remained 
undissolved for 24 h, in contrast to Adalat® OROS which was almost 100% dissolved. 
1.7. Meal-related food effect 
Drug food effect relates to the nature of the meal. Meal characteristics such as fat 
content, viscosity, caloric content, size, and volume are parameters which can affect its 
absorption. 
Increased fat content in the fed state relates to delayed drug absorption due to slower 




formulation [80]. Increased viscosity of the gastric contents due to the administered meal 
delays the rate of gastric emptying [81]. Increased meal viscosity can decrease the diffusion 
coefficient of a compound according to Stokes-Einstein equation [82], which could in turn 
decrease drug absorption if it is only absorbed in a specific part of the gastrointestinal tract, as 
the drug goes past this site. The effect of meal viscosity is impaired in the small intestine due 
to secretions and digestion products. The most common effect of high meal viscosity is an 
increase in the Tmax values of drugs. In an in vivo study using canine subjects, when a calorie 
free viscosity enhancer, HPMC (hydroxypropylmethylcellulose) was added, a delay in the Tmax 
of the antiarrhythmic bidisomide was observed [83]. The meal’s residence time depends also 
on its caloric content [26]. 2–4 kcal of caloric content per minute is transferred to the duodenum 
[17], meaning that meals with high caloric content will reside in the stomach for longer periods, 
affecting drug’s transit time in the gastrointestinal tract. Nutrient drinks of 1 kcal/mL content 
are emptied at a rate of 2–2.5 mL/min, while nutrient drinks of 0.2 kcal/mL content have an 
emptying rate of 10 mL/min [17]. A calorie-dependent decrease in the gastric emptying rate 
was observed for the solid portion of the meal (45 ± 3.4% of the meal mass retained in the 
stomach for the 68 kcal solid meal and 65 ± 4% for the 633 kcal solid meal at 100 min), while 
its liquid portion is emptied to the duodenum at a rate independent of its energy content [11]. 
Meal size and volume relate to its gastric residence time [11]. Meals of fourfold mass and 
similar caloric content resulted in a 388% higher emptying rate, attributed to activation of 
stretch or volume receptors in stomach, increasing peristalsis. Using different volumes of 
isocaloric meals, a statistically significant increase in gastric emptying rate with the larger 
volume was noted for volumes of liquid meals between 200 mL and 800 mL [84]. 
1.8. Analytical techniques and challenges for sample treatment and drug 
quantification 
Most of the gastric fed state media used until now are milk based or o/w emulsions; 
therefore, several sample preparation processes have been developed for the extraction of the 
drugs from these matrices. Milk is a complex biological fluid containing proteins, lipids, 
carbohydrates, divalent and trivalent cations which can be bound to the compounds of interest 
making drug analysis challenging. The analytical techniques, issues and challenges described 
in this section refer mainly to fed state gastric biorelevant media which are at least partly 
comprised of milk or contain other types of lipid and protein sources. The quantification of 




(HPLC) and therefore, the analytical challenges and problems presented below refer mainly to 
this technique. 
1.8.1. Filtration 
The first challenge with drug analysis when biorelevant media are used is filtration 
itself. Filtration is an essential step in the analytical procedure, as biorelevant media contain a 
range of particles deriving from lipids, carbohydrates, fat and salts, which have to be removed 
before the sample’s injection in the HPLC. Moreover, when fed biorelevant media such as milk 
or FeSSGF are used, the use of small pore size filters for the sample analysis during solubility 
or dissolution studies cannot be used due to clogging from the presence of large proteins [9]. 
Several types of filters such as 0.45 or 0.22 µm polytetrafluoroethylene (PTFE) [64] or 
regenerated cellulose (RC) [44] have been used for sample analysis prior to HPLC injection 
for drug quantification in both milk and lipid-based media but a sample clean-up step is 
required before for these type of media. Glass microfiber (GF) 2.7 µm filters have also been 
used in drug solubility and dissolution studies in milk based media [85], in order to remove 
undissolved drug or formulation particles prior to sample treatment and filtration through the 
filters of smaller pore size. Filters of bigger pore size, attached to the sampling cannulas of the 
USP Apparatus 1/2 (polyethylene sticks, 10 µm and nylon membrane filters, 5 µm) have also 
been used in dissolution studies with FeSSGF and milk for the same reason [56, 85]. 
Adsorption of the analyte on the filters should be studied in order to evaluate and choose 
the appropriate filters. Salicylic acid and sodium saccharine are example of drugs which 
demonstrate significant adsorption on nylon filters as shown in a study by Carlson and 
Thompson [86], where 85.8% and 60.4% of salicylic acid at 0.005 mg/mL and 0.05 mg/mL 
concentrations respectively were adsorbed on 25 nm nylon filters. Sodium saccharine 
demonstrated even higher adsorption with the entire drug (100%) being adsorbed on the same 
filters at a 0.1 mg/mL concentration [86, 87]. It should be noted that if the first few drops of 
the filtrate are not discarded, the percentage of adsorption can reach extremely high values. 
1.8.2. Medium 
The analysis of the drug content in milk based media can be challenging as the content 
of the medium itself is comprised of a lipid and an aqueous phase that requires separation of 
the phases before an HPLC analysis can be performed. Analysis could be affected by the 
differential distribution of the drug in the multiple phases of the milk based media, as it could 




the medium. Several drugs have shown binding in milk at amounts higher than 50%; diazepam, 
indomethacin, grizeofulvin and dicumarol demonstrated binding percentages from 
approximately 55–95% in low and full fat milk (37 °C) after equilibrium dialysis against a 
phosphate buffer solution (pH 6.5). For some drugs, their percentage bound was more 
significantly affected by milk’s temperature (dicumarol, prednisolone) and fat content (e.g. 
binding of diazepam increased more than 13% in full fat milk in comparison with low fat milk 
at temperatures 15–37 °C) [88]. A factor affecting the analysis of milk is its variable fat, 
carbohydrate and lipid content. Its composition differs among different mammalian species, 
and is also affected by parameters such as their diet or the onset of their lactation period [89]. 
Therefore, milk of the same commercial brand and batch should be used when different drugs 
and dissolution conditions are compared, as changes in the medium composition may affect 
parameters such as recovery, precision, and analytical method compatibility. 
1.8.3. Sample treatment and analysis 
1.8.3.1. Protein precipitation (PP) 
One simple method of sample clean-up prior to drug quantification in gastric milk-
based fed state media is protein precipitation. Protein precipitation is the technique mainly used 
until now with the addition of a volume of an organic reagent to a volume of medium, followed 
by a centrifugation and a filtration step before its analysis in HPLC. The precipitation of the 
milk’s proteins can be performed using an organic reagent followed by filtration and 
centrifugation steps [9]. 
A range of solvents such as acidified MeOH [90], acetone [91] and HCl [92] have been 
used as protein precipitation reagents for the extraction of drugs from milk-based media. 
Parameters such as their compatibility with the analytical technique chosen, their volatility in 
case organic phase evaporation is needed, their selectivity and their cost have to be considered 
during the selection of an appropriate protein precipitation solvent [88]. 
Fotaki et al. [60] suggested a precipitation and centrifugation method for the 
quantification of l-sulpiride, a BSC class III drug, in a milk based dissolution medium, 
proposing an assay involving centrifugation at 4000 rpm for 10 min (8 °C) for the separation 
of the aqueous phase from the lipid phase with acetonitrile being added in the aqueous filtrate 
(1:2) and a last centrifugation and filtration step (Titan® filters 0.45 µm) following. Sample 
treatment in nutrient drinks and emulsions requires a more time consuming clean-up procedure. 




and possibly an extra filtration step with a larger pore size filter (5 µm) prior to filtering with a 
0.45 µm filter and injecting the supernatant in the HPLC. 
A study by Williams et al. [10] used 1:2 with ice-cold 12% (w/v) trichloroacetic acid 
for milk protein precipitation and then centrifugation at 10,000 rpm for 15 min extracting 0.2 
mL of the supernatant for the HPLC analysis [10] for the quantification of caffeine in both 
milk-based (0.1%, 1.7%, 3.6% fat milk) and fat emulsion type [30% fat emulsion (Intralipid®)] 
media. Despite the fact that a protein precipitation step, followed by centrifugation and 
filtration, was adequate for both types of media, the recovery of the drug in the fat emulsion 
was significantly lower. A challenge associated with the selection of protein precipitation 
reagents is their compatibility with the HPLC method for the analysis of the selected drug. 
Peak fronting is a common issue when organic reagents of higher strength than the mobile 
phase are used: an issue that can usually be resolved with evaporation of the reagent under 
nitrogen and reconstitution in the mobile phase. Another disadvantage of this technique is its 
inability of complete removal of the lipid part of the medium [89], as for the selective removal 
of lipids, a supplementary step is required. This step may be a wash with hexane, given that the 
compound of interest is ionised or not extracted in hexane, so as not to be lost during the 
washing step [93]. 
1.8.3.2. Solid phase extraction (SPE) 
Another method used for the extraction of the analyte of interest from milk is solid 
phase extraction (SPE). Solid phase extraction (SPE) is widely used for the extraction of drugs 
from biological fluids such as whole blood [94], plasma [95], urine [96] and milk [97], and is 
often preceded by a protein precipitation step. SPE cartridges are comprised of a polypropylene 
tube with their sorbent between two porous frits. A typical experimental protocol involves 4 
main steps: (i) cartridge conditioning, (ii) sample loading, (iii) sample washing and (iv) sample 
elution [98]. 
Most cartridges are either comprised of bonded silica phases, similar to the material of 
the reversed phase HPLC columns but with bigger diameter particles (10–60 µm), or of 
polymeric resins (e.g. polystyrene-divinylbenzene) [99]. SPE C18 cartridges have been used for 
the quantification of several drugs, such as β-lactam antibiotics [100] or nonsteroidal anti-
inflammatory drugs (NSAIDs) [101], in milk. In the above studies, a protein precipitation step 
similar to the one previously described [60] took place before the extraction, due to the milk’s 




on the cartridge. An elution solvent of high water percentage is preferable for extraction from 
milk-based media, and has to be able to elute the drug and retain most of the lipids on the 
cartridge [10]. The extraction yield of lipid drugs using SPE may be low due to the drug’s 
interaction with milk’s fat globules. A way to disrupt this drug-fat globule interactions would 
be sonication and dilution of the medium before its loading on the cartridge [89]. A challenge 
for the analysis with SPE when it comes to biorelevant media, is the interference from the 
matrix in HPLC analysis. Therefore, clean-up with a solid phase extraction cartridge can help 
towards the development of more sensitive and robust methods in drug analysis in fed state 
biorelevant media. Disadvantages of SPE as a drug’s extraction method from gastric fed state 
media include the quick drying of the cartridges and the difficulty to adjust the vacuum during 
the multiple steps without the presence of an automated manifold, affecting the reproducibility 
of the method [102, 103]. 
1.8.3.3. Liquid-liquid extraction (LLE) 
Liquid-liquid extraction is based on the analyte partitioning between an aqueous phase 
and a water-immiscible solvent [99]. Several extraction protocols have been successfully 
applied for a wide range of drugs such as mycotoxins [104], mycrocyclic lactones [105], 
vitamins [106] and analgesics [107]. The main advantages of LLE is the short time required 
for method development and its low cost. A serious drawback is the fact that it is a time-
consuming and labour intensive method. Moreover, the possible presence of the milk’s lipid 
content in the extraction solvent after the LLE process, leads to phase separation of the sample 
and lipid partitioning in the stationary phase of the HPLC column during drug analysis. 
Therefore a washing step with hexane is usually required, so as to remove the lipids [89], 
making the whole procedure even more time consuming. The following protocol used in milk 
for the quantification of Ochratoxin A is a typical case of liquid-liquid extraction [104]; 0.2 
mL saturated NaCl solution and 2.4 mL chloroform were added to 1 mL milk, mixed gently 
for 3 min, centrifuged (4500 rpm, 20 min) and after the removal of the chloroform layer, 
evaporation to dryness under nitrogen steam and reconstitution in acetonitrile followed. Lipid 
removal was performed by double extraction (2 × 0.4 mL petroleum ether for 1 min). After 
discarding the etheric layer, acetonitrile was blown to dryness, reconstituted in 1 mL of mobile 






1.8.3.4. Ion selective Electrode (IsE) sensor 
An online monitoring system, in an attempt to avoid the sample treatment traditionally 
required for the extraction of the analytes of interest from FeSSGF has been published [9]. An 
Ion Selective Electrode (ISE) sensor system was used, with two electrodes placed constantly 
in the dissolution vessel which were able to monitor the changes in drug concentration through 
the changes in potential. With this proposed methodology, diphenhydramine hydrochloride 
was successfully quantified in a dissolution study using the USP Apparatus 2 in several fasted 
[Fasted State Simulated Gastric Fluid (FaSSGF), Fasted State Simulated Intestinal Fluid 
(FaSSIF) and Fasted State Simulated Intestinal Fluid Version Two (FaSSIF-V2)] and fed 
(FeSSGF) state biorelevant media. Sample preparation steps needed with extraction techniques 
were avoided, and a continuous dissolution profile and a much faster and less laborious 
alternative were offered. Disadvantages of this method are as follows: (a) its limitation to the 
analysis of ionised drugs, (b) the complicated correction of the baseline needed for the 
heterogeneous biorelevant media and (c) its inability for the analysis of compounds of 
extremely low aqueous solubility [9]. 
1.8.3.5. Other techniques 
Several other techniques have been used for drug quantification in milk and may have 
the potential to be used in fed state gastric media, some of which are briefly listed below: 
Matrix solid-phase dispersion (MSPD) 
The matrix solid-phase dispersion (MSPD) technique was firstly developed by Barker 
et al. [108]. MSPD involves the grinding of biological samples with sorbent particles producing 
a column material acting as a solid support from which the drugs in the matrix can be 
selectively extracted [109, 110]. MSPD has been successfully used in drug quantification in 
milk with sorbents, such as C18 [111], C8, silica gel [112], mixed-mode/cationic-exchange 
(MCX), mixed-mode/anion-exchange (MAX) and weak anion–exchange (WAX) [113], and 
more recently molecularly imprinted polymers (MIPs) [110]. An advantage of this method is 
the combination of homogenisation, fractionation and purification in one single step and could 
be also used to milk-based gastric dissolution media [109]. It is also cheap and environmentally 






Solid phase microextraction (SPME) 
SPME is a sample preparation technique which is based on a concentration equilibrium 
between an extracting phase associated with a solid support and a biological matrix [115]. Two 
different SPME designs are the most commonly used: in-tube mode and fibre design. In this 
technique, small quantities of the sorbent are exposed to the headspace or solution of the 
biological sample using a suitable format. After a predefined amount of time and when 
equilibrium between the coating and the matrix has been reached, the sorbent does not absorb 
any additional quantity of the analyte of interest, meaning that the amount of drug extracted for 
a specific concentration is constant [116]. The main advantages of SPME are its low cost and 
the fact that it is time saving and environmentally friendly [117]. Some of its disadvantages are 
the slow time for equilibrium between the analyte and the extraction phase to be reached [118], 
the poor selectivity and the limited type of fibres commercially available [119]. 
Ultrafiltration 
Ultrafiltration is a technique extensively used in food industry and water treatment. It 
is based on the selective passage of drugs of low molecular weight through the pores of a 
membrane of a specific MW cut-off, which inhibits the passage of molecules of higher MW. 
This technique does not involve time-consuming steps but its use is limited by reduced 
sensitivity due to interferences from the matrix in drug analysis and is usually used in 
combination with other clean-up techniques [89]. Ultrafiltration was successfully employed for 
the quantification of tetracyclines in milk, by adding solid EDTA at 10 mM concentration, 
before sample centrifugation at 5000 rpm for 1 h. Ultrafree MC/PL devices (nominal molecular 
weight limit 5000) were used in this study [120]. 
1.9. Conclusion 
Prediction of gastric food-effect of drugs has been a challenge of the pharmaceutical 
industry. Even though the in vivo properties of the fed state gastric environment have been 
determined in some cases, the complicated fed environment due to differences in the meals 
administered makes the determination of the precise gastric conditions difficult. Despite the 
fact that some progress has been made with the development of gastric biorelevant media, a 
universal robust predictive analytical method has not been yet developed. The development of 
suitable biorelevant media in combination with a simple and robust analytical method could 
potentially provide a means of understanding of a potential food effect in regard of a drug’s 




drinks or Fed State Simulated Gastric Fluid (FeSSGF) have been developed in an attempt to 
simulate the human postprandial conditions. Nevertheless, none have managed to achieve 
precise representation and fully overcome issues such as the need of a time-consuming 
preparation for the quantification of the drug, possible matrix interferences and compatibility 






[1] J.B. Dressman, C. Reppas, G.L. Amidon, V.P. Shah, Dissolution testing as a prognostic 
tool for oral drug absorption: immediate release dosage forms, Pharm. Res. 15 (1998) 11–22.  
[2] Q. Wang, N. Fotaki, Y. Mao, Biorelevant dissolution: methodology and application in drug 
development, Dissolut. Technol. 16 (2009) 6–12. 
[3] A. Simon, V.R. Almeida Borges, L.M. Cabral, V.P. Sousa, Development and validation of 
a discriminative dissolution test for betamethasone sodium phosphate and betamethasone 
dipropionate intramuscular injectable suspension, AAPS PharmSciTech 14 (2013) 425–434.  
[4] M. Vertzoni, J. Dressman, J. Butler, J. Hempenstall, C. Reppas, Simulation of fasting 
gastric conditions and its importance for the in vivo dissolution of lipophilic compounds, Eur 
J. Pharm. Biopharm. 60 (2005) 413–417.  
[5] B. Abrahamsson, T. Albery, A. Eriksson, I. Gustafsson, M. Sjöberg, Food effects on tablet 
disintegration, Eur. J. Pharm. Sci. 22 (2004) 165–172.  
[6] A. Müllertz, Biorelevant dissolution media, in: P. Augustijns, M. Brewster E (Eds.), Solvent 
Systems and Their Selection in Pharmaceutics and Biopharmaceutics, Springer, New York, 
2007, pp. 151–177.  
[7] S. Klein, The use of biorelevant dissolution media to forecast the in vivo performance of a 
drug, AAPS J. 12 (2010) 397–406.  
[8] N. Fotaki, M. Vertzoni, Biorelevant dissolution methods and their applications in in vitro-
in vivo correlations for oral formulations, TODDJ 4 (2010) 2–13.  
[9] D. Juenemann, H. Bohets, M. Ozdemir, R. de Maesschalck, K. Vanhoutte, K. Peeters, L. 
Nagels, J.B. Dressman, Online monitoring of dissolution tests using dedicated potentiometric 




[10] H.D. Williams, D.A. Barrett, R. Ward, I.J. Hardy, C.D. Melia, A liquid chromatography 
method for quantifying caffeine dissolution from pharmaceutical formulations into colloidal, 
fat-rich media, J. Chromatogr. B 878 (2010) 1739–1745.  
[11] J.G. Moore, P.E. Christian, J.A. Brown, C. Brophy, F. Datz, A. Taylor, N. Alazraki, 
Influence of meal weight and caloric content on gastric emptying of meals in man, Digest. Dis. 
Sci. 29 (1984) 513–519.  
[12] A. Lindahl, A.L. Ungell, L. Knutson, H. Lennernas, Characterization of fluids from the 
stomach and proximal jejunum in men and women, Pharm. Res. 14 (1997) 497–502.  
[13] L. Kalantzi, K. Goumas, V. Kalioras, B. Abrahamsson, J. Dressman, C. Reppas, 
Characterization of the human upper gastrointestinal contents under conditions simulating 
bioavailability/bioequivalence studies, Pharm. Res. 23 (2006) 165–176.  
[14] P.B. Pedersen, P. Vilmann, D. Bar-Shalom, A. Müllertz, S. Baldursdottir, Characterization 
of fasted human gastric fluid for relevant rheological parameters and gastric lipase activities, 
Eur. J. Pharm. Biopharm. 85 (2013) 958–965.  
[15] S.G. Hughes, Prescribing for the elderly patient: why do we need to exercise caution?, Br 
J. Clin. Pharmacol. 46 (1998) 531–533.  
[16] O. Gursoy, D. Memis, N. Sut, Effect of proton pump inhibitors on gastric juice volume, 
gastric pH and gastric intramucosal pH in critically ill patients: a randomized, double-blind, 
placebo-controlled study, Clin. Drug Invest. 28 (2008) 777–782.  
[17] F. Kong, R.P. Singh, Disintegration of solid foods in human stomach, J. Food Sci. 73 
(2008) R67–R80.  
[18] C.J.H. Porter, C.W. Pouton, J.F. Cuine, W.N. Charman, Enhancing intestinal drug 
solubilisation using lipid-based delivery systems, Adv. Drug Deliv. Rev. 60 (2008) 673–691.  
[19] F. Carriere, J.A. Barrowman, A. Verger, R. Laugier, Secretion and contribution to lipolysis 





[20] Y. Pafumi, D. Lairon, P.L. de la Porte, C. Juhel, J. Storch, M. Hamosh, M. Armand, 
Mechanisms of inhibition of triacylglycerol hydrolysis by human gastric lipase, J. Biol. Chem. 
277 (2002) 28070–28079. 
[21] M. Armand, P. Borel, B. Pasquier, C. Dubois, M. Senft, M. Andre, J. Peyrot, J. Salducci, 
D. Lairon, Physicochemical characteristics of emulsions during fat digestion in human stomach 
and duodenum, Am. J. Physiol. 271 (1996) G172–G183.  
[22] W.N. Charman, C.J.H. Porter, S. Mithani, J.B. Dressman, Physicochemical and 
physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH, 
J. Pharm. Sci. 86 (1997) 269–282.  
[23] B. Singh, Effects of food on clinical pharmacokinetics, Clin. Pharmacokinet. 37 (1999) 
213–255.  
[24] K. Kleberg, J. Jacobsen, A. Müllertz, Characterising the behaviour of poorly water soluble 
drugs in the intestine: application of biorelevant media for solubility, dissolution and transport 
studies, J. Pharm. Pharmacol. 62 (2010) 1656–1668.  
[25] P. Dewar, R. King, D. Johnston, Bile acid and lysolecithin concentrations in the stomach 
in patients with duodenal ulcer before operation and after treatment by highly selective 
vagotomy, partial gastrectomy, or truncal vagotomy and drainage, Gut 23 (1982) 569–577.  
[26] J. Dressman, Comparison of canine and human gastrointestinal physiology, Pharm. Res. 
3 (1986) 123–131. [27] D.M. Mudie, G.L. Amidon, G.E. Amidon, Physiological parameters 
for oral delivery and in vitro testing, Mol. Pharm. 7 (2010) 1388–1405.  
[28] J. Dressman, R. Berardi, L. Dermentzoglou, T. Russell, S. Schmaltz, J. Barnett, K. 
Jarvenpaa, Upper gastrointestinal (GI) pH in young, healthy men and women, Pharm. Res. 7 
(1990) 756–761.  
[29] E.L. McConnell, H.M. Fadda, A.W. Basit, Gut instincts: explorations in intestinal 




[30] D. Horter, J.B. Dressman, Influence of physicochemical properties on dissolution of drugs 
in the gastrointestinal tract, Adv. Drug Deliv. Rev. 46 (2001) 75–87.  
[31] T. Yamaguchi, A. Seza, T. Odaka, T. Shishido, M. Ai, S. Gen, T. Kouzu, H. Saisho, 
Placement of the Bravo wireless pH monitoring capsule onto the gastric wall under endoscopic 
guidance, Gastrointest. Endosc. 63 (2006) 1046–1050.  
[32] S. Di Maio, R.L. Carrier, Gastrointestinal contents in fasted state and post-lipid ingestion: 
in vivo measurements and in vitro models for studying oral drug delivery, J. Control. Release 
151 (2011) 110–122.  
[33] M.W. Rudolph, S. Klein, T.E. Beckert, H.-U. Petereit, J.B. Dressman, A new 5- 
aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis, Eur. J. Pharm. 
Biopharm. 51 (2001) 183–190.  
[34] M. Koziolek, G. Garbacz, M. Neumann, W. Weitschies, Simulating the postprandial 
stomach: biorelevant test methods for the estimation of intragastric drug dissolution, Mol. 
Pharm. 10 (2013) 2211–2221.  
[35] M. Efentakis, J.B. Dressman, Gastric juice as a dissolution medium: surface tension and 
pH, Eur. J. Drug Metab. Pharmacokinet. 23 (1998) 97–102.  
[36] B.L. Pedersen, A. Mullertz, H. Brondsted, H.G. Kristensen, A comparison of the solubility 
of danazol in human and simulated gastroiatestinal fluids, Pharm. Res. 17 (2000) 891–894.  
[37] E. Jantratid, N. Janssen, C. Reppas, J. Dressman, Dissolution media simulating conditions 
in the proximal human gastrointestinal tract: an update, Pharm. Res. 25 (2008) 1663–1676.  
[38] P.G. Welling, Effect of food on drug absorption, Pharmacol. Ther. 43 (1989) 425–441.  
[39] H. Jung, A.A. Peregrina, J.M. Rodriguez, R. Moreno-Esparza, The influence of coffee 
with milk and tea with milk on the bioavailability of tetracycline, Biopharm. Drug Dispos. 18 
(1997) 459–463.  




[41] H. Gin, M.B. Orgerie, J. Aubertin, The influence of Guar gum on absorption of metformin 
from the gut in healthy volunteers, Horm. Metab. Res. 21 (1989) 81–83.  
[42] C.A.S. Bergström, R. Holm, S.A. Jørgensen, S.B.E. Andersson, P. Artursson, S. Beato, A. 
Borde, K. Box, M. Brewster, J. Dressman, K.-I. Feng, G. Halbert, E. Kostewicz, M. McAllistar, 
U. Muenster, J. Thinnes, R. Taylor, A. Mullertz, Early pharmaceutical profiling to predict oral 
drug absorption: current status and unmet needs, Eur. J. Pharm. Sci. 57 (2013).  
[43] S. Klein, J. Butler, J. Hempenstall, C. Reppas, J. Dressman, Media to simulate the 
postprandial stomach I. Matching the physicochemical characteristics of standard breakfasts, 
J. Pharm. Pharmacol. 56 (2004) 605–610.  
[44] A. Diakidou, M. Vertzoni, J. Dressman, C. Reppas, Estimation of intragastric drug 
solubility in the fed state: comparison of various media with data in aspirates, Biopharm. Drug 
Dispos. 30 (2009) 318–325.  
[45] G. Amidon, H. Lennernäs, V. Shah, J. Crison, A theoretical basis for a biopharmaceutic 
drug classification: the correlation of in vitro drug product dissolution and in vivo 
bioavailability, Pharm. Res. 12 (1995) 413–420.  
[46] D. Fleisher, C. Li, Y. Zhou, L.-H. Pao, A. Karim, Drug, meal and formulation interactions 
influencing drug absorption after oral administration, Clin. Pharmacokinet. 36 (1999) 233–254.  
[47] E. Sjögren, B. Abrahamsson, P. Augustijns, D. Becker, M.B. Bolger, M. Brewster, J. 
Brouwers, T. Flanagan, M. Harwood, C. Heinen, R. Holm, H.-P. Juretschke, M. Kubbinga, A. 
Lindahl, V. Lukacova, U. Münster, S. Neuhoff, M.A. Nguyen, A.v. Peer, C. Reppas, A.R. 
Hodjegan, C. Tannergren, W. Weitschies, C. Wilson, P. Zane, H. Lennernäs, P. Langguth, In 
vivo methods for drug absorption – comparative physiologies, model selection, correlations 
with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization 
including food effects, Eur. J. Pharm. Sci. 57 (2014) 99–151.  
[48] C.-Y. Wu, L.Z. Benet, Predicting drug disposition via application of BCS: 
transport/absorption/elimination interplay and development of a biopharmaceutics drug 




[49] K. Lentz, M. Quitko, D. Morgan, J. Grace, C. Gleason, P. Marathe, Development and 
validation of a preclinical food effect model, J. Pharm. Sci. 96 (2007) 459– 472.  
[50] EMA, Guideline on the Investigation of Drug Interactions, European Medicines Agency, 
United Kingdom, 2013, pp. 60.  
[51] FDA, Guidance for Industry Food-Effect Bioavailability and Fed Bioequivalence Studies, 
U.S. Department of Health and Human Services Food and Drug Administration Center for 
Drug Evaluation and Research (CDER), 2002, pp. 5.  
[52] F. Kees, G. Mair, M. Dittmar, M. Bucher, Cicloral versus neoral: a bioequivalence study 
in healthy volunteers on the influence of a fat-rich meal on the bioavailability of cicloral, 
Transplant. Proc. 36 (2004) 3234–3238.  
[53] B.E. Gidal, M.M. Maly, J. Budde, G.L. Lensmeyer, M.E. Pitterle, J.C. Jones, Effect of a 
high-protein meal on gabapentin pharmacokinetics, Epilepsy Res. 23 (1996) 71–76.  
[54] M. Koziolek, G. Garbacz, M. Neumann, W. Weitschies, Simulating the postprandial 
stomach: physiological considerations for dissolution and release testing, Mol. Pharm. 10 
(2013) 1610–1622.  
[55] P. Macheras, M. Koupparis, C. Tsaprounis, Drug dissolution studies in milk using the 
automated flow injection serial dynamic dialysis technique, Int. J. Pharm. 33 (1986) 125–136.  
[56] L. Kalantzi, B. Polentarutti, T. Albery, D. Laitmer, B. Abrahamsson, J. Dressman, C. 
Reppas, The delayed dissolution of paracetamol products in the canine fed stomach can be 
predicted in vitro but it does not affect the onset of plasma levels, Int. J. Pharm. 296 (2005) 87–
93.  
[57] F. Carrière, C. Renou, V. Lopez, J. de Caro, F. Ferrato, H. Lengsfeld, A. de Caro, R. 
Laugier, R. Verger, The specific activities of human digestive lipases measured from the in 




[58] E. Galia, E. Nicolaides, D. Horter, R. Lobenberg, C. Reppas, D. Hörter, R. Löbenberg, 
J.B. Dressman, Evaluation of various dissolution media for predicting in vivo performance of 
class I and II drugs, Pharm. Res. 15 (1998) 698–705.  
[59] A. Diakidou, M. Vertzoni, B. Abrahamsson, J. Dressman, C. Reppas, Simulation of gastric 
lipolysis and prediction of felodipine release from a matrix tablet in the fed stomach, Eur. J. 
Pharm. Sci. 37 (2009) 133–140.  
[60] N. Fotaki, M. Symillides, C. Reppas, Canine versus in vitro data for predicting input 
profiles of l-sulpiride after oral administration, Eur. J. Pharm. Sci. 26 (2005) 324–333. 
[61] J. Brouwers, B. Anneveld, G.-J. Goudappel, G. Duchateau, P. Annaert, P. Augustijns, E. 
Zeijdner, Food-dependent disintegration of immediate release fosamprenavir tablets: in vitro 
evaluation using magnetic resonance imaging and a dynamic gastrointestinal system, Eur. J. 
Pharm. Biopharm. 77 (2011) 313–319.  
[62] L.J. Ashby, A.E. Beezer, G. Buckton, In vitro dissolution testing of oral controlled release 
preparations in the presence of artificial foodstuffs. I. Exploration of alternative methodology: 
microcalorimetry, Int. J. Pharm. 51 (1989) 245–251.  
[63] Ensure Products, Abbott Laboratories (assessed 2016). 
[64] F. Franek, P. Holm, F. Larsen, B. Steffansen, Interaction between fed gastric media 
(Ensure Plus) and different hypromellose based caffeine controlled release tablets: Comparison 
and mechanistic study of caffeine release in fed and fasted media versus water using the USP 
dissolution apparatus 3, Int. J. Pharm. 461 (2014) 419–426.  
[65] C. Reppas, M. Vertzoni, Biorelevant in-vitro performance testing of orally administered 
dosage forms, J. Pharm. Pharmacol. 64 (2012) 919–930.  
[66] C. Markopoulos, C.J. Andreas, M. Vertzoni, J. Dressman, C. Reppas, In-vitro simulation 
of luminal conditions for evaluation of performance of oral drug products: choosing the 




[67] M. Armand, P. Borel, C. Dubois, M. Senft, J. Peyrot, J. Salducci, H. Lafont, D. Lairon, 
Characterization of emulsions and lipolysis of dietary lipids in the human stomach, Am. J. 
Physiol. 266 (1994) G372–G381.  
[68] J.A. Barone, J.G. Koh, R.H. Bierman, J.L. Colaizzi, K.A. Swanson, M.C. Gaffar, B.L. 
Moskovitz, W. Mechlinski, V. Van de Velde, Food interaction and steady-state 
pharmacokinetics of itraconazole capsules in healthy male volunteers, Antimicrob. Agents 
Chemother. 37 (1993) 778–784.  
[69] T. Zimmermann, R.A. Yeates, H. Laufen, G. Pfaff, A. Wildfeuer, Influence of 
concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole 
and fluconazole, Eur. J. Clin. Pharmacol. 46 (1994) 147– 150.  
[70] H.S. Ghazal, A.M. Dyas, J.L. Ford, G.A. Hutcheon, In vitro evaluation of the dissolution 
behaviour of itraconazole in bio-relevant media, Int. J. Pharm. 366 (2009) 117–123.  
[71] MHRA, Medicines Information: SPC & PILs. (assessed 2015).  
[72] B.S. Schug, E. Brendel, E. Chantraine, D. Wolf, W. Martin, R. Schall, H.H. Blume, The 
effect of food on the pharmacokinetics of nifedipine in two slow release formulations: 
pronounced lag-time after a high fat breakfast, Br. J. Clin. Pharmacol. 53 (2002) 582–588.  
[73] K. Ueno, S. Kawashima, K. Uemoto, T. Ikada, K. Miyai, K. Wada, K. Yamazaki, K. 
Matsumoto, I. Nakata, Effect of food on nifedipine sustained-release preparation, DICP 23 
(1989) 662–665. 
[74] M. Wonnemann, B. Schug, K. Schmucker, E. Brendel, K. Schmucker, P.A. van Zwieten, 
H. Blume, Significant food interactions observed with a nifedipine modified-release 
formulation marketed in the European Union, Int. J. Clin. Pharm. Therap. 44 (2006) 38–48.  
[75] B. Schug, E. Brendel, M. Wonnemann, D. Wolf, M. Wargenau, A. Dingler, H. Blume, 
Dosage form-related food interaction observed in a marketed oncedaily nifedipine formulation 




[76] D.G. Bailey, J. Malcolm, O. Arnold, J.D. Spence, Grapefruit juice-drug interactions, Br. 
J. Clin. Pharmacol. 46 (1998) 101–110. [77] C. Wagner, K. Thelen, S. Willmann, A. Selen, J. 
Dressman, Utilizing in vitro and PBPK tools to link ADME characteristics to plasma profiles: 
case example nifedipine immediate release formulation, J. Pharm. Sci. 102 (2013) 3205– 3219.  
[78] B. Abrahamsson, M. Alpsten, B. Bake, U.E. Jonsson, M. Eriksson-Lepkowska, A. 
Larsson, Drug absorption from nifedipine hydrophilic matrix extendedrelease (ER) tablet-
comparison with an osmotic pump tablet and effect of food, J. Control. Release 52 (1998) 301–
310.  
[79] J. Janssens, G. Vantrappen, T.L. Peeters, The activity front of the migrating motor 
complex of the human stomach but not of the small intestine is motilin-dependent, Regul. 
Peptides 6 (1983) 363–369.  
[80] P. Macheras, M. Koupparis, S. Antimisiaris, An in vitro model for exploring CR 
theophylline-milk fat interactions, Int. J. Pharm. 54 (1989) 123–130.  
[81] L. Marciani, P.A. Gowland, R.C. Spiller, P. Manoj, R.J. Moore, P. Young, S. AlSahab, D. 
Bush, J. Wright, A.J. Fillery-Travis, Gastric response to increased meal viscosity assessed by 
echo-planar magnetic resonance imaging in humans, J. Nutr. 130 (2000) 122–127.  
[82] E.A. Mun, C. Hannell, S.E. Rogers, P. Hole, A.C. Williams, V.V. Khutoryanskiy, On the 
role of specific interactions in the diffusion of nanoparticles in aqueous polymer solutions, 
Langmuir 30 (2014) 308–317.  
[83] L.H. Pao, C. Cook, T. Kararli, C. Kirchhoff, S.Y. Zhou, J. Truelove, A. Karim, D. Fleisher, 
Reduced systemic availability of an antiarrhythmic drug, bidisomide, with meal co-
administration: relationship with regiondependent intestinal absorption, Pharm. Res. 15 (1998) 
221–227.  
[84] M.A. Kwiatek, D. Menne, A. Steingoetter, O. Goetze, Z. Forras-Kaufman, E. Kaufman, 
H. Fruehauf, P. Boesiger, M. Fried, W. Schwizer, M.R. Fox, Effect of meal volume and calorie 




combined fiber-optic pressure measurement and MRI, Am. J. Physiol. Gastrointest. Liver 
Physiol. 297 (2009) G894–G901.  
[85] C. Wagner, E. Jantratid, F. Kesisoglou, M. Vertzoni, C. Reppas, J.B. Dressman, Predicting 
the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant 
dissolution and transfer model tests coupled with a physiologically based pharmacokinetic 
model, Eur. J. Pharm. Biopharm. 82 (2012) 127–138.  
[86] M. Carlson, R.D. Thompson, Analyte loss due to membrane filter adsorption as 
determined by high-performance liquid chromatography, J. Chromatogr. Sci. 38 (2000) 77–83.  
[87] K. Kiehm, J. Dressman, Evaluation of drug adsorption to membrane filters under 
biowaiver test conditions, Dissolut. Technol. 15 (2008) 13–17.  
[88] P. Macheras, M. Koupparis, S. Antimisiaris, Drug binding and solubility in milk, Pharm. 
Res. 7 (1990) 537–541. [89] D.T. Rossi, D. Scott Wright, Analytical considerations for trace 
determinations of drugs in breast milk, J. Pharmaceut. Biomed. 15 (1997) 495–504.  
[90] K. Nagy, K. Redeuil, R. Bertholet, H. Steiling, M. Kussmann, Quantification of 
anthocyanins and flavonols in milk-based food products by ultra performance liquid 
chromatography-tandem mass spectrometry, Anal. Chem. 81 (2009) 6347–6356.  
[91] S. Ou, K.C. Kwok, Y. Wang, H. Bao, An improved method to determine SH and –S–S– 
group content in soymilk protein, Food Chem. 88 (2004) 317–320.  
[92] M.-Y. Pinero, R. Garrido Delgado, R. Bauza, L. Arce, M. Valcarcel, R. GarridoDelgado, 
M. Valcarcel, Easy sample treatment for the determination of enrofloxacin and ciprofloxacin 
residues in raw bovine milk by capillary electrophoresis, Electrophoresis 33 (2012) 2978–
2986.  
[93] L.A. Dostal, R.P. Weaver, B.A. Schwetz, Excretion of high concentrations of cimetidine 
and ranitidine into rat milk and their effects on milk composition and mammary gland nucleic 




[94] L. Zhang, Z.-H. Wang, H. Li, Y. Liu, M. Zhao, Y. Jiang, W.-S. Zhao, Simultaneous 
determination of 12 illicit drugs in whole blood and urine by solid phase extraction and UPLC–
MS/MS, J. Chromatogr. B 955–956 (2014) 10–19.  
[95] J. Shentu, L. Fu, H. Zhou, X.J. Hu, J. Liu, J. Chen, G. Wu, Determination of amlodipine 
in human plasma using automated online solid-phase extraction HPLC–tandem mass 
spectrometry: application to a bioequivalence study of Chinese volunteers, J. Pharmaceut. 
Biomed. 70 (2012) 614–618.  
[96] R. Cazorla-Reyes, J.L. Fernández-Moreno, R. Romero-González, A.G. Frenich, J. L.M. 
Vidal, Single solid phase extraction method for the simultaneous analysis of polar and non-
polar pesticides in urine samples by gas chromatography and ultra high pressure liquid 
chromatography coupled to tandem mass spectrometry, Talanta 85 (2011) 183–196.  
[97] U. Koesukwiwat, S. Jayanta, N. Leepipatpiboon, Solid-phase extraction for multiresidue 
determination of sulfonamides, tetracyclines, and pyrimethamine in Bovine’s milk, J. 
Chromatogr. A 1149 (2007) 102–111.  
[98] SPE Method Development, Waters (assessed 2016).  
[99] C.A. James, Sample preparation, in: R.F. Venn (Ed.), Principles and Practice of 
Bioanalysis, Taylor & Francis Group, Boca Raton, US, 2008. [100] M. Cámara, A. Gallego-
Picó, R.M. Garcinuño, P. Fernández-Hernando, J.S. Durand-Alegría, P.J. Sánchez, An HPLC-
DAD method for the simultaneous determination of nine b-lactam antibiotics in ewe milk, Food 
Chem. 141 (2013) 829–834.  
[101] P. Gallo, S. Fabbrocino, F. Vinci, M. Fiori, V. Danese, L. Serpe, Confirmatory 
identification of sixteen non-steroidal anti-inflammatory drug residues in raw milk by liquid 
chromatography coupled with ion trap mass spectrometry, Rapid Commun. Mass Spectrom. 
22 (2008) 841–854.  
[102] M. Anastassiades, S.J. Lehotay, D. Stajnbaher, F.J. Schenck, Fast and easy multiresidue 
method employing acetonitrile extraction/partitioning and ‘‘dispersive solid-phase extraction” 




[103] S.J. Lehotay, A.R. Lightfield, J.A. Harman-Fetcho, D.J. Donoghue, Analysis of pesticide 
residues in eggs by direct sample tntroduction/gas chromatography/tandem mass spectrometry, 
J. Agric. Food Chem. 49 (2001) 4589–4596.  
[104] A. Gürbay, G. Girgin, S.A. Sabuncuoǧlu, G. Sahin, M. Yurdakök, S. Yiǧit, G. Tekinalp, 
Ochratoxin A: is it present in breast milk samples obtained from mothers from Ankara, 
Turkey?, J Appl. Toxicol. 30 (2010) 329–333.  
[105] G. Rübensam, F. Barreto, R.B. Hoff, T.L. Kist, T.M. Pizzolato, A liquid–liquid extraction 
procedure followed by a low temperature purification step for the analysis of macrocyclic 
lactones in milk by liquid chromatography–tandem mass spectrometry and fluorescence 
detection, Anal. Chim. Acta 705 (2011) 24–29.  
[106] M. Kašparová, J. Plíšek, D. Solichová, L. Krcˇmová, B. Kucˇerová, M. Hronek, P. Solich, 
Rapid sample preparation procedure for determination of retinol and a-tocopherol in human 
breast milk, Talanta 93 (2012) 147–152.  
[107] V. Kmetec, R. Roškar, HPLC determination of tramadol in human breast milk, J. 
Pharmaceut. Biomed. 32 (2003) 1061–1066.  
[108] S.A. Barker, A.R. Long, C.R. Short, Isolation of drug residues from tissues by solid phase 
dispersion, J. Chromatogr. A 475 (1989) 353–361.  
[109] S.A. Barker, Matrix solid phase dispersion (MSPD), J. Biochem. Biophys. Methods 70 
(2007) 151–162.  
[110] J. Gañán, S. Morante-Zarcero, A. Gallego-Picó, R. María Garcinuño, P. Fernández-
Hernando, I. Sierra, Evaluation of a molecularly imprinted polymer for determination of 
steroids in goat milk by matrix solid phase dispersion, Talanta 126 (2014) 157–162.  
[111] S. Nász, L. Debreczeni, T. Rikker, Z. Eke, Development and validation of a liquid 
chromatographic-tandem mass spectrometric method for determination of eleven coccidiostats 




[112] Q.-H. Zou, Y. Liu, M.-X. Xie, J. Han, L. Zhang, A rapid method for determination and 
confirmation of the thyreostats in milk and urine by matrix solid-phase dispersion and gas 
chromatography–mass spectrometry, Anal. Chim. Acta 551 (2005) 184–191.  
[113] G. Alberti, V. Amendola, M. Pesavento, R. Biesuz, Beyond the synthesis of novel solid 
phases: review on modelling of sorption phenomena, Coord. Chem. Rev. 256 (2012) 28–45.  
[114] Y. Chen, Z. Guo, X. Wang, C. Qiu, Sample preparation, J. Chromatogr. A 1184 (2008) 
191–219.  
[115] J. Pawliszyn, Theory of solid-phase microextraction, J. Chromatogr. Sci. 38 (2000) 270–
278.  
[116] H. Lord, J. Pawliszyn, Evolution of solid-phase microextraction technology, J. 
Chromatogr. A 885 (2000) 153–193.  
[117] H. Kataoka, K. Saito, Recent advances in SPME techniques in biomedical analysis, J. 
Pharmaceut. Biomed. 54 (2011) 926–950.  
[118] N. Khodaee, A. Mehdinia, R. Esfandiarnejad, A. Jabbari, Ultra trace analysis of PAHs 
by designing simple injection of large amounts of analytes through the sample reconcentration 
on SPME fiber after magnetic solid phase extraction, Talanta 147 (2016) 59–62.  
[119] A. Spietelun, M. Pilarczyk, A. Kloskowski, J. Namiesnik, Current trends in solid-phase 
microextraction (SPME) fibre coatings, Chem. Soc. Rev. 39 (2010) 4524–4537.  
[120] K. Kishida, Simplified extraction of tetracycline antibiotics from milk using a centrifugal 
ultrafiltration device, Food Chem. 126 (2011) 687–690.  
[121] P.T. Männistö, R. Mäntylä, S. Nykänen, U. Lamminsivu, P. Ottoila, Impairing effect of 
food on ketoconazole absorption, Antimicrob. Agents Chemother. 21 (1982) 730–733.  
[122] R. Padwal, R. Gabr, A. Sharma, L.-A. Langkaas, D. Birch, S. Karmali, D. Brocks, Effect 
of gastric bypass surgery on the absorption and bioavailability of metformin, Diabetes Care 34 




[123] S.D. Ladas, P.E. Isaacs, G.M. Murphy, G.E. Sladen, Comparison of the effects of 
medium and long chain triglyceride containing liquid meals on gall bladder and small intestinal 
function in normal man, Gut 25 (1984) 405–411.  
[124] D.R. Robertson, I. Higginson, B.S. Macklin, A.G. Renwick, D.G. Waller, C.F. George, 
The influence of protein containing meals on the pharmacokinetics of levodopa in healthy 
volunteers, Br. J. Clin. Pharmacol. 31 (1991) 413–417.  
[125] P.E. Luner, D. VanDer Kamp, Wetting characteristics of media emulating gastric fluids, 
Int. J. Pharm. 212 (2001) 81–91.  
[126] H.D. Williams, K.P. Nott, D.A. Barrett, R. Ward, I.J. Hardy, C.D. Melia, Drug release 





Chapter 2: Strategic drug analysis in fed-state gastric biorelevant 
media based on drug physicochemical properties  
Abstract 
Milk-based media such as the Fed State Simulated Gastric Fluid (FeSSGF) are commonly used 
in order to simulate the in vivo properties of the fed state stomach. Due to the lack of a specific 
guideline for standardised sample clean-up in these media, the aim of the current study was to 
develop an optimum protocol for the extraction and quantification of drugs from the fed state 
gastric medium based on the APIs’ physicochemical properties (lipophilicity, ionisation, 
aqueous solubility and protein binding). Two different extraction techniques, protein 
precipitation (PP) and solid phase extraction (SPE) were assessed. A pilot study in six model 
drugs was performed, with tests using seven different protein precipitation reagents at four 
different medium:reagent ratios and two drug concentrations as well as different solid phase 
extraction cartridges and elution protocols. % recovery was analysed using partial least squares 
(PLS) regression so as to determine the physicochemical parameters affecting the drug 
percentage recovered. For protein precipitation protocols, drug concentration, selection of 
protein precipitation reagent and ratio added to the medium significantly affected drug % 
recovery from FeSSGF (p < 0.05). The same applied for the selection of elution solvent and 
cartridge type for solid phase extraction. Optimum protocols using MeOH, ΑCN and 10% w/v 
TCA at a 1:2 FeSSGF:reagent ratio were effective to a larger group of drugs of a wide range 
of lipophilicity and ionisation, with ΑCN being the most effective in the whole range of log P 
values (-0.56-8.81). Solid phase extraction was proven to be effective for compounds of poor 
to moderate lipophilicity (log P < 4), with extremely hydrophobic compounds demonstrating 
lower % recovery values (down to 10% recovery). PLS demonstrated that only for 10% w/v 
TCA (protein precipitation) and HLB (solid phase extraction) can the effect of key drug 
physicochemical properties on the final amount of drug recovered be accurately predicted. 
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The presence of food in the gastric environment as a factor affecting drug dissolution 
and absorption has been extensively discussed in the literature over the last 30 years. Even 
though most drugs are mainly absorbed in the small intestinal environment, the role of the 
gastric environment is equally important; the stomach acts as a reservoir, with the presence of 
food having a significant influence on the absorption of drugs through various mechanisms 
such as delayed gastric emptying [1], increased gastric residence time [2] and interaction of 
drugs with meal components [3]. 
The FDA proposes the use of high fat standard meals for the determination of a drug’s 
food effect, as meals of high caloric and fat content can stimulate bigger changes in the 
gastrointestinal physiology and consequently have a more pronounced effect on drug 
bioavailability when this is affected by the presence/absence of food [4]. In theory, the optimal 
medium for the determination of food effect in vitro would be a homogenised standard meal, 
similar to the ones which have been successfully used for in vivo studies [5]. Due to difficulties 
in aspiration and handling of such a medium though [6], a range of biorelevant dissolution 
media has been developed in order to simulate the in vivo conditions of the fed state stomach. 
These media were developed with an aim of having the same physicochemical properties with 
the standard meal recommended by FDA for BA/BE studies [4]. 
Milk and milk-based media have been used as dissolution media for gastric fed state 
simulation for more than twenty years. Despite milk’s simplicity and convenience though, its 
energy content differs to that of a standard high-fat breakfast used in BA/BE studies [7] and 
does not accurately simulate the gastric fed state conditions, because of deviations in osmolality 
and buffer capacity compared to the FDA-proposed standard meal [5]. Moreover, its pH value 
is significantly higher (pH ≈ 6.5) than the gastric pH after a meal administration (5.8 ± 0.2 at 
50% of the meal emptied by the gastric compartment, liquid meal administered) [8]. In order 
to improve the gastric environment simulation, a milk-based medium called Fed State 
Simulated Gastric Fluid (FeSSGF) was developed. This medium consists of 3.5% fat milk, 
diluted with acetate buffer at 1:1 ratio [6, 9]. Three FeSSGF versions with different pH values 
have been used so as to mimic the three phases of gastric digestion with the pH values being 
6.4, 5.0 and 3.0 for the early, middle and late phases respectively [10]. Despite its limited ability 
to simulate the gastric fed conditions at each point of ingestion, middle phase FeSSGF is used 




[10]. Unlike aqueous media, laborious techniques are usually required for extraction of drug 
from these milk-based media. A study where the extraction process was avoided [11] used an 
ion selective electrode (ISE) sensor system with two electrodes constantly in the dissolution 
vessel offering the possibility of a continuous dissolution profile. The method though was 
limited to the analysis of ionised drugs, it required a complicated correction of the baseline and 
was unable to analyse compounds of extremely low aqueous solubility.  
Protein precipitation is the most frequently used sample clean-up technique, in which 
an organic reagent is added to the milk-based medium, followed by a centrifugation and a 
filtration step. Organic reagents like acetonitrile, added at 1:1 [12] and 1:2 [13, 14] 
FeSSGF:reagent ratios, isopropanol (1:1 ratio) [15] and ethyl acetate (1:4 ratio) [16] have been 
successfully used so far, but the rationale regarding the selection of the optimum reagent has 
not been yet clarified.  
Solid phase extraction (SPE) is another extraction technique widely used for the 
extraction of drugs from heterogeneous media and biological fluids such as whole blood [17], 
plasma [18], urine [19], and milk [20], often preceded by a protein precipitation step. SPE 
cartridges consist of a polypropylene tube with the sorbent placed between two porous frits. 
Most cartridges are either comprised of bonded silica phases, similar to the material of the 
reversed phase HPLC columns but with bigger diameter particles (10-60 µm), or of polymeric 
resins (e.g. polystyrene-divinylbenzene) [21]. 
So far, there has been no specific guideline for the treatment of each compound 
according to its characteristics and every drug is examined separately as far as its effective 
extraction and quantification in fed gastric biorelevant media are concerned [22]. Due to the 
absence of a general in vitro predictive test, the aim of this study was the development of an 
optimised protocol for drug quantification in fed gastric biorelevant media, towards the buildup 
of an in vitro predictive test of food effect observed in vivo. To achieve the above, an analytical 
protocol in milk-based fed gastric biorelevant media dictating the optimum sample treatment 
maximising the method sensitivity was developed, providing an analytical roadmap guide 
according to the drug’s physicochemical properties.  
For the current study, a series of compounds of a wide range of lipophilicity and 
ionisation were selected as model compounds for the development of the analytical protocol, 
assessing the efficiency of the two extraction techniques mentioned above; protein precipitation 




least squares (PLS) regression was used to understand the impact of certain variables (drug 
lipophilicity, aqueous solubility, drug ionisation properties and protein binding) on the 
performance of two commonly used sample clean-up techniques for drugs dissolved in milk-
based fed state biorelevant media. Its main advantage compared to the latter is its ability to 
analyse data with collinear independent variables [23]. To our knowledge, this is the first time 
the creation a general analytical guideline for a range of compounds in fed gastric media is 
being attempted. Moreover, an innovation of the study is the use of partial least squares 
regression in order to define the critical parameters which affect the efficacy of protein 
precipitation and solid phase extraction in fed gastric media, justifying their selection with 
statistical tools. 
2.2. Materials and Methods 
2.2.1. Materials 
Furosemide (≥ 98% (HPLC), (±)-metoprolol (+)-tartrate salt (≥ 98% (titration)), 1,1-
dimethylbiguanide hydrochloride (metformin hydrochloride, 97%), danazol (≥ 98%), 
itraconazole (≥ 98% (TLC)), celecoxib (≥ 98% (HPLC)), azithromycin (≥ 95% (NT)) and 
atovaquone (≥ 98% (HPLC)) were all purchased from Sigma-Aldrich, UK. Nifedipine (98 to 
102% (on dried substance)), paracetamol (97.5% min. (HPLC)), atorvastatin calcium 
(pharmaceutical secondary standard; traceable to USP, PhEur), atenolol (≥ 98% (TLC)) and 
ketoconazole (inclusive between 98%) were all purchased from Fisher Scientific, UK. 
Pravastatin sodium (≥ 98%) and lapatinib (≥ 99% (HPLC)) were purchased from Carbosynth, 
UK. MK-C1, MK-C2, MK-C3 and MK-C4 were provided by Merck & Co, INC, US. 
Sodium chloride, sodium hydroxide, sodium dodecyl sulphate, sodium acetate 
trihydrate, dipotassium hydrogen orthophosphate, potassium dihydrogen phosphate, 
ammonium acetate, hydrochloric acid 37% glacial acetic acid ≥ 99% and trichloroacetic acid 
10% w/v were all purchased from Fisher Scientific, UK. HPLC grade methanol, ethanol, 
acetonitrile, acetone, trifluoroacetic acid (≥ 99%) were all purchased from Sigma- Aldrich, UK.  
3.6% fat UHT milk was commercially purchased (Sainsbury’s, UK).  
Cronus 13 mm regenerated cellulose (RC) syringe filters 0.45 µm were purchased from 
LabHut Ltd, UK, Whatman 13 mm glass microfiber syringe filters 2.7 µm (GF/D) from Fisher 
Scientific, UK and SPE cartridges (Sep-Pak tC18 3 cc Vac Cartridge, 500 mg Sorbent per 




Cartridge, 37-55 µm Particle Size and Oasis HLB 1 cc Vac Cartridge, 30 mg Sorbent per 
Cartridge, 30 µm Particle Size) from Waters, UK.  
2.2.2. Instrumentation  
All samples were analysed in an HPLC system consisting of an Agilent 1200 series 
binary pump (G1312A), an Agilent 1200 series DAD detector (G1315D), an Agilent 1200 
series autosampler (G1329A), an Agilent 1200 series controller (G1316A) and a Chemstation 
software (Agilent Technologies, Santa Clara, United States).  
A pH meter Mettler-Toledo AG (model SevenCompact pH/Ion S220, Schwerzenbach, 
Switzerland), a centrifuge Hereus Biofuge Primo R (Thermo Scientific, Hanau, Germany), a 
vortex mixer Rotamixer (HTZ, Chesire, UK) and, a UV-Vis Thermo Spectronic Helios Gamma 
spectrophotometer (Thermo Scientic, UK) were used. 
2.2.3. Fed state medium selection 
Fed State Simulated Gastric fluid (FeSSGF) was selected as the working medium due 
to its simplicity in its preparation and stability for 72 h, with its pH, osmolality and buffer 
capacity remaining constant at ambient temperature [10]. Its buffer capacity, osmolality and 
surface tension values are in total closer to the values measured in vivo after the administration 
of a standard meal than the equivalent properties of milk, which has been extensively used as 
a gastric fed state medium in dissolution studies [24]. Finally, as it is less viscous than milk, its 
handing and loading/elution from the SPE cartridges was feasible without back pressure.  
2.2.4. Medium preparation  
Fed State Simulated Gastric Fluid (FeSSGF) was prepared according to Jantratid et al. 
[10], by mixing 3.6% fat milk and acetate buffer pH = 5 (17.12 mM CH3COOH, 29.75 mM 
CH3COONa, 237.02 mM NaCl in the medium) at a 1:1 volume ratio. For the preparation of 1 
L of medium, 500 mL milk and 480 mL buffer were mixed under constant stirring using a 
magnetic stirrer. pH was adjusted to 5 with 1 N HCl and the volume was adjusted to 1 L with 















2.1.5. Pilot study and selection of optimum conditions 
20 drugs of a wide range of physicochemical properties (lipophilicity, ionisation, 
aqueous solubility and protein binding) were selected as model compounds (Table 2.2). Six 
compounds were selected for the pilot study in order to assess the optimum extraction 
techniques and protocols and determine the parameters affecting the extraction technique’s 
efficiency. The rationale behind the selection of the compounds of the pilot study was the 
inclusion of active substances of a wide range of lipophilicity and ionisation properties, in order 
to assess their effect on the extraction method efficacy. The pilot study was performed on 
hydrophilic to extremely lipophilic (log P = -0.56–6.20) which included weak acids, weak 
bases and a neutral compound. Each compound’s % absolute recovery was expressed as 
described in the equation (Eq. 1.1) below, 
% absolute recovery= "#$%	'(	)$%*	'(	(+,-$#$.	%,+/0'-"#$%	'(	)$%*	'(	1-%2.%#.	1',0-+'2	'(	$/0+3%,$2-	4'24$2-#%-+'2	+2	%4$-%-$	50(($#	'#	6$78:	%4$-%-$	50(($#               (Eq. 1.1) 
where filtered aliquot denotes the filtered drug solutions after protein precipitation or 
elution from the SPE cartridge. 
In protein precipitation, four organic and three aqueous reagents were tested to 
determine the best % absolute recovery values; methanol (MeOH), ethanol (EtOH), acetonitrile 
(ΑCN) and acetone [organic reagents] and 2M HCl, 10% w/v trichloroacetic acid (TCA) and 
10% w/v trifluoroacetic acid (TFA) [aqueous reagents]. Four different FeSSGF:precipitation 
reagent ratios (1:1, 1:2, 1:3 and 1:5) were tested to determine possible differences in % absolute 




order to assess the method efficiency at a range of  drug concentrations. The parameter assessed 
in SPE was elution volume, using tC18 cartridge (2 mL and 5 mL). 
The efficiency of two extraction techniques [protein precipitation (PP) and solid phase 
extraction (SPE)] was investigated in the pilot study with the optimised protocol being applied 
to all compounds in Table 2.2. The optimum conditions (drug concentration, reagent and ratio) 
were selected and applied to all model compounds. The minimum efficiency limit for the pilot 
study was arbitrarily set to 50% (absolute recovery > 50%). Higher ratios (1:1, 1:2 were 
generally preferred due to higher method sensitivity (no need for dilution to overcome peak 
fronting). Similarly, for SPE, lower elution volume was preferred in case of similar recovery 








(mg/ mL) [25-29] 
log P  
[26, 28-41] 
pKa  
[28, 39, 42-50] 
Working 
concentrations 




Metformin hydrochloride 2.48 -0.56 12.40 2000/2 0.035 III 
Atenolol 1.11 (a) 0.23 9.60 200 0.129 III 
Paracetamol 1.24 (a) 0.30 9.50 200 0.124 III 
Furosemide -1 (b) 0.74 3.90 80/1 0.031 IV 
Metoprolol tartrate 1.01 1.95 9.70 200/10 0.244 I 
Pravastatin sodium -0.42 (b) 2.20 4.36 40 0.767 III 
Nifedipine -1.90 2.91 3.93 60/1 0.999 II 
Propafenone hydrochloride -0.82 (b) 3.39 9.27 600 0.957 II 
Celecoxib -2.52 (b) 3.47 11.10 100 0.975 II 
Ketoconazole -2.57 (a) 3.72 3.25, 6.22 150 0.986 II 
MK-C1 -2.53 (c) 4 (c) 6.5 (c) 35 0.908 N/A 
Azithromycin 3 (a) 4.02 8.74, 9.45 1000 0.558 II 
Danazol -3 4.20 none (b) 25/1 0.983 II 




Atovaquone -3.37 5.07 5.01 (b) 25 0.995 II 
MK-C2 -3 (c) 5.11 (b) 4.48, 5.74 (c) 1300 0.985 N/A 
Itraconazole -6 6.20 3.70 0.5/0.1 0.997 II 
Lapatinib -5.68 (a) 6.30 (a) 6.34 (a) 8.7 0.998 IV 
MK-C3 insoluble (c) 6.31 (b) 3.53 (c) 500 0.997 N/A 
MK-C4 -4 (c) 8.81 (c) none (c) 4.5 0.999 N/A 
(a) Sci-Finder  
(b) Calculated using Advanced Chemistry Development (ACD/Labs) Software V11.02 (© 1994-2016 ACD/Labs) 
(c) Data provided by Merck and Co, INC 
(d) “High” concentration/“Low” concentration: 
“High” concentration = !"#$	!&'(	(*$),--	 *. (/&0#*(	123456002	#'(!	47	$6'1"45	8(!	!4''&0#14&7	'1#!4(') or solubility in mik/FeSSGF (literature values) or 
performed solubility study (24 h) in FeSSGF. “Low” concentration = 10 x LOQ in acetate buffer, MeOH:buffer (1:1) or ΑCN:buffer 





2.2.6. HPLC analysis 
Stock solutions of the drugs were prepared in MeOH, EtOH, ΑCN or H2O, based on 
the drug solubility in the above solvents. Calibration standards were prepared in organic 
solvent:“blank” acetate buffer 1:1 (pH adjusted to 5) mixture or acetate buffer pH 5, (where 
organic solvent is MeOH, EtOH or ΑCN, according to drug solubility in organic solvents). The 
drugs were analysed in HPLC with published HPLC methods (or modifications of published 
methods) which are stated in Table 2.3. 
Adsorption studies were performed in triplicate for each model drug for all types of 





Table 2.3. HPLC methods (or modification of published methods) used for the quantification of the model compounds. 











Thermo Hypersil BDS 
C18, 300Å, 250 x 4.6 
mm, 5 µm 
MeOH:H2O 
60:40  
1 20 50 238 
Furosemide  
[52] 
Thermo Hypersil BDS 
C18, 300Å, 250 x 4.6 
mm, 5 µm 
MeOH:Formic acid 0.1% v/v  
60:40 
0.8 25 20 233 
Metoprolol tartrate  
[53] 
Thermo Hypersil BDS 
C18, 300Å, 250 x 4.6 
mm, 5 µm 
MeOH:TFA 0.1% v/v  
47:53 
0.8 10 50 274 
Danazol 
[54] 
Thermo Hypersil BDS 
C18, 300Å, 250 x 4.6 
mm, 5 µm 
MeOH:H2O  
85:15 




Vydac Diphenyl, 300Å, 
250 x 4.6 mm, 5 µm 
ΑCN:Phosphate buffer 0.02 
M 
(pH = 7) 70:30 
1 20 20 236 
Itraconazole  
[56] 
Thermo Hypersil BDS 
C18, 300Å, 250 x 4.6 
mm, 5 µm 
MeOH:H2O 80:20 1 35 100 260 
Celecoxib 
[57] 
Thermo Hypersil BDS 
C18, 300Å, 250 x 4.6 
mm, 5 µm 
MeOH:H2O  
70:30 






Waters Spherisorb S5 
ODS2, C18, 80Å, 250 x 
4.6 mm, 5 µm 
ΑCN:TFA 0.4% v/v 
70:30 
1.5 25 50 253 
Paracetamol  
[59] 
Thermo Hypersil BDS 
C18, 300Å, 250 x 4.6 
mm, 5 µm 
MeOH:H2O 20:80 1 10 20 257 
Ketoconazole  
[60] 
Thermo Hypersil BDS 
C18, 300Å, 250 x 4.6 
mm, 5 µm 
MeOH:H2O:DEA  
75:25:0.1 
1 25 50 260 
Atenolol  
[61] 
Thermo Hypersil BDS 
C18, 300Å, 250 x 4.6 
mm, 5 µm 
MeOH:Phosphate buffer 0.01 
M  
(pH = 4.5) 20:80 
1 25 50 240 
Azithromycin  
[62] 
Waters Symmetry C8, 
100Å, 250 x 4.6 mm, 5 
µm 
MeOH:Phosphate buffer 
0.3 M  
(pH = 7.5) 20:80 
1.2 40 100 210 
Pravastatin sodium  
[63] 
Agilent Eclipse XDB 
C18, 120Å, 250 x 4.6 
mm, 5 µm 
MeOH:Phosphate buffer 
0.03 M (pH = 7) 55:45 




Poroshell, 150 x 4.6 
mm, 2.7 µm 
ΑCN:Ammonium acetate 
0.05 M  
(pH = 4.5) 
Gradient (0-5 min 40:60/ 5-
13 min 58:42/ 13-17 min 
90:10/ 17-19 min 40:60) 







Agilent Eclipse XDB 
C18, 120Å, 250 x 4.6 
mm, 5 µm 
MeOH:ΑCN:TEA: 
H2O  
50:7.5:0.1: q.s 100 (pH= 2.9)  
0.8 25 20 248 
Atorvastatin calcium  
[66] 
Thermo Hypersil BDS 
C18, 300Å, 250 x 4.6 
mm, 5 µm 
ΑCN:Phosphate buffer 0.025 
M  
(pH = 6) 40:60 
1.5 30 50 246 
MK-C1* 
Waters Symmetry 
Shield C18, 100Å, 50 x 
4.6 mm, 5 µm 
ΑCN:Phosphate buffer 0.025 
M  
(pH = 2.5) 
Gradient (0-2 min 65:35/ 2-
2.01 min 90:10/ 2.01-3 min 
90:10/ 3-3.01 min 65:35) 
3 40 20 214 
MK-C2* 
Phenomenex Onyx 
monolithic C18, 300Å, 
100 x 4.6 mm 
ΑCN: 0.1% H3PO4 70:30 5 40 10 240 
MK-C3* Agilent Prorochell C18, 120 Å, 50 x 2.7 mm 
ΑCN:Sodium Phosphate 
0.005 M  
(pH = 7) 
Gradient (0-0.5 min 40:60/ 3-
3.5 min 10:90/ 3.51-5 min 
40:60 
1 40 25 250 
MK-C4* 
Phenomenex Onyx 
monolithic C18, 300Å, 
100 x 4.6 mm 
ΑCN:H2O 70:30 3.5 40 100 220 




2.2.7. FeSSGF solubility studies 
Where FeSSGF or milk solubility data was not available in the literature, drug 24 h- 
solubility values in FeSSGF were determined by using a modification of a protocol used by 
Wagner et al. in FeSSGF [15]. The solubility of the model compounds was determined by 
weighing excess amounts of the drug into 5 mL Eppendorf tubes, followed by the addition of 
5 mL of FeSSGF. The samples were left to equilibrate in a shaking water bath at 37 °C for 24 
hours, and then filtered through a GF/D filter of 2.7 µm pore size. 1 mL of ΑCN was added to 
0.5 mL of the filtered sample, vortexed for 30 sec and centrifuged (15 min, 8000 rpm, 4 °C). 
The supernatant, was filtered through a 0.45 µm RC filter, diluted and analysed using HPLC. 
Drug was quantified against calibration standards in FeSSGF which had undergone the same 
treatment as the sample. Each measurement was performed in triplicate. 
2.2.8. Protein precipitation (PP) 
2.2.8.1. Protein precipitation methodology  
1 mL of working solution of each drug in FeSSGF was placed in a plastic centrifuge 
tube. A volume of the protein precipitation reagent according to the FeSSGF:protein 
precipitation reagent ratios as defined below (1, 2, 3, 5 mL) was added. The mixture was 
vortexed at full speed for 30 sec and centrifuged at 8000 rpm (9800 × g) for 15 minutes (4 °C). 
The supernatant was filtered through a 0.45 mm RC filter and assayed. The sample was diluted 
with acetate buffer or MeOH:acetate buffer 1:1 when diluent was more highly eluting than the 
mobile phase and peak shape needed to be improved.  
2.2.8.2. Drug purity in the supernatant 
Full scans of the supernatants of the six drugs used in the pilot study plus atovaquone 
(a compound which demonstrated big differences in recovery between the three optimum 
reagents used.), with MeOH, acetonitrile and 10% w/v TCA used as protein precipitation 
reagents, were performed using the diode array detector of the HPLC instrument. Scans were 
performed over a range from 190 to 400 nm. Standards were prepared in a mixture comprising 
one part of buffer and two parts of PP reagent so as to maintain the same amount of precipitation 
reagent as the extracted FeSSGF samples with the selected reagents. Spectra of a supernatant 
after proteins were precipitated with a specific reagent and spectra of the same drug, dissolved 




normalised to peak intensity and superimposed using the “best possible match of the entire 
spectrum” mode in Chemstation software.  
2.2.9. Solid phase extraction (SPE)  
Three different types of cartridges were used: tC18 (500 mg bed weight), HLB (30 mg 
bed weight), C8 [(500 mg bed weight)-used for the extraction of metformin hydrochloride 
only]. The extraction cartridges were conditioned by washing with 5 mL [tC18 (trifunctional 
octadecyl silica), C8] or 1 mL MeOH (HLB), followed by 5 mL and 1 mL of H2O respectively. 
1 mL of FeSSGF was loaded and the columns were 5 washed with 5 mL and 1 mL of H2O 
respectively. The drugs were eluted with 5 or 2 mL MeOH:H2O 70:30 (tC18 and C8 cartridges) 
or 1 mL MeOH (HLB cartridges). The main difference between tC18 and classic C18 cartridges 
is the ability of the former to be used in extreme pH values (pH < 4 and pH > 7).  
As in the case of protein precipitation, a pilot study with the initial six compounds was 
performed and the optimal conditions of the parameters examined were applied for the rest of 
the model compounds. Modifications of the above protocols were performed in cases of % 
absolute recovery values < 50%, with different approaches according to each drug’s 
physicochemical properties and are described in detail in SPE protocol optimisation part of 
Results and Discussion section. Protocols were optimised by: modifications in cartridge 
conditioning (a. use of an ion-pair reagent, b. conditioning of the cartridge with an acid or a 
base so as to improve its retention characteristics) or modifications in elution (a. use of 
different elution solvents, b. addition of acid or base in elution solvent so as to increase its 
elution strength). Specifically: 
Metformin: A C8 cartridge which retains hydrophilic compounds better was used and 
either the washing step was omitted or the HLB cartridge was pre-treated with 2 mM Sodium 
dodecyl sulphate (SDS) solution before the loading step. SDS was selected based on the 
hypothesis that due to the stationary phase’s chemistry, the equilibration of the HLB cartridges 
with an ion pair reagent would lead to the retention of the drug to the cartridge through 
development of hydrophobic interactions between drug and cartridge with the complex easily 
be broken during the elution of the drug with an organic elution solvent [67]. Atovaquone, 
lapatinib, MK-C1, MK-C2, MK-C3, MK-C4: Elution with MeOH for the more effective 
disruption lipophilic interactions between the drug and the lipophilic chains of the tC18 




(weak base) on the cartridge (HLB) and elution with 0.25 M formic acid in MeOH for a more 
efficient elution in its ionised form. 
2.2.10. Statistical Analysis 
Comparisons were performed in order to assess significant changes in drug recovery 
using different precipitation reagents, medium:reagent ratios, drug concentration, different SPE 
cartridges and elution volumes. For protein precipitation, % absolute recovery and correlation 
with added protein precipitation reagent, (FeSSGF:reagent ratio) and drug concentration were 
evaluated in the context of a multiple way Analysis of Variance (ANOVA) (Statgraphics v. 
XVI, StatPoint Technologies Inc, US) with a post-hoc Bonferroni test. In solid phase 
extraction, effect of different elution volumes and cartridges on drug % absolute recovery were 
compared using a two-tailed t-test. (Statgraphics v. XVI). Comparisons where p < 0.05 
suggested a statistically significant difference.  
The absolute % drug recovery using different protein precipitation or SPE protocols 
was correlated to drug physicochemical properties by partial least squares (PLS) regression 
using the XLSTAT software (Microsoft, US). The parameters evaluated were: lipophilicity 
(log P), log aqueous solubility in mg/mL, drug unionised fraction at pH = 5, acid/base 
properties and drug protein bound fraction in plasma proteins (drug bound fraction to plasma 
proteins was used as a measure of protein affinity due to the lack of available data in milk 
proteins in the literature). The physicochemical properties selected as independent variables 
were decided on the basis of their potential effect on drug distribution in the aqueous and lipid 
phases of the medium and its interaction with milk proteins. PLS regression analysis was 
performed with % recovery of the three reagents used for the extraction of the 20 model 
compounds being the dependent variable. Selected interactions were also included in the model 
(log P*log aqueous solubility, log P*acid/base properties, aqueous solubility*drug unionised 
fraction, aqueous solubility*acid/base properties, unionised fraction*acid/base properties). The 
model quality was evaluated on the square of the coefficient of determination (R2) and 
goodness of prediction (Q2). R2 and Q2 values close to 1 refer to a model of good fit and 
prediction power respectively while a difference lower than 0.2-0.3 between them is indicative 
of a successful model [68]. Full cross-validation (leave-one-out procedure) was used to develop 
and evaluate the regression model. The optimum number of calibration factors for each model 
was selected based on the model’s optimum predictability (Q2) and predicted residual error 




predictability [69]. Lower PRESS values indicate better prediction [70] with the number of 
latent variables where PRESS starts increasing indicating the number of variables which to be 
retained in the model [71]. The standardised coefficients of the factors plotted indicate the 
relative positive/negative effect of their corresponding variables on the % drug recovery 
(response value). High standardised coefficients for variance X have a big positive or negative 
effect on response Y. The importance of each parameter was evaluated by its variable 
importance in projection (VIP) value. Values above 1.0 are considered to have a significant 
effect on the dependent variable, whereas values < 0.7-0.8 are not of significance for the 
prediction of the dependent variable [68].  
2.2.11. Roadmap design 
The roadmaps leading to selection of optimal protein PP and SPE protocols for drug 
analysis were constructed combining the results from the complete study for the 20 model 
drugs (and selected PP and SPE conditions) and the variables affecting the drug percentage 
recovered, as demonstrated by the PLS regression analysis. Only models with Q2 values > 0.5 
were considered for the roadmap design. For protein precipitation, optimum conditions were 
selected on the basis of absolute % absolute recovery. If absolute % recovery was > 85% for 
more than one reagent, MeOH or 10% w/v TCA were preferred over ΑCN, as they give peaks 
of better shape without the need of dilution. 
2.3. Results and Discussion 
2.3.1. Drug analysis: Optimisation of protein precipitation conditions 
2.3.1.1. Pilot study and selection of optimum extraction conditions  
When added to media containing proteins, organic reagents act by decreasing the 
dielectric constant of the proteins of the medium, a. increasing electrostatic interactions 
between them and b. displacing water molecules around their hydrophobic areas. Thus, their 
solubility in the medium decreases, leading to aggregation and protein precipitation [21]. 
All four organic reagents used (MeOH, EtOH, ΑCN, acetone) gave acceptable recovery 
values (> 69.5%) for the six model compounds in the pilot study with clear supernatants for 
drugs’ analysis in the HPLC after filtration (Figure 2.1). The only exception was EtOH when 
was as a precipitation reagent for danazol (Figure 2.1), which resulted in poor peak shape in 




Acidic reagents act by forming insoluble salts with the positively charged amino acids 
of a milk-based medium at pH below their isoelectric point [21]. The use of weak acids as 
protein precipitation reagents may be challenging for drugs demonstrating instability in acidic 
conditions. Hydrochloric acid, trichloroacetic acid and trifluoroacetic acid were particularly 
effective as precipitation reagents giving high recovery values (92.4–106.7%) for all ratios of 
hydrophilic (metformin, metoprolol) (Figure 2.1). They were not able to recover high amounts 
of the two most lipophilic drugs (danazol, itraconazole) from the medium though, with 2.4 ± 
0.1% maximum recovery at a 1:5 ratio for danazol and 0% recovery for all ratios for 
itraconazole achieved. As expected, a reason for the poor recoveries of lipophilic compounds 
in acidic reagents is their lower aqueous solubility, which is a barrier for the extraction potential 
of compounds of similar lipophilicity. The two weak acids (nifedipine, furosemide) were 
partially recovered using acidic reagents with the recovery percentage ameliorating by 
decreasing the FeSSGF:reagent ratio. The two weak bases (metformin, metoprolol tartrate) 
were almost 100% recovered at all ratios (Figure 2.1).  
	
Figure 2.1. Protein precipitation reagent-ratio-log P gradient map; contour plot of % recovery 
after protein precipitation of drug solution at “high” concentration in FeSSGF for the six 
compounds of the pilot study. “Warm” colours (red, orange) indicate high recovery values and 
“cold” colours (green, blue) indicate poor reagent performance. 
A three-way analysis of variance showed that the selection of protein precipitation 
reagent affected the % recovery values for all six drugs of the pilot study (p < 0.05) (Figure 
2.2). Acetonitrile was proven the most effective (higher mean absolute recovery) for three out 
of six drugs, acetone for two and ethanol for one compound respectively in terms of mean 
absolute recovery. The presence of NaCl in the medium can increase drug recovery when 
acetone is used as protein precipitation reagent. Crowell et al. [72] demonstrated that in acetone 




medium led to protein % recovery values close to 100% for a number of proteins, such as α-
casein, β-lactoglubulin and bovine serum albumin which are present in milk [73]. The effective 
entrapment of proteins in the precipitate possibly led to an increased amount of free drug 
available in the supernatant, resulting in higher recovery. Differences in efficiency among 
precipitation reagents can be attributed to the remaining proteins in the supernatant; since 
protein precipitation can only remove the larger proteins, leaving small proteins and peptides 
behind. These may interfere with the compounds of interest and have unpredictable effects 
(such as unexpectedly low drug recoveries) on drug quantification [21]. 
The effect of the FeSSGF:precipitation reagent ratio was evaluated in the pilot study 
for achieving maximum absolute drug recovery and adequate method sensitivity. Decreasing 
the medium:precipitation reagent ratio (from 1:1 to 1:5) did not show profound differences in 
drug absolute recovery as far as organic reagents were concerned. With the exception of 
itraconazole, for which the % absolute recovery increased from approximately 78% to 99.9-
106.6% when decreasing the FeSSGF:organic reagent ratio from 1:1 to 1:2, 1:3 and 1:5, all 
organic reagents resulted in % absolute recovery > 80% at all ratios used (Figure 2.2). A higher 
amount of organic solvent may increase the percentage of drug recovered by reducing solvation 
of the proteins in the aqueous medium, causing their precipitation. The statistical analysis 
showed that the ratio in which the precipitation reagent was added was statistically important. 
Reported p values for 4/6 drugs used in the pilot study were < 0.05 with the recoveries of 
metoprolol tartrate and danazol not being affected (p = 0.86 and 0.66 respectively) by the 
amount of precipitation reagent added (Figure 2.2). For the other drugs, 3 or 5 parts of protein 
precipitation reagent added in 1 part of FeSSGF resulted in higher % drug recovery than 1 part 
of reagent added to 1 part of FeSSGF prior to vortexing and centrifugation (Figure 2.1; red 
parts of the contour plot). Even though the differences among the protocols with different ratios 
were statistically significant, the difference may not always be practically important, as in most 
cases the method efficiency threshold set for the study (50% absolute recovery) was met. 
Nifedipine is given as an example; the addition of 1 part of methanol in 1 part of FeSSGF, 
recovered approximately 101% of the drug, while addition of 5 parts recovered approximately 
107% (Figures 2.1, 2.2). The same protocol by using 10% w/v TFA gave 26% and 72% values 
respectively. It is obvious that in the first case selection of a 1:5 ratio would not improve the 
extraction method but it would result in a loss of sensitivity, due to the bigger dilution of the 




therefore for a compromise, % recovery, desired method sensitivity and HPLC method 
compatibility with the medium have to be considered. 
Drug concentration had an effect on the percentage recovered using organic or aqueous 
solvents for protein precipitation. For the hydrophilic base (metformin), the % recovery values 
were not affected by the drug concentration (p > 0.05) (Figure 2.2). In all other drugs of the 
pilot study, drug at high concentration was more effectively recovered (p < 0.05). Similarly to 
the example given above for the effect of protein precipitation ratio, the average difference 
between recoveries of “high” and “low” concentrations as given by the post-hoc Bonferroni 
test lied within a range between 0.5 and 12.3% in the range of drugs studied, with the highest 
recovery observed for “high” concentrations. Despite the slight differences in absolute 
recovery between concentrations, the method can still be used for drug analysis if the 50% 
absolute recovery limit is met and linearity is proven in the working concentration range. 
Reagents added at a 1:3 or 1:5 ratios to FeSSGF often dilute the sample significantly, driving 
its recovery below the LOQ of the method for the “low” concentration (Figure 2.2).  
The reagents (two organic and one aqueous) selected were methanol, acetonitrile and 
10% w/v trichloroacetic acid at a 1:2 FeSSGF:reagent ratio with the rationale of selection 
explained in the Materials and Methods part. Since the pilot study proved that the volume of 
reagent added for protein precipitation was statistically important, a relatively high reagent: 
FeSSGF ratio was selected (1:2), so that high % recovery and adequate method sensitivity 
could be maintained. For the final study and assessment for the rest of the model compounds, 






	 p concentration p reagent p ratio  p concentration p reagent p ratio 
























Figure 2.2. Three-way ANOVA results of protein precipitation conditions for the six drugs of the pilot study. Graphs denote % drug recovery for 
all reagents at high (blue) and low (green) concentrations. Purple squares denote the FeSSGF:reagent ratio used in the protocol (* p < 0.05, ** p 





2.3.1.2. Main study and selected protocol application 
The two organic reagents used, methanol and acetonitrile, added at a 1:2 
FeSSGF:reagent ratio, gave high recovery values for all the compounds of a wide range of 
lipophilicity (log P = -0.56-8.81) and ionisation with the exceptions of atovaquone and MK-
C4. Atovaquone was only recovered by 33.4% at 25 µg/mL in FeSSGF when methanol was 
used, while acetonitrile recovered 82.2% of the same drug concentration (Figure 2.3). For 
extraction with acetonitrile, atovaquone studies in in plasma [74] and whole blood [75] gave 
similar results to our study. For methanol, since atovaquone’s solubility in it is much higher 
than the concentration used, a possible reason of the significantly low recovery values could 
be the loss of analyte due to its occlusion in the precipitate [76]. The drug’s extremely high 
affinity for plasma proteins (> 99.5% bound) [77] and its high affinity to fat, as described in in 
vivo studies which showed increased drug bioavailability after co-administration with a high 
fat meal [78], could indicate a strong interaction with fat or proteins of the fed state medium. 
This interaction may have not been disrupted by the application of methanol, with the drug 
being entrapped in the precipitate.  
The aqueous reagent (10% w/v TCA) added at the ratio mentioned (1:2) was proven 
effective only for highly soluble (aqueous solubility > 100 µg/mL) APIs with log P values < 2 
with the % recovery of weak bases (metformin hydrochloride, metoprolol tartrate, atenolol, 
paracetamol), approaching 100% (Figure 2.3). The above compounds were mostly unionised 
at pH 5 but were likely negatively ionised at the low pH of the acidic supernatant. Precipitation 
with trichloroacetic acid gave poor recovery values (0%) for atovaquone, because the drug as 
a lipophilic weak acid co- precipitated with the proteins [79]. The same applied for MK-C4, 
which is an extremely lipophilic drug with high affinity for adipose tissue [80].  
% recovery values lower than 100% when organic reagents were used for protein 
precipitation were probably not attributable to the interaction of the drug with protein 
molecules of the supernatant, but to its entrapment in the precipitate. This hypothesis was 
confirmed by superimposing the spectra of the supernatant and drug standards in an acetate 
buffer:precipitation reagent mixture. The drugs selected demonstrated variable % recovery 
values in the three reagents selected (methanol, acetonitrile, 10% w/v TCA). Nevertheless, the 
spectra were identical in all cases despite high or low % drug recovery values and no other 
interference was observed in the peak of the drug. Moreover, the retention time of all drugs in 




of the drug molecule (data not shown). Therefore, the results indicated that the drug quantified 
was the free drug in solution without any interference from the biological matrix.  
	
Figure 2.3. Mean % recovery values of the selected protein precipitation reagents (MeOH, 
ACN, 10% w/v TCA) for the 20 model drugs (Table 1), a. vs. log P and log of aqueous 
solubility in mg/mL, b. vs. log P and pKa, c. vs unionized fraction and log P and d. vs charge 
vs protein bound fraction as 3D scatter plots. 
2.3.1.3. Prediction of the effect of physicochemical properties on extraction protocol (PP) 
selection 
The variables and their interactions of the PLS models examined are summarized in 
Figure 2.4. The PLS models constructed for % recovery values when MeOH, ΑCN and 10% 
w/v TCA were used as protein precipitation reagents were defined by 1, 1 and 2 Principal 
Components respectively. The PLS model developed for 10% w/v TCA was a good fit to the 
experimental values (R2 = 0.87) and showed good predictive power (Q2 = 0.83). The models 
developed for MeOH and ΑCN can only account for a very low percent of Y variability (R2 = 
0.34 and 0.23 respectively), and have limited predictive power (Q2 = 0.24 and 0.05 
respectively), according to the threshold (Q2 = 0.5) set for the study. 	
The model demonstrated that lipophilicity (log P) is defined as negative predictor for 
% drug recovery in all three cases when MeOH, ΑCN and 10% w/v TCA were used as protein 




w/v being statistically significant, as indicated by the high VIP factor (Figure 2.4). A higher 
partition coefficient indicates higher tendency of the solutes distribution to the lipid phase of 
the medium [81], which could be limiting the extraction potential of the reagent. 	
In cases where methanol was selected as protein precipitation solvent, drug lipophilicity 
affected the extraction of compounds regardless of their ionisation state, with a bigger effect 
on neutral and acidic compounds (VIP > 1), and compounds being in the unionised state in the 
working pH, as indicated by the negative standardised coefficients of log P interactions with 
the properties mentioned. Drug distribution in the lipid medium fraction is facilitated for 
unionised drugs, as ionised molecules have to dispose a part of their hydration water in order 
to permeate the lipid bilayer, a process energetically unfavourable [82]. The above observations 
of the drug physicochemical properties which affect extraction from FeSSGF using methanol, 
denote that even though the effect of ionisation percentage does not have a significant impact 
by itself, it can have a negative effect of the amount recovered in lipophilic drugs.  
For the use of 10% w/v TCA in protein precipitation, the main factors governing the % 
recovery are the drug’s log P, drug bound protein fraction (negative effect) and its aqueous 
solubility (positive effect). Even though the exact mechanism of protein precipitation is not 
fully understood, a proposed mechanism of action suggests the segregation of the protein bound 
water, with the type of the proteins not affecting the method efficiency, which is also acid-
concentration dependent [83]. The concentration of TCA used in the current study may only 
be adequate to precipitate a portion of proteins, with the drugs highly bound to proteins being 
trapped in the precipitate. High lipophilicity and high aqueous solubility as negative and 
positive predictors respectively may be explained by the aqueous nature of the precipitation 
reagent. Moreover, the fact that the interactions of drug protein bound fraction with log P and 
aqueous solubility have a negative effect on drug recovery, strengthens our hypothesis that the 
inability of the TCA to break the drug-protein interactions under the stated experimental 
conditions is an unfavourable factor, even for the extraction of water soluble drugs. As 
observed in the pilot study, PLS regression showed that TCA is suitable reagent for highly 
soluble weak bases (positive log aq sol*base interaction, Figure 2.4), while it affects the 
extraction of lipophilic bases or bases which are unionised in the medium’s pH in a negative 
manner, which was demonstrated by the negative log P*base and union fr*base negative 




The lack of the model’s predictive ability when ΑCN was used as a PP reagent can be 
explained by the reagent’s extremely high extraction ability in the whole range of drugs (> 90% 
recovery for 17/20 drugs studied) and low variance, with most values falling close to 100%. 
	
Figure 2.4. Variable importance in the projection (VIP) plot with the variables classed 
according to their importance of the response (left) for the selected protein precipitation 
protocols. Standardised coefficients corresponding to the variables (and their interactions) 
studied. Green colour denotes coefficients of VIP values > 1, which are considered influential 




2.3.1.4. Designing a roadmap for effective sample treatment using protein precipitation 
In summary, MeOH and ΑCN can be effective for drugs of a wide range of lipophilicity 
and the use of one of the other is usually effective for drugs of log P values of -0.5 to 5 (Figure 
5). For hydrophilic to moderately lipophilic bases (metformin, metroprolol tartrate, log P < 2), 
the use of 10% w/v TCA was preferred over the two organic solvents, due to a better peak 
shape in the HPLC analysis. According to the findings of the PLS regression analysis, TCA is 
the most efficient reagent (higher absolute % recovery) for highly soluble drugs and drugs 
which exhibit a low affinity for proteins. Drugs of moderate lipophilicity were equally well 
recovered using either MeOH or ΑCN, therefore, both reagents could be used for the extraction 
of drugs of log P between 2 and 5. Issues with low % recovery with the use of MeOH were 
only encountered some drugs of extreme lipophilicity (log P > 5), for which ΑCN was the most 
effective option (atovaquone, MK-C4). Consequently, ΑCN would be the best choice of the 
three reagents (Figure 2.5), as drugs at this log P range were in all cases at more than 80% 
which could give absolute recoveries as low as 24 and 0% respectively. 
	
Figure 2.5. Roadmap of protein precipitation conditions selected for maximum % drug 





2.3.2. Drug analysis: Optimisation of solid phase extraction conditions 
2.3.2.1. Pilot study and effect of elution volume 
The results of the pilot study, where tC18 cartridge was selected as a starting point are 
presented in Figure 2.6b. It can be seen that the specific cartridge can be effectively used for a 
range of compounds from moderately polar to non-polar. Drugs of log P between 0.74 and 4.2 
were recovered at a percentage higher than 60% (Figure 2.6b). Even though the minimum 
elution solvent (2 mL) is higher than two bed volumes (500 mg sorbent = 600 µL bed volume) 
which is required for effective extraction [21], it was shown that elution with 5 mL increased 
the % recovery values by a significant amount (p < 0.05) compared to 2 mL for all compounds 
of the pilot study (from 6.5% increase for nifedipine to 1700 % increase for danazol) (Figure 
2.6b). Therefore, 5 mL were selected as the elution volume to proceed with the rest of the 
model compounds.  
	
Figure 2.6. a. % recovery values of model drugs using the SPE protocols for tC18 and HLB 
cartridges. b. % recovery values of model drugs of pilot study using different elution volumes 
(tC18 SPE cartridge). Stars denote significant differences between % recoveries of a. different 
cartridges and b. elution volumes (b) (* p< 0.05, ** p < 0.01, *** p < 0.001, two-sided t-test). 
2.3.2.2. Effect of cartridge 
The results of the complete study where the cartridges and elution conditions selected 




generally be used for a range of compounds from moderately polar to non-polar. Non-polar 
parts of the analyte develop Van der Waals interactions with the C18 non-polar groups of the 
sorbent, leading to selective retention of the analyte of interest, before its elution with an 
appropriate elution solvent. HLB was another type of sorbent used in this study and is a co-
polymer comprised of two different monomers; one hydrophilic (N-vinylpyrrolidone) and one 
hydrophobic (divinylbenzene). The use of HLB cartridges has also been found to be effective 
for both polar and non-polar compounds [84]. 
For compounds of log P values between 1.95 and 4, there was no clear pattern as to 
which should be selected in favour of the other for optimum % recovery values using log P as 
a selection criterion. Nevertheless, the use of one or the other cartridge (tC18 or HLB) in 
compounds of moderate lipophilicity (log P 2-4) recovered a minimum value of 69.5% of the 
initial compounds in FeSSGF for the optimum protocol at each case (Figure 2.6a). MK-C1, a 
compound on the verge of the threshold set for moderate lipophilicity (log P = 4) was poorly 
recovered in all cases 1.76 ± 0.33% and 0.15 ± 0.0 %for tC18 and HLB cartridges respectively. 
Its recovery was not improved despite protocol modification (tC18 and elution with MeOH, 
recovery = 8.80 ± 0.61). 
For most hydrophilic and lipophilic compounds, HLB was proven more effective, as it 
increased the % recovery values of the compounds which could not be effectively extracted (< 
15% absolute recovery) using tC18 cartridges (metformin hydrochloride, paracetamol, 
atovaquone, itraconazole, MK-C1, MK-C2, MK-C4), but not always to a great extent. For the 
drugs which could not be effectively extracted with the protocol used with tC18 cartridges, a 
switch to HLB achieved a meaningful improvement in extraction performance only for 
paracetamol MK-C2 (Figure 2.6a).  
SPE was incompatible with the extremely lipophilic model drugs studied. Using the 
current protocols, the recoveries of drugs of extreme lipophilicity (log P > 5) were higher with 
the use of HLB cartridges but still relatively low (5.7 ± 0.2%, 27.9 ± 0.7%, 22.1 ± 3.5% and 
0% against 1.9 ± 0.1%, 0 %, 15.3 ± 0.2% and 0% for tC18, for atovaquone, itraconazole, 
lapatinib, and MK-C4 respectively (Figure 2.6a). Previous studies with extraction of 
itraconazole with HLB cartridges from biological matrices demonstrated higher recovery 
values than the ones presented in this study. Although HLB cartridges have been more 
successfully used for extraction of itraconazole, these studies were in blood, [85] plasma [86] 




used. The modification proposed in the methodology did not improve the recovery of the drug 
(Figure 2.7). The low recoveries of the extremely lipophilic compounds and the lack of pattern 
in terms of cartridge selection for the extraction of the moderately lipophilic compounds could 
indicate that the critical parameter for SPE optimisation is not the log P value of an API, but 
the type of interactions it develops with components (lipids, proteins) of the milk-based matrix. 
For atovaquone, 5 mL MeOH were also tested with tC18 cartridge giving somewhat better 
results but still low recovery values (17.5 ± 0.6 %) (Figure 2.7). The poor SPE recovery values 
for the specific drug, along with the low % recovery when MeOH was used in protein 
precipitation, supports the initial hypothesis that strong interaction with components of the fed 
state medium could be the main obstacle which has to be surpassed for effective extraction. In 
the cases of lapatinib, MK-C2, MK-C3 and MK-C4, 100% methanol was used as elution 
solvent in order to increase the protocol efficiency with tC18 cartridges with the stronger elution 
volume improving the percentage of drug eluted significantly in all drugs apart from MK-C3 
(Figure 2.7).  
For hydrophilic drugs (log P < 2), significant difficulties in effective drug recovery 
were encountered only in the case of metformin. Metformin is an extremely polar molecule 
which lacks hydrophobic functional groups. It was suggested that, due to the molecule’s 
polarity, retention on the cartridge’s hydrophobic functional groups was poor. While SDS 
conditioning did improve the recovery of metformin, the amount of drug recovered was still 
low (< 10%, data not shown). The most effective strategy in the case of metformin was the 
omission of the washing step. The omission of the washing step (tC18 and HLB cartridges), 
which improved the % recovery significantly (≈ 34% and 20% respectively-data not shown), 
was a far more effective strategy. Its combination with a change to a more hydrophilic cartridge 
like C8, a recovery value of 49.6 ± 1.9% was achieved (Figure 2.7). The functionalization of its 
silanol groups comprises of chains of eight carbon molecules instead of the eighteen like in 
tC18, therefore it is suggested that the drug is retained to the column via weaker hydrophobic 





Figure 2.7. % recovery values of model drugs after modification of the standard SPE protocols.  
Our observations for metformin and itraconazole (extremely hydrophilic and extremely 
lipophilic compounds respectively) (Figures 2.6a, b) were in agreement with previous studies 
which suggested that C18 cartridges are often a poor choice for drugs of extreme or poor 
hydrophilicity. Metformin [88] and itraconazole [89] were recovered by < 20% and < 40% 
respectively when eluted from C18 cartridges using methanolic solutions (studies in aqueous 
solutions and human liver microsomal’ fraction respectively). Recoveries using the two 
different cartridges were significantly different in the majority of cases, (p < 0.05, 16/20 drugs), 
in the range of model compounds studied (Figure 2.6a), meaning that selecting one over the 
other can have a significant impact on the amount of drug to be recovered using a specific 
protocol in a study. 
2.3.2.3. Prediction of the effect of physicochemical properties on extraction protocol (SPE) 
selection 
 The variables and their interactions of the PLS models examined are summarized in 
Figure 2.8. The PLS models constructed for % recovery values when tC18 and HLB cartridges 
were used (standard protocol) were defined by 1 and 3 Principal Components respectively. The 
PLS model developed for HLB was a good fit to the experimental values (R2 = 0.87) and 
showed good predictive power (Q2 = 0.83), while the model developed for the SPE extraction 
using a tC18 cartridge can only account for a low percent of Y variability (R2 = 0.34), and has 
poor predictive power (Q2 = 0.24). In both cases, the parameter having the most prominent 
positive effect was the log P*log aqueous solubility interaction (Figure 2.8), which is attributed 
to retention of a higher amount of drug in the SPE cartridge during the initial loading step, and 




tC18, drug lipophilicity alone, but also its interactions with basic and neutral compounds, 
affected drug extraction negatively. The same applied for compounds which act as ampholytes 
in an aqueous environment while acidic compounds were easier to extract (positive 
standardised coefficient for weakly acidic compounds, VIP > 1). The recovery dependence of 
the compounds’ ionisation state can be attributed to the presence of ionic interactions between 
charged drugs with the residual silanol groups of the cartridge which are unable to break with 
unbuffered MeOH:H2O elution solvents [90]. Similar conclusions were deducted from the PLS 
regression model for HLB, with the difference being the negative correlation between log P 
and extraction efficiency, which was only present for unionised drugs in the working pH (log 
P*union fr interaction, Figure 2.8). The positive effect of aqueous solubility and its interaction 
with log P can be attributed to the more effective elution of polar compounds, when eluted with 
MeOH.  
	
Figure 2.8. Variable importance in the projection (VIP) plot with the variables classed 
according to their importance of the response (left) for the selected SPE protocols. Standardised 
coefficients corresponding to the variables (and their interactions) studied. Green colour 





2.3.2.4. Designing a roadmap for effective sample treatment using solid phase extraction 
In summary, tC18 and HLB cartridges can be effectively used for drugs of low to 
intermediate lipophilicity (log P = 0-5) while for extremely hydrophilic compounds, the use of 
C8 cartridge and the omission of the washing step (where possible) were the most effective 
options (Figure 2.9). In the whole range of compounds, it was shown that both HLB and tC18 
cartridges can be used, with HLB being more efficient for highly soluble drugs and also for 
weak acids, which are fully unionised at the working pH. Therefore, for highly soluble or 
weakly acidic compounds of log P between 0 and 5 the use of HLB cartridges is suggested. For 
drugs of extreme lipophilicity (log P > 5), increasing the strength of the elution solvent to 100% 
organic content usually increased the amount of drug recovered, but in certain cases recovery 
did not exceed 10-20% despite the attempted modifications of the initial protocol. Taking that 
into consideration, we suggest the use of 100% MeOH as elution solvent for compounds of 
extreme lipophilicity (using either one of the cartridges). HLB is suggested as the SPE cartridge 
of choice for the same reason as in compounds of moderate lipophilicity. For extremely 
lipophilic compounds (log P < 0), alternative cartridges could must possibly be used (e.g. C8) 
for maximum efficiency, and if the medium permits, the washing step after sample loading in 
order could be omitted so as to maximise the amount of compound still retained on the cartridge 
before the elution step.  
	
Figure 2.9. Roadmap of solid phase extraction conditions selected for maximum % drug 





Prediction of gastric food effect on drug absorption has been a big challenge for the 
pharmaceutical industry. Even though the in vivo properties of the fed state gastric environment 
have been quite well determined and some progress has been made with the development of 
gastric biorelevant media, a universal robust predictive analytical method has not been yet 
developed. The utility of such a method will allow the effective extraction and drug 
quantification of a range of drugs in heterogeneous fed biorelevant media selected on the basis 
of properties related to the medium, active ingredient or both. The above would drive drug 
analysis towards more standardised protocols and away from the current drug-by-drug 
assessment for optimal treatment conditions. The current study assessed the effective 
quantification of drugs, based on their physicochemical properties from milk-based media 
using two extraction techniques: i. Protein precipitation and ii. Solid phase extraction. The 
current study demonstrated that the use of three precipitation reagents (methanol, acetonitrile 
and 10% trichloroacetic acid) at a FeSSGF:reagent ratio of 1:2, when used according to the 
guidelines proposed, provided a simple sample preparation method which can be decided based 
on drugs’ selected physicochemical properties. 10 % trichloroacetic acid was mostly suitable 
for weak bases of log P < 2, while either methanol or acetonitrile were effective for all the other 
model drugs. It has also been shown that the solid phase extraction protocols proposed using 
three different cartridges (tC18, C8 and HLB) provided good sample treatment methods for all 
drugs of a wide range of log P values (0.30–4) achieving recovery values > 69.5%. 
Modifications of the initial protocols, involving cartridge treatment and different elution 
solvents, improved the % recovery of the extremely lipophilic and extremely hydrophilic model 
drugs (9-60%), but with results still indicating that solid phase extraction is possibly not the 
method of choice for drugs of higher lipophilicity. Knowledge of the drug’s key 
physicochemical properties is critical for the selection of the optimum extraction protocol for 
milk-based fed state media. In this study, the effect of the drug’s physicochemical properties 
(lipophilicity, ionisation, aqueous solubility, protein affinity) and their interactions on recovery 
efficiency from fed state media were assessed, allowing the selection of the optimum extraction 
tool for drug quantitative analysis. The roadmaps developed for the two extraction techniques, 
can provide a starting point towards the development of a unified guideline, where selection of 
the extraction method can be made on the drug physicochemical profile. It is evident though 
that further studies are required for the elucidation of the analytical profile of a range of 
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Chapter 3: Impact of presence of excipients in drug analysis in fed-
state gastric biorelevant media 
Abstract 
 In this study, the impact of the presence of excipients in drug analysis in milk-based media 
which simulate the in vivo properties of the fed state stomach was investigated. 15 excipients, 
normally present in solid dosage forms of five APIs tested (atenolol, paracetamol, furosemide, 
nifedipine and propafenone hydrochloride) were mixed (one at a time) with the active 
pharmaceutical ingredient of interest either via vortexing, co-grinding or shaking of the 
physical mixture and dissolved in FeSSGF. The objective of the study was the assessment of 
the extraction efficiency of three protein precipitation protocols (using MeOH, ΑCN and 10% 
w/v TCA), typically used in drug analysis, in milk-based biorelevant media in the presence of 
the excipients. The efficiency of three different protein precipitation reagents in powder 
mixtures was compared against the equivalent drug amount recovered in the absence of the 
excipient in Fed State Simulated Gastric Fluid (FeSSGF). Most excipients had a significant 
negative effect (p < 0.05) on drug recovery in the milk-based medium as indicated by the 
multiple linear regression (MLR) analysis performed. For magnesium stearate and HPMC, the 
% recovery values were the lowest in four out of the five drugs studied, with a range of 10-
100% depending on the API, mixing technique and protein precipitation protocol selected. The 
negative excipient-dependent effect was more profound in nifedipine and propafenone 
hydrochroride, the most lipophilic compounds of the study. Acetonitrile was the most effective 
protein precipitation reagent for most drugs in the presence of excipients, followed by methanol 
and 10% w/v trichloroacetic acid. Data analysis also revealed a dependence of the extraction 
method efficiency on the medium lipid content. Application of the above extraction protocols 
in commercially available formulations highlighted the need for assessment of the effect of 
excipients in extraction efficiency, before transferring the method directly to dissolution studies 
of formulations in milk-based fed gastric media. In conclusion, the presence of excipients and 
the selection of protein precipitation protocol are parameters which can affect significantly the 
efficiency of protein precipitation when FeSSGF is used as dissolution medium and need to be 
taken into consideration when developing a quantitative method based on the above sample 
clean-up technique. 






Poor drug solubility has always been one of the biggest challenges the pharmaceutical 
industry has had to overcome. Approximately 40% of marketed drugs are classified as poorly 
soluble, while 90% of the drugs entering the screening process during drug development have 
a poor solubility according to Biopharmaceutics Classification System (BCS) [1]. Therefore, 
different formulation strategies were employed in order to improve the solubility and 
dissolution characteristics of the active pharmaceutical ingredients (APIs). Several cases where 
excipients such microcrystalline cellulose [2], kaolin [2], starch [3] and PEG 4000 [4] were 
used so as to improve the dissolution characteristics of poorly soluble drugs have been reported 
in the literature.  
A second challenge concerns the media used for drug in vitro dissolution testing. 
Dissolution tests, as dictated by the United States Pharmacopoeia (USP) [5], cannot always 
provide information on the behaviour of the drugs in vivo, and therefore the need for multi-
phase dissolution media able to simulate the gastrointestinal environment arose. The 
employment of media more “biorelevant”, targets to simulate the passage of the formulation 
through the different compartments of the gastrointestinal tract both in the fasted and fed states. 
The use of such media can contribute towards the correlation of the results of the drug in vitro 
release with its in vivo pharmacokinetic performance (IVIVC), with an aim to decrease the 
number of in vivo studies conducted pre- and post-approval [6]. As far as gastric fed 
environment is concerned, the media developed could be classified in two categories: i. milk-
based media, such as full-fat milk, digested milk and Fed State Simulated Gastric Fluid 
(FeSSGF) and ii. Lipid emulsions, such as Ensure®, Ensure Plus® and Intralipid® [7]. The 
media of the above two categories were developed as an attempt to simulate the gastric 
environment after the administration of a high or low fat standard breakfast respectively [8]. 
The composition of such media is constantly updated [9] and takes into consideration the 
protein/carbohydrate/lipid ratio and content as well as the fed gastric physicochemical 
properties measured in vivo [8, 10], making reasonable compromises. A disadvantage in the 
use of such media concerns their treatment prior to the sample analysis, which usually requires 
laborious steps for the extraction of drug before its quantification. 
When a formulation is dissolved in such media, interactions may be formed between 
the excipients (excipient-excipient interactions) and also between the excipient and the active 




interactions). Not only can such interactions affect the solubility and dissolution rate of the 
drug in biorelevant media, but they can also play a role in the design of sample clean-up 
techniques, the effectiveness of which may be compromised if only designed based on the 
physicochemical properties of the APIs. Therefore, an appropriate design would elucidate the 
role of excipients in the analysis in heterogeneous biorelevant media, such as the milk-based 
media used for the simulation of the gastric fed state in dissolution studies, with the current 
study focusing on the last two types of interactions. The type of interactions between drugs and 
excipients are described as physical or chemical [11], depending on their ability to induce 
chemical changes in the drug or excipient. Binding of drugs which have primary amine 
functional groups in the molecule to microcrystalline cellulose is a typical example of a 
physical interaction, leading to drug entrapment in the cellulose [12]. Primary amines can also 
interact with double bonds of certain excipients, like sorbitan monooleate via a reaction 
analogous to Michael addition, which is considered a chemical interaction. Changes in the 
excipient behavior, as a result of their interaction with the heterogeneous gastric environment, 
have been characterised a challenge which needs to be addressed in drug dissolution and 
analysis [13]. A known example of interactions between excipient and medium involves 
polyvinylpyrrolidone, which can form hydrogen bonds with water molecules through its 
carbonyl group [14], and undergo phase separation in aqueous 1.5 M KF solutions. In cases 
where the milk-based or lipid emulsion-gastric biorelevant media of interest are used in drug 
dissolution studies, such medium-excipient interactions may be even more complicated. The 
formation of protein and fat gel layers around hydroxypropyl methylcellulose (HPMC) 
matrices, which could potentially affect drug extraction when nutrient drinks or milk are used 
as dissolution media, is a typical example of medium-excipient interaction [15, 16].  
In the present study, we investigated the impact of the presence of excipients in drug 
extraction when dissolved in the milk-based gastric fed state biorelevant media. Three 
hydrophilic (paracetamol, atenolol, furosemide) and two moderately lipophilic (propafenone 
hydrochloride and nifedipine) drugs were selected as model compounds. The excipients 
selected for the study consist of binders, lubricants, extended release matrix agents, emulsifiers, 
wetting agents and disintegrants. Hydroxypropyl methylcellulose is the most common 
cellulose used in hydrophilic matrices. It is used as a binder and also provides extended release 
characteristics to oral dosage forms [17, 18]. Magnesium stearate and stearic acid are used as 
tablet and capsule lubricants, avicel (microcrystalline cellulose) as binder and lubricant and 




employed as emulsifying, solubilizing and wetting agents [18]. Polyethylene glycols have 
various uses, such as suspending agents, co-solvents, binders, plasticizers or lubricants, 
depending on their solid state and molecular weight [18]. Croscarmellose sodium is used as 
disintegrant in tablets and capsules and Eudragit L100 and Eudragit E are brand names for 
polymethacrylate copolymers used as drug coatings for enteric drug delivery and taste masking 
respectively [19]. Finally, carbomer 974P is used as a binder and also as suspending, gelling 
and emulsifying agent [18]. Drug analysis in commercially available formulations was also 
assessed. The impact of excipients in drug analysis in a fed gastric medium was analysed using 
a regression analysis method [multiple linear regression (MLR)]. The study is a follow up of a 
previous study [20], where the impact of the active ingredients’ physicochemical properties 
(log P, ionisation, aqueous solubility and protein binding) on analysis in FeSSGF using 
different extraction protocols (protein precipitation and solid phase extraction) was assessed. 
The objective of this work is the investigation of the impact of excipients in the efficiency 
(given by the percentage of drug recovered) of the protein precipitation protocols, developed 
and optimized for the analysis of the APIs. Except for the drugs’ physicochemical properties, 
the current work aims to assess the dependence of drug-excipient mixing technique, protein 
precipitation extraction method, and dissolution medium’s lipid content in an attempt to 
provide further insight towards the optimization of drug analysis in fed state media, and the 
analytical methods’ application in formulations. 
3.2. Materials and Methods 
3.2.1. Materials 
Furosemide (≥ 98% (HPLC)) and propafenone HCl (≥ 98% (HPLC)), were purchased 
from Sigma- Aldrich, UK. Nifedipine (98.0 to 102.0% (on dried substance)), paracetamol 
(97.5% min. (HPLC)) and atenolol (≥ 98% (TLC)) were purchased from Fisher Scientific, UK.  
Sodium docecyl sulfate (≥ 99.0%) (GC)), povidone K30 (meets USP testing 
specifications), PEG 400 (202398), hydroxypropyl methylcellulose (H7509), were purchased 
from Sigma- Aldrich, UK. PEG 300 (Eur Pharm), stearic acid ((≥ 99.0%) (GC)) and PEG 6000 
were purchased from Merck Millipore, UK. Microcrystalline cellulose (Ph-302) and 
croscarmellose sodium, (NF, Ph. Eur., JP) were purchased from FMC Biopolymers, UK. 
Carbomer 974P (Carbopol), PEG 4000 and magnesium stearate (Ph.Eur., BP, USP) were 
purchased from Fischer Scientific, UK. Tween 80 was purchased from VWR. Eudragit E 




Adalat® LA 30 mg tb and Arythmol® 300 mg tb were bought from Bayer, UK and 
Abbot Healthcare, UK respectively. 
Cronus 13 mm regenerated cellulose (RC) syringe filters 0.45 µm were purchased from 
LabHut Ltd, UK. Whatman 13 mm glass microfiber syringe filters 2.7 µm (GF/D) were 
purchased from Fisher Scientific, UK. 
Sodium acetate trihydrate, hydrochloric acid (36.5-38%), glacial acetic acid (≥ 99%), 
trichloroacetic acid 10% w/v and all phosphate salts were purchased from Fisher Scientific, 
UK. HPLC grade methanol, acetonitrile, trifluoroacetic acid (≥ 99.0%) and formic acid were 
all purchased from Sigma- Aldrich, UK.  
0, 3.6 and 5% fat UHT milk was commercially purchased (Sainsbury’s, UK). 
3.2.2. Instrumentation  
All samples were analysed in an HPLC system consisting of an Agilent 1200 series 
binary pump (G1312A), an Agilent 1200 series DAD detector (G1315D), an Agilent 1200 
series autosampler (G1329A), an Agilent 1200 series controller (G1316A) with a Chemstation 
software (Agilent Technologies, Santa Clara, United States).  
A pH meter Mettler-Toledo AG (model SevenCompact pH/Ion S220, Schwerzenbach, 
Switzerland), a centrifuge Hereus Biofuge Primo R (Thermo Scientific, Hanau, Germany) and 
a vortex mixer Rotamixer (HTZ, Cheshire, UK) were used.  
3.2.3. Medium selection and preparation  
Fed State Simulated Gastric fluid (FeSSGF) was selected as the working fed state 
medium due to its simplicity in its preparation. Its buffer capacity, osmolality and surface 
tension values are overall closer to the values measured in vivo after the administration of a 
standard meal than the equivalent properties of milk, which has been extensively used as a 
gastric fed state medium in dissolution studies [21]. FeSSGF was prepared according to 
Jantratid et al. [9] by mixing 3.6% fat milk and acetate buffer pH = 5 at a 1:1 volume ratio. 
Volume was adjusted to pH with 1 N HCl. Except for the standard version, two other different 






3.2.4. Selection of drug-excipient combinations  
Assessment of the impact of excipients on % recovery in FeSSGF was conducted for 
five drugs (atenolol, paracetamol, furosemide, nifedipine, propafenone hydrochloride) selected 
from the study which involved the optimisation of extraction protocols for 20 APIs of a wide 
range of lipophilicity, ionisation and aqueous solubility [20]. Drug working concentration was 
defined as the drug dose dissolved in 500 mL of medium, unless limited by the solubility of 
drug in FeSSGF (Table 3.1). The current study assessed the effect of 15 excipients commonly 
used in commercial formulations of the above drugs (Table 3.2), using the optimised protein 
precipitation protocols for the quantification of active pharmaceutical ingredients developed in 
the previous study [20]. In summary, the extraction protocol involves addition of 2 parts of 
either MeOH, or ΑCN or 10% w/v TCA in 1 part of medium, brief vortexing (30 sec), 
centrifugation (8000 rpm, 15 min, 4 °C) and filtration through a regenerated cellulose 0.45 µm 
filter. The sample was diluted with “blank” acetate buffer pH 5 or MeOH:acetate buffer 1:1 pH 
5, according to the drug solubility, where peak shape needed to be improved. The excipients 
used were selected based on the ones present in their commercial formulations as given in the 
Electronic Medicines Compendium (eMC) [22]. The percentage of the drug in the mixture was 
arbitrarily set as 30% w/w of the formulation. Extraction efficiency was given by drug absolute 
% recovery, expressed as per Eq. 2.1 below, 
% absolute recovery =	"#$%&'	$(	)*%+	,&	)*%+-./0,1,.&'	#,/'%*.	2.3342	5$6%',$&"#$%&'	$(	)*%+	,&	5'"&)"*)	2.3342	5$6%',$&           (Eq. 2.1) 
where the amount of drug in the presence and absence of excipient was quantified 
against calibration standards of the drug in FeSSGF, with both the mixture and drug standards 
treated with the same protein precipitation reagent. 
Table 3.1. Physicochemical properties and working concentrations of model compounds. 





Atenolol 0.23 9.60 200 
Paracetamol      0.46  9.50  200 
Furosemide 0.74 3.90 80 
Nifedipine 2.91 3.93 60 
Propafenone 
hydrochloride 





Table 3.2. Mixtures and ratios of excipients and APIs used. “ü” denotes the presence of each excipient and API in the mixture. 
 Paracetamol Furosemide Propafenone 
hydrochloride 
Nifedipine Atenolol Drug:excipient 
ratio in the 
mixture 
Povidone K30 ü   ü  10 
HPMC ü  ü ü ü 0.6 
Microcrystalline cellulose 
(Avicel) 
ü ü ü ü  1.2 
SLS ü    ü 20 
Carbopol 974P    ü  6 
Eudragit E    ü  3 
Eudragit L100    ü  3 
Magnesium Stearate ü ü ü ü ü 10 
Stearic acid ü     10 
Tween 80    ü  10 
PEG 300     ü 10 
PEG 400   ü   
PEG 4000 ü   ü  
PEG 6000   ü ü  
Croscarmellose sodium  ü ü   10 





3.2.5. Assessment of drug-excipient mixing process, type of medium and formulation 
analysis 
The effect of the drug mixing process was assessed in a pilot study using three (atenolol, 
paracetamol and propafenone) of the five drugs. The mixing method of choice was selected on 
the basis of method robustness and lower data variability. An appropriate quantity of drug 
powder (10-200 mg) was mixed for 3 minutes with one related excipient at a time by either i. 
Using mortar and pestle, ii. Manual shaking in an Eppendorf tube or iii. Vortexing in an 
Eppendorf tube. API:excipient ratios were selected based on the percentage of each excipient 
in commercial formulations (Table 3.2), within the range dictated in the “Handbook of 
Pharmaceutical Excipients” [18]. PEG 300 and PEG 400, which are liquid, were mixed with 
the drug by manual shaking in a volumetric flask for 3 min before the addition of FeSSGF. A 
quantity of drug-excipient mixture, containing an amount of drug equivalent to the working 
drug concentration (Table 3.1) was transferred in a 200 mL volumetric flask and filled with 
FeSSGF. The flasks were incubated at 37 °C in a shaking water bath (200 shakes per min) for 
90 min. Three 1 mL samples were taken from the top of each volumetric flask, filtered through 
GF/D filter, and each was treated with a different protein precipitation reagent (methanol, 
acetonitrile, 10% w/v TCA) as explained in the study for the extraction of the active 
pharmaceutical ingredients previously conducted [20]. The samples were filtered through 0.45 
µm filters and were analysed using HPLC.  
The same process was performed in the high fat (FeSSGFhf) and no fat (FeSSGFsk) 
versions of FeSSGF, in the drug-excipient mixtures where drug recovery was < 50% (where 
drug was extracted with MeOH) in order to assess the effect of the medium lipid content in 
drug recovery.  
Commercial nifedipine and propefenone hydrochloride formulations (Adalat® LA tb 30 
mg and Arythmol® tb 300 mg) were each placed in glass bottles filled with 500 mL of FeSSGF 
and were incubated at 37 °C under strong agitation (200 rpm) for 48 h so as to achieve 
maximum drug release. A sample was taken from each flask, filtered through a GF/D syringe 
filter and drug was extracted with the same precipitation reagent used for the physical mixtures 
and analysed as explained above. All experiments were performed in triplicate and % recovery 





3.2.6. HPLC analysis 
Stock solutions of propafenone hydrochloride, nifedipine, atenolol, furosemide and 
paracetamol were prepared in MeOH. Calibration standard solutions were prepared in FeSSGF, 
FeSSGFhf and FeSSGFsk. The drugs were analysed in HPLC with the analytical methods 
(modification of published methods) used specified in the table below (Table 3.3). 
Adsorption studies were performed in triplicate for each model drug for all types of 
filters used. No adsorption issues were observed for the drugs studied. 
Table 3.3. HPLC methods (modification of published methods) used for the quantification of 
the model compounds. 















C18, 300Å, 250 
x 4.6 mm, 5 µm 
MeOH:H2O 
60:40 





C18, 300Å, 250 
x 4.6 mm, 5 µm 
MeOH:Formi
c acid 0.1% 
v/v 
60:40 





C18, 300Å, 250 
x 4.6 mm, 5 µm 
MeOH:H2O  
20: 80 





C18, 300Å, 250 





(pH = 4.5) 
20:80 






120Å, 250 x 4.6 




q.s 100 pH = 
2.9 
0.8  25  20  248 
 
3.2.7. Statistical Analysis 
% absolute recovery and correlation with excipient type, mixing method and protein 
precipitation reagent used in drug analysis were evaluated in the context of a multi-way 




StatPoint Technologies Inc, US). Comparisons where p < 0.05 suggested a statistically 
significant difference.  
The % recovery data was analysed via multiple linear regression (MLR) so as to 
investigate the impact of the selected excipient using SPSS v.22.0 (SPSS®, Chicago, IL, USA). 
Interactions of selected excipients with drug lipophilicity (log P) were included in the model 
on the basis of the lowest % recovery observed for the specific excipients (HPMC and 
magnesium stearate) in the pilot study. The generated MLR models were evaluated in terms of 
their regression coefficient (R2) and variance inflation factor (VIF) with high R2 values 
referring to a good fit to the model and VIF values < 3 indicating absence of multicollinearity 
among the independent variables [38]. The standardized coefficients of the factors plotted 
indicate the relative positive/negative effect on their corresponding values. The importance of 
each factor was evaluated but its p value. Statistical significance was set at p < 0.05. 
3.3. Results and Discussion 
3.3.1. Effect of drug-excipient mixing technique on % drug recovery in milk-based media 
(pilot study) 
The contour graphs for the three model drugs of the pilot study express the % drug 
recovered as a function of type of excipient and mixing process (Figures 3.1a-c) for every 
protein precipitation reagent (MeOH, ΑCN, 10% w/v TCA) used for their extraction. It can be 
observed that % recovery was affected in all three drugs; an effect denoted by the colour change 
across the mixing process axis (y axis). For the three compounds selected, the mixing process 
had a significant effect on their % recovery after the medium’s protein precipitation (Figure 
3.2). Vortexing and grinding gave significantly different % recovery values (p < 0.05) in all 
three drugs (Figure 3.2), which implied that the powders’ handling may affect their 
homogenous mixing.  
As observed in Figure 3.1a, the % recovery of paracetamol was close to 100% in the 
vast majority of cases with all reagents, excipients and mixing methods (mean paracetamol 
recovery = 100.9 ± 9.6%), a fact possibly attributed to paracetamol’s increased wettability. 
Contact angle measurement is a method of determination of the wettability of a compound, 
with angles > 90° being indicative of poor compound wettability [39]. The measured contact 
angles of paracetamol’s polymorph commercially used, monoclinic form I [40], against water 




The % recovery values of furosemide (Figure 3.1b) ranged between 40.9 and 110.2% 
depending on the excipient and extraction reagent used for drug recovery. Water’s contact 
angle against furosemide has been measured > 90° and could provide a reason for the lower 
recovery values compared to paracetamol [42].  
In both hydrophilic drugs (paracetamol and furosemide), grinding process led to lower 
recovery values than in the other two mixing processes (Figure 3.2). Grinding is a common 
strategy used to reduce drug particle size, often applied to drugs of poor solubility with an aim 
to increase their bioavailability in vivo [43], and although co-grinding of drugs with several 
excipients, such as lactose monohydrate [44] and avicel [45] accelerated their dissolution 
profile, there are cases when co-grinding may be used to prolong dissolution and lead to a 
sustained release profile [46]. A study with theophylline, a hydrophilic compound with log P 
value similar (log P = -0.02 [47]) to the above drugs, demonstrated that co-grinding with 
magnesium stearate decreased the dissolution efficiency and mean dissolution rate of the 
formulation [48] in comparison to a physical mixture of the same powder quantities. Therefore, 
a reason for the decreased drug % recovery when an excipient more hydrophobic than the active 
ingredient and the drug are co-ground could possibly be the concentration of hydrophobic 
particles of decreased particle size around the API, leading to delayed drug dissolution in the 
fed state medium.  
The extraction values of propafenone hydrochloride, a lipophilic drug, were lower than 
in the two hydrophilic drugs described above (Figures 3.1c, 3.2), and had a wider range. % 
recovery values were as low as 17 ± 7.9% (HPMC/shaking mixing method/drug extracted with 
10% w/v TCA). In this case, grinding led to significantly higher drug recovery values than in 
the other two mixing methods, despite the fact that some of the excipients were common in the 
other drugs as well (HPMC, magnesium stearate), which suggests that the extraction efficiency 
in the milk-based medium depends both on the API and ingredient’s properties. 
The decrease in particle size and the possible alteration of the powders’ surface 
properties when ground with mortar and pestle were two parameters which had to be taken into 
consideration in assessing the effect of excipients and protein precipitation solvent. Therefore, 
vortexing was selected as the powder mixing method for the assessment of the above 
parameters in all drugs and excipients. Despite showing equally high deviation between 




speed) and provided homogenous mixing with minimal changes of the powders’ surface 







Figure 3.1. Drug-excipient gradient maps for a. paracetamol, b. furosemide and c. propafenone hydrochloride. Contour plot of % recovery values 
as a function of drug-excipient mixing method and excipient. “Warm” colour regions (yellow, red) indicate that amounts of drug similar to their 
theoretical recovery values in the absence of excipient (% recovery > 80%) were able to be extracted from the medium, whereas “cold” regions 






Figure 3.2. Three-way ANOVA of excipient, protein precipitation reagent and mixing method 
effects (from left to right) on drug % recovery for the three model drugs. Different letters denote 
a statistical difference in the % recovery between excipients, reagents or mixing processes (p 
< 0.05). 
3.3.2. Effect of excipient type and extraction reagents (protein precipitation solvents) on 
drug % recovery in milk-based media 
The protein precipitation results of the full study (mixtures of the 5 drugs with the 15 
excipients) are presented in Figure 3.3, with the drug % recovery expressed as a function of 
combined excipient and drug. Drugs are sorted by increasing log P values from bottom to top. 
Multiple linear regression analysis of the results of the full study, in combination with the 
multiple comparisons of the pilot study were used to evaluate the effect of the excipients and 
protein precipitation solvent on % drug recovery. Overall, the results of the MLR analysis of 
the drug-mixtures excipients for the extraction of each protein precipitation solvent showed 
good fits with high R2 values (0.76, 0.66 and 0.7 for the extraction with MeOH, ΑCN and 10% 




3.4). The analysis demonstrated statistical significance for most of the variables tested (p < 
0.05). 
3.3.2.1. Excipient effect in drug recovery from milk-based media 
The pilot study performed with the three drugs, revealed that the % recovery is both 
API and excipient dependent. The multiple comparisons’ test performed with the three drugs 
showed that in all cases, their mixtures with magnesium stearate and HPMC led to significantly 
different recoveries compared to the rest of the drug-excipient mixtures, with lower mean % 
recovery values (Figure 3.2). When the excipient effect was evaluated for all five drugs 
(vortexing), decreased % recovery values were observed in more drug-excipient mixtures in 
addition to the two mentioned above, denoted by the blue and green zones in the contour plots 
of the vortexed mixtures (Figure 3.3). Furthermore, most excipients showed a statistically 
significant negative effect on % drug recovery, as demonstrated by the results of the MLR 
analysis (Figure 3.4), with the excipient effect discussed for each drug separately below. From 
the contour map of the full study (Figure 3.3), it can be observed that the recovery values for 
the three hydrophilic drugs (atenolol, paracetamol, furosemide) were distinctively higher than 
in the mixtures of the lipophilic ones (nifedipine, propafenone hydrochloride). 
In the case of paracetamol, none of the excipients decreased % drug recovery more than 
15% except for HPMC, which was attributed to the drug increased wettability as reported 
above. When HPMC was mixed with other active ingredients as well, (atenolol, nifedipine, 
propafenone hydrochloride) the % recovery of the drugs ranged from approximately 80 % for 
paracetamol down to approximately 20% for propafenone hydrochloride, regardless of the 
extraction solvent of choice (Figure 3.3). In the case of atenolol, similar results were observed. 
The effect of PEG 300 and SLS in drug recovery was minimal (> 79.5% in all mixtures). In the 
cases of HPMC and magnesium stearate, recovery values as low as 61.3 and 56.9% were 
observed for the two excipients respectively. In furosemide mixtures, the drug recovery was 
mainly controlled by the extraction reagent, rather than the excipient, an effect discussed in the 
section below. Specifically, the % recovery in the presence of avicel, croscarmellose sodium 
and magnesium stearate were all approximately 60, 80 and 100% when 10% w/v TCA, MeOH 
and ΑCN were used for the extraction of drug from FeSSGF respectively (Figure 3.3).  
One possible reason for the lower recovery in the presence of HPMC could be the 
formation of a barrier of fat and/or proteins formed around the powder in the milk-based 




in several studies where nutrient drinks like Ensure Plus® or Nutrison® were used as fed gastric 
dissolution media [15] [50]. It was also demonstrated that the initial gel formation layer of 
HPMC matrices during dissolution increased according to the fat percentage of the fed state 
medium, although the difference could be attributed to other properties of the medium, such as 
its viscosity [16]. Magnesium stearate acts by preventing the adhesion of the powder during 
tablet compression, forming a non-uniform hydrophobic layer on the surface of the powder 
mixture [51, 52]. Therefore, the decreased % recovery values in all drugs mixed with 
magnesium stearate could be attributed to the slower drug dissolution in the medium, due to 
the excipient’s hydrophobic nature [53]. Interestingly, although most excipients demonstrated 
a significant negative effect on drug % recovery (green bars), and HPMC and magnesium 
stearate showed a negative effect in the multiple comparisons test of the pilot study, they did 
not have a statistically significant contribution to the MLR final model (Figure 3.4). Their 
interactions with drug lipophilicity though demonstrated a highly significant effect, as shown 
by the high standardized coefficients of the respective variables (HPMC*log P, magnesium 
stearate*log P) (Figure 3.4). Therefore, the negative impact of HPMC and magnesium stearate 
on drug recovery is more profound in drugs of high lipophilicity (log P) and can attributed to 
the possible formation of layers around the drug powder either self-induced or in combination 
with the milk-based medium [15, 51, 52]. 
As far as the effect of the excipient on the dissolution of the lipophilic drugs is 
concerned, the short duration of the study (90 min) seems to be the most probable reason for 
the log P/excipient-dependent % recovery. Most of the excipients appear to have a log P- 
dependent effect on the dissolution of the APIs, meaning that a time > 90 min would be required 
for the total amount of lipophilic drugs to be solubilized. The combinations of nifedipine with 
all excipients demonstrated % recovery values < 80%. Except for the HPMC and magnesium 
stearate, the effect of which on drug dissolution was previously described, the lowest values 
reported for nifedipine were in its mixtures with Eudragit L100, Eudragit E and carbopol 974P. 
Eudragit L100 is insoluble below pH 6, according to the manufacturer, which could result in 
co-precipitation of the drug in the FeSSGF of pH= 5. Eudragit E is soluble at gastric fluid of 
pH up to 5, meaning that in the working pH, after the addition of methanol or acetonitrile, 
precipitation of the excipient along with the drug could take place due to the pH of the 
supernatant (pH of the supernatant measured > 5). The reason of the decreased drug recovery 
values when APIs were mixed with carbopol 974P can be attributed to the same reason as 




ingredient decreasing the diffusion coefficient of the drug in the medium [54]. Another possible 
mechanism suggesting reduced drug transport to the dissolution medium due to interaction 
between the drug and the polymer has also been reported in the literature [55]. Avicel’s 
negative effect on nifedipine recovery (< 60% with all protein precipitation reagents) (Figure 
3.3) could also be attributed to the entrapment of the smaller drug particles between the 
microcrystalline cellulose’s particles leading to slower drug wetting and dissolution [56]. 
Water soluble polyethylene glycols (PEG 4000, PEG 6000) and Tween 80 were normally 
expected not to affect % drug recovery negatively, as they act as solubility enhancers [57] and 
surfactant [58], improving the solubility and dissolution characteristics of poorly soluble drugs. 
Therefore, the low values observed for all excipients and the big differences in drug recovery 
among different protein precipitation solvents (maximum drug recovered = 31.7% with 10% 
w/v TCA) point in a recovery in this case being log P- or extraction solvent-driven, rather than 
excipient type-dependent. A similar explanation could be given for the negative effect of 
povidone K30, a hydrophilic polymer which has been shown to increase both wettability and 
dissolution rate of lovastatin, a drug of similar lipophilicity to the lipophilic drugs (nifedipine, 
propafenone hydrochloride) of the study [59] (log P = 4.26 [47]). Finally, similar results were 
observed in the mixtures of propafenone with its excipients, with the drug % recovery in the 
presence of avicel, croscarmellose sodium and polyethylene glycols affected negatively, driven 
by the excipient- and log P-related mechanisms described above. In the case of this more 
lipophilic drug, drug recovery in the presence of HPMC and magnesium stearate was 
significantly lower than in the presence of the other excipients (p < 0.05) (Figure 3.2). % 
recovery values were the lowest in the presence of the former, and did not exceed 40% 
regardless of the choice of the extraction solvent. The challenging nature of the extraction of 
lipophilic drugs from HPMC matrixes has been reported and attributed to the high API 
lipophilicity and the gelation properties of the polymer [60], an effect demonstrated in the 
current study too, as indicated by the high negative HPMC*log P standardised coefficients in 
MLR analysis (Figure 3.4). 
3.3.2.2. Protein precipitation reagent effect in drug recovery from milk-based media 
For the three hydrophilic drugs (atenolol, paracetamol, furosemide), recovery values > 
60% were observed for all three reagents (Figure 3.3), with the highest recovery observed in 
ΑCN extraction, as the red zones of the graph (Figure 3.3) indicate. In regard to the lipophilic 
drugs (nifedipine, propafenone hydrochloride), the amounts of drug extracted were 




recovered in the presence of excipients was extremely low; less than 40% of the drug was 
recovered in 15 of the total 16 nifedipine/propafenone hydrochloride and excipient mixtures 
(Figure 3.3). At the TCA concentrations used, unfolding of the medium’s proteins is set off by 
negatively charged ions of the acid, which cause the disruption of the electrostatic forces 
maintaining the structure of its proteins. This mechanism of action can potentially expose non-
polar protein surfaces and lead to plotting of the molecules and precipitation [61]. It is possible 
that the presence of excipients may inhibit the solubilisation of the drugs by the acid and 
facilitate its occlusion in the precipitate.  
The effect of the type of protein precipitation solvent was statistically significant in 
terms of % recovery (p < 0.05), as demonstrated by the ANOVA analysis of the pilot study 
(Figure 3.2). The differences can be observed in the different reagent levels of the visual 
ANOVA representation (Figure 3.2) and also in the different colour zones of the contour graphs 
(Figure 3.3); the reddest zones observed belong to ΑCN and the bluest to 10% w/v TCA, 
indicating the highest and lowest recovery values respectively. The above order of extraction 
efficiency (ΑCN > MeOH > 10% w/v TCA) was followed in four of the five drugs regardless 
of excipient of mixing method, except for atenolol as observed in the contour plots (Figures 
3.1, 3.3). In the case of atenolol mixtures, which was the only drug more poorly extracted with 
ΑCN than with TCA, the better applicability of trichloroacetic acid cannot be directly justified 
by the drug’s physicochemical properties, as in the absence of excipient both ΑCN and 10% 
w/v TCA were able to recover approximately 100% of the drug in FeSSGF [20]. It could be 
suggested that drug’s comparatively higher solubility in trochloroacetic acid than in acetonitrile 
[62] led to faster drug solubilisation in its mixture with the excipient. 
It is evident that the properties of the active ingredients alone cannot account for the 
differences in recovery among the different extraction methods, as the reference standard for 
100% recovery was defined for each reagent separately and given by the amount of drug 
recovered from the medium in the absence of its excipient. It is worth mentioning, that the 
extraction efficiency (in terms of effective drug recovery) of the three reagents used in the 
presence of excipients, followed the same pattern as in their absence, as demonstrated in a 
previous study [20]. In both studies, drug lipophilicity had a negative effect on the amount of 
drug recovered, which may suggest that the presence of excipients may amplify the differences 
in drug recovery, previously correlated with the drug’s physicochemical properties. Therefore, 
the physicochemical properties of the API need to be taken into consideration in the design of 





Figure 3.3. Drug-excipient gradient map (mixed by vortexing). Contour plot of % recovery values as a function of drug and excipient. Red x 






Figure 3.4. Standardised coefficients of MLR analysis after protein precipitation with a. 
MeOH, b. ΑCN and c. 10% w/v TCA. Green colour denotes statistical significance. 
3.3. Effect of medium fat content on drug %recovery in milk-based media and 
assessment of drug extraction method in solid oral dosage forms  
Analysis in media of different fat content was performed for the two lipophilic drugs 
of the study, nifedipine and propafenone hydrochloride, in mixtures with excipients 
demonstrating the low (< 50%) drug % recovery (magnesium stearate, carbomer 974P, 
Eudragit L100 and HPMC).  
The recoveries in the high and no fat media for the excipient mixtures with nifedipine 
were equally low. Nifedipine recovered ranged from approximately 3 to 16% and from 4 to 
18% for the low and high fat medium, while the equivalent values for FeSSGF gave values 
from 7 to 50% for the three reagents used (Figure 3.5). The reduced values in the low fat 
medium, compared to FeSSGF, were attributed to the lower drug solubility. Nifedipine’s 
solubility in FeSSGF is approximately 70 µg/mL [63]; a value approximately 7 to 10-fold 
higher than the drug’s aqueous solubility, with the difference possibly attributed to the 
solubilisation of the lipophilic drug in the lipid portion of the medium. Therefore, the absence 




recovery. In the high-fat medium, low recovery values are possibly attributed to the decreased 
extraction efficiency in media of high fat content, a common issue of sample clean-up methods 
in milk-based media [7]. A study of HPMC-nimodipine mixtures in acetate buffer pH = 4.5 
(log P = 3.41 [64], similar structure and lipophilicity to nifedipine) showed an increase in the 
drug solubility and dissolution efficiency by a factor of 4 compared to the drug in the absence 
of the excipient [65]. This which points that low solubility and dissolution rates cannot always 
be attributed to the excipient but to the interactions between the mixture and the dissolution 
medium as well. In the case of propafenone, medium prepared with skimmed milk (FeSSGFsk) 
gave higher drug recovery values when ΑCN and TCA were used as protein precipitation 
reagents (Figure 3.5), which was again attributed to the difficulty of designing an effective 
extraction protocol in media of high lipid content.  
Extraction of drug of commercial formulations revealed that despite the presence of the 
excipients, their extraction was in no case affected to such an extent as with the simple mixing 
of each excipient separately. The % recovery value was in all cases between 67.2 and 99.5% 
(Figures 3.5a, b) and its dependence of the solvent selection profound, in the same way as with 
the physical mixtures of APIs and excipients. Acetonitrile was most effective, followed by 
methanol and 10% w/v TCA. The reagent-dependent recovery results in drug formulation 
indicate that suitability of the extraction method for the active ingredient does not necessarily 
guarantee equivalent extraction performance in formulation analysis. The reduced recovery in 
extraction with trichloroacetic acid may indicate entrapment or adsorption of the drug in 
excipients, and inability of the method to break these excipient-drug interactions. A use of such 
a method without prior assessment of drug-excipient interactions could lead to erroneous 
results if potentially used for drug quantification in a dissolution study using milk-based media. 
The differences in recovery values among formulations and reagents, along with the results of 
the assessment of the mixing technique, confirmed that the process via which drugs and 
excipients are formulated has to be considered for the development and optimisation of a 







Figure 3.5 a. Nifedipine-excipient and b. propafenone-excipient mixtures, media and 
commercial formulations gradient map. Contour plot of % recovery values as a function of 
medium and excipient/formulation. Red x points denote the drug-excipient-medium 
combinations. 
3.4. Conclusion 
The presence of excipients can have an effect on the amount of drug extracted from 
milk-based gastric media and should therefore be taken into consideration when developing a 
quantitative method for drug analysis. Using a previously developed extraction protocol [20], 
the effect of excipients used in commercial formulations in the recovery of drugs when 
dissolved in milk-based fed gastric media was investigated. The results demonstrated 
dependence of the type of excipient, mixing technique and protein precipitation protocol 
selected with the interaction between lipophilicity and certain excipients (HPMC, magnesium 
stearate) being highly influential in most cases, as indicated by the MLR analysis. The 
differences in the impact of the same excipients in drugs of different lipophilicity highlighted 
the need for further investigation of excipient-drug interactions and the way both the 




media. The study revealed a medium-dependent recovery in the presence of excipients, but 
without indications of a direct correlation between medium’s fat percentage and amount of 
drug recovered. Finally, it was concluded that excipient processing during drug manufacturing 
may affect the efficiency of the sample clean-up methods, and has to be taken into consideration 
in drug analysis and quantification. Therefore, to accomplish the accuracy required in drug 
analysis in fed state milk-based media, the effect of drug properties, type of excipient, changes 
in medium composition and formulation manufacturing have to be individually assessed in 
regard of their effect on the extraction efficiency. Further studies which will assess the full 
applicability of the optimized extraction protocols developed for the active pharmaceutical 
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Chapter 4: Investigation of drug partition kinetics to fat in 
simulated fed state gastric conditions based on drug properties 
Abstract 
The presence of fat in the gastric environment can affect the pharmacokinetic behaviour 
of drugs with mechanisms which have not been yet fully understood. The objective of the 
current study was to assess the drug partition to the lipid part of the fed gastric content under 
different emulsification conditions, using in vitro discriminating setups. The model drugs used 
in the study were selected on the basis of different physicochemical properties (lipophilicity, 
ionization, molecular weight and aqueous solubility) and different food effect observed in in 
vivo human studies. Fed State Simulated Gastric Fluid prepared with skimmed milk 
(FeSSGFsk) and anhydrous milk fat were used as surrogates for the aqueous and fat portions of 
the fed gastric environment respectively. An optimized biphasic model was developed so as to 
predict the differences in partition rates to fat, for model drugs of a wide range of the properties 
mentioned above. Molecular weight, molecular weight and log D pH 5 interaction and negative 
food effect act as negative factors to the rate of fat partition, while absence of food effect and 
logD pH 5 interaction with aqueous solubility affect the rate of partition to fat favourably.  






The oral route is considered the most common route of drug administration, due to its 
convenience, lower cost of formulations developed and patient compliance. Drug solubility, 
dissolution and permeability are critical processes taking place in the gastrointestinal tract and 
determine the drug’s bioavailability. For most solid dosage forms (with the exception of 
orodispersing formulations), the gastric environment is the part of the GI tract where 
dissolution begins as the volumes and transit time in the oral cavity and oesophagus are 
insignificant. The stomach can be divided in three distinct parts: fundus, corpus and antrum; 
the fundus acts as a gastric reservoir, the antrum is the site where trituration and particle size 
reduction takes place, while the corpus connects these two parts [1]. Food forms layers in the 
stomach, with fat floating on top of an aqueous layer and heavier particles sedimenting in the 
sinus [2], while the aqueous layer contains small particles which are emptied from the stomach 
as the gastric emptying process takes place [1]. The lipid part of the meal administered has a 
prominent role in a potential drug food effect through many possible mechanisms. Some 
common ones involve the increase of lymphatic transport of drugs [3], the constriction of 
intestinal efflux transporters and the formation of intestinal mixed micelles (bile 
salt/phospholipids/cholesterol) as a result of exogenously administered lipids [4]. The 
mechanism affecting the food effect of drugs which is related to the presence of fat in the 
stomach, mainly involves the increase in gastric residence time of drugs which thus allows 
more time for drug dissolution. Therefore, the presence of lipid components in meals can 
modify the in vivo behaviour of the certain molecules either promoting the formation of mixed 
micelles with bile salts or by drug solubilisation by fat. 
Thus, when developing in vitro predictive tests towards the evaluation of drug 
dissolution in the GI tract it is important to simulate the effect of the lipid part of the meal, 
incorporating it to the dissolution media used, with an aim to predict effectively possible food 
effects on their pharmacokinetic behaviour. Since fat can improve the dissolution 
characteristics of poorly soluble drugs in the stomach, the knowledge of possible drug-lipid 
interactions is essential. Also, knowing the rate that the drug partitions to fat is equally 
important, as the meal remains in the gastric compartment for 1-4 hours (depending on the type 
of meal) [5], with one part of the released drug being dispersed in the lipid phase and the rest 
solubilised or precipitated in the aqueous gastric phase. Of the total solubilised amount of drug, 
which includes both the free and partitioned drug, only the free fraction has the potential to be 




interactions and evaluate possible dependence of drug physicochemical properties. Knowledge 
of the physicochemical parameters controlling this type of interactions can shed light towards 
the understanding of the mechanisms inducing positive or negative food effect after drug co-
administration with high-fat meals.  
Another factor which can affect drug dissolution and permeability in the gastrointestinal 
tract is the presence of lypolytic enzymes. Lipid digestion starts in the oral cavity with the help 
of lingual lipases and continues in the stomach from lingual and gastric lipases; while the major 
part of the lipolysis process takes part in the small intestine, where drug absorption takes place, 
by the pancreatic lipase [7]. Gastric lipolysis was believed to account for 10-20% of the total 
lipolysis process in the GI tract [8, 9]. More recent evidence though, showed that human gastric 
lipase (HGL) may be responsible for up to 40 % of the total lipolytic activity [10]. Gastric 
lipase hydrolyses long and medium-chain to diglycerides, monoglycerides and fatty acids. 
These digestion products along with the shear forces developed in the stomach during digestion 
lead to fat emulsification, creating a coarse lipid emulsion [11]. Because of the limited role of 
HGL in the dissolution of conventional tablets, its use in gastric dissolution media has been 
relatively limited. Its presence though may be important for lipid-based drug delivery systems 
[12] and possibly in the prediction of drug dissolution behaviour after administration of lipid 
rich meals, as these ezymatic processes take place in both cases (lipids derived from food or 
lipid based formulations) [13]. In the fed state, gastric lipase contributes to a greater extent to 
the total lipolysis, due to higher HGL stimulation at higher pH values, with its activity 
measured more than 10 times higher at pH=5.4 than at pH=2.8. [12].  
In the fed stomach, un-digested fat forms a lipid layer floating on the top of the gastric 
content while emulsified fat particles move with the aqueous phase to the pyloric antrum; the 
aqueous content fills the distant antrum and moves towards the duodenum faster than fat and 
solid residues [2]. Because of the complex stratification of aqueous phase and un-digested and 
emulsified fat in the fed stomach, it is important to assess the interactions formed between the 
drugs and each of the phases so as to explain certain lipid-induced changes in drugs’ 
pharmacokinetic parameters and also problems in the analysis of biorelevant media related to 
the presence of fat.  
 The current study, aimed to determine not only the percentage of drug partitioned to 
fat from the “aqueous” phase of the stomach under physiological conditions in the fed state, 




drugs. The purpose of the current work is to study the role of the lipid part of a meal, simulated 
in a gastric fed state medium, in inducing changes of drug pharmacokinetic parameters. Finally, 
the study assessed the impact of related drug physicochemical properties and drug food effect 
observed in vivo (changes in the drug’s pharmacokinetic behaviour after meal administration) 
on drug partition using statistical tools [partial least squares (PLS) regression analysis]. 	
4.2. Materials and Methods 
4.2.1. Materials 
Atorvastatin calcium salt trihydrate (≥ 98% (HPLC)), danazol (≥ 98%), furosemide (≥ 
98%), phenytoin (pharmaceutical secondary standard; traceable to USP and PhEur),	
itraconazole (≥ 98% (TLC)), propafenone hydrochloride (≥ 98% (HPLC)), indomethacin (≥ 
99%) and indoprofen (analytical standard) were purchased from Sigma- Aldrich, UK, while 
nifedipine (98.0-102.0% (on dried substance)) and ketoconazole (inclusive between 98.0%) 
from Fisher Scientific, UK. Griseofulvin (> 97%) and felodipine were purchased from Alfa 
Aesar, UK and ibuprofen (97-103%) was purchased from Fagron, UK. MK-C1 and MK-C4 
were provided by Merck & Co, US.  
Sodium acetate trihydrate, sodium chloride, hydrochloric acid (36.5-38%), glacial 
acetic acid (≥ 99%), sodium dodecyl sulphate (S/5200/53) and all phosphate salts were 
purchased from Fisher Scientific, UK. HPLC grade methanol, acetonitrile, trifluoroacetic acid 
(≥ 99.0%), diethylamine (≥ 99.5%), thriethylamine (≥ 99.5%) and formic acid were all 
purchased from Sigma- Aldrich, UK.  
Cronus 13 mm regenerated cellulose (RC) syringe filters 0.45 µm were purchased from 
LabHut Ltd, UK and 2.7 µm (GF/D) filters from Fisher Scientific, UK. 
Lipase from Rhizopus niveus (Lipase RN, approximately 83 kDa, cat# 62310) and 
calcium chloride dehydrate (≥ 99.0%) were purchased from Sigma–Aldrich, UK. < 0.1% fat 
UHT milk and anhydrous milk fat were commercially purchased. Dialysis tubing cellulose 









Partition experiments were run in triplicate at 37 °C, using 50 mL Corning® PP self-
standing centrifuge tubes, the USP 2 paddle apparatus (Agilent 708-DS Dissolution Apparatus) 
or 100 mL glass DURAN™ bottles (Fischer). All samples were analysed in an HPLC system 
consisting of an Agilent 1200 series binary pump (G1312A), an Agilent 1200 series DAD 
detector (G1315D), an Agilent 1200 series autosampler (G1329A), an Agilent 1200 series 
controller (G1316A) and Chemstation software (Agilent Technologies, Santa Clara, United 
States). A pH meter Mettler-Toledo AG (model SevenCompact pH/Ion S220, Schwerzenbach, 
Switzerland), a centrifuge Hereus Biofuge Primo R (Thermo Scientific, Hanau, Germany) and 
a vortex mixer Rotamixer (HTZ, Cheshire, UK) were used.  
4.2.3. Model drugs selection 
Assessment of the drug partition to fat was conducted for 15 drugs of a wide range of 
lipophilicity, ionisation, aqueous solubility, and in vivo food effect (Table 4.1). Working drug 
concentrations were selected according to experimental drug aqueous solubility values as 
reported in the literature or calculated values where experimental values were not available 
(Advanced Chemistry Development (ACD/Labs) Software v.11.02, Sci-finder), so as to avoid 
possible drug precipitation as the drug was initially dissolved in the “aqueous” (the part which 
does not contain fat, consisting of a mixture of skimmed milk and acetate buffer, FeSSGFsk) of 
the fed-state medium used in the study. Due to its extremely low solubility in water (< 0.1 µg/ 
mL), working concentration of MK-C4 was selected according to its solubility in the “aqueous” 
phase of the medium in a 24 h period, performed using the shake-flask method [14]. In 
summary, an excess of drug was added to the solubility medium and left to equilibrate for 24 
h at 37 °C under constant shaking. An aliquot of the saturated medium was initially filtered 
through a GF/D 2.7 µm filter and quantified after addition of ΑCN (2 parts in 1 part of medium), 
vortex (30 sec at full speed), centrifugation (15 min, 8000 rpm, 37 °C) and finally filtration 






Table 4.1. Physicochemical properties and working concentrations of model drugs; “+” 






[28-40] log D pH 5





Furosemide - 0.74 0.90 4.25 3.07 80 
Griseofulvin + 2.18 2.51 - 100 8.6 
Phenytoin + 2.47 2.52 9.47 99.95 27 
Ibuprofen n.e 2.48 2.86 4.91 16.63 84 
Indoprofen n.e 2.86 1.86 3.74 16.20 128 
Nifedipine + 2.91 3.48 5.33 99/93 10 
Propafenone 
hydrochloride + 3.39 0.68 9.63 0.01 150
b 
Ketoconazole - 3.72 2.47 6.75 3.35 2.7b 
MK-C1c n.e 4 4.11 6.5 99.75 3c 
Danazol + 4.20 3.35 - 100 1 
Atorvastatin 
calcium n.e 4.22 4.07 4.33 17.83 2.6
b 
Indomethacin n.e 4.27 3.67 3.8 23.80 15 
Felodipine n.e 4.5 4.84 - 99.93 1.1  
Itraconazole + 6.20 5.09 3.70 22.82 3.7c 
MK-C4c + 8.81 9.06 - 100 3.2d 
a Calculated using Advanced Chemistry Development (ACD/Labs) Software V11.02 (© 1994-2016 ACD/Labs) 
b Sci-Finder 
c Physicochemical properties and food effect data provided by Merck 
d Solubility study (24 h) performed in FeSSGFsk  
4.2.4. Drug partition to fat studies 
A modified version of Fed State Simulated Gastric Fluid (FeSSGFsk) was selected in 
order to simulate the “aqueous” phase of the working fed state medium. FeSSGFsk was 
prepared according to Jantratid et al. [46] by mixing skimmed milk and acetate buffer pH = 5 




acetate buffer were mixed under constant stirring using a magnetic stirrer. pH was adjusted to 
5 with 1 N HCl and the volume was adjusted to 1 L with the “blank buffer”. Anhydrous milk 
fat was selected as a surrogate of the lipid phase of FeSSGF. It is a cream or butter derivative, 
having water and proteins removed, and contains at least 99.8% milk fat [47].	
Three different setups were developed for the assessment of drug partition rate from 
the aqueous to the lipid part of the fed gastric medium (Table 4.2). The three setups used 50 
mL centrifuge tubes for diffusion through a dialysis membrane (setup I), the USP dissolution 
apparatus 2 (setup II) or 100 mL glass bottles for partition assessment of drugs in a smaller 
scale (setup III). For every drug, working solutions were prepared in FeSSGFsk and left under 
constant stirring at 37 °C for 60 min at concentrations equal to the drugs’ aqueous solubility 
values. Appropriate quantities of anhydrous milk fat, equivalent to the desired w/v percentage 
of the total volume of each setup (pre-heated at 37 °C) (Table 4.2) were weighed. Appropriate 
volume of the FeSSGFsk drug solution was placed in the receptor vessel of each setup. A 
working temperature of 37 °C was maintained by the means of a 37 °C incubator room, a 
thermostated jacket or a heating plate for setups I, II and III respectively. Drug partition rate to 
fat was described by measuring the % decrease in the donor concentration with time, with 
samples taken from the middle of the FeSSGFsk layer at defined time points for a period of 24 
or 48 hours. Experiments were performed in triplicate and % drug partition to fat was expressed 
as mean ± standard deviation. The exact quantities and volumes of lipid and aqueous parts, 
sampling time points and agitation conditions are stated in Table 4.2. The experimental setup 
suitability was evaluated with a pilot study of five drugs of different lipophilicity [propafenone 
hydrochloride, ketoconazole, nifedipine, danazol and atorvastatin calcium, (log D pH 5 = 0.68-
4.07)]. 
The effect of fat percentage used was assessed in setup I (dialysis membrane setup), 
using nifedipine as the model drug. The quantity of fat placed in the membrane was equivalent 
to 5%, 8%, 15%, 20%, 25% w/v fat concentrations. 0.5 mL samples were collected from the 
donor compartment (30 mL of milk-based medium) at defined time-points (Table 4.2) and 
agitation was maintained by a 15 x 6 mm magnetic bar rotating at 300 rpm in a centrifuge tube 
with conical base and skirted bottom. Partition experiments using setup I were performed for 
the other four drugs of the pilot study using the 25% w/v fat concentration.  
The effect of agitation speed in was evaluated in setup II, using the dissolution 




and fat quantity equivalent to 25% w/v concentration of the total medium (Table 4.2). The 
volume of FeSSGFsk used was 500 mL. Agitation was stopped for 2 min for the two layers to 
separate before sampling. 5 mL samples were withdrawn at defined time-points for a duration 
of 8 hours and volume was replaced with drug solution in FeSSGFsk. Partition experiments 
using setup II were performed for the other four drugs of the pilot study using 150 rpm agitation 
speed. Setup III, like setup II, was a biphasic setup without the presence of dialysis membrane, 
but performed at a smaller scale (30 mL of FeSSGFsk). Agitation was provided by a 15 x 6 mm 
magnetic bar at 300 rpm and 0.5 mL samples were collected from the drug donor compartment 
at defined time-points for a period of 8 hours.  
Once optimum parameters (fat percentage, medium volume, agitation means and speed) 
were selected, they were applied to all 15 drugs of the study. The experimental setup and fat 
percentage added for the final setup developed were selected on the basis of providing adequate 
discrimination among drug partition profiles and reasonable times for complete profiles.   
Partition experiments in the presence of a surfactant were conducted using the partition 
setup III in order to assess the effect of emulsification conditions in the fed gastric environment 
on drug rate of partition. The partition rate was evaluated in the presence of an anionic 
surfactant (SLS) and also in the presence of a gastric lipase equivalent (RN lipase) dissolved 
in a CaCl2 solution added at a concentration yielding activity similar to the physiological values 
(approximately 40 U/mL) [10, 48]. 6 mL of a stock solution of SLS or RN lipase in acetate 
buffer pH 5 was added to 24 mL of drug solution in FeSSGFsk (same drug concentrations as in 
partition “control” experiments without the presence of SLS or enzyme). CaCl2 was added to 
a total 1.4 mM concentration. The concentration of the surfactant/enzyme stock solutions were 
selected so as to achieve a 1% w/v (for SLS) or 40 mg/mL (for lipase) concentration in the total 
volume of the system. FeSSGFsk and surfactant/lipase were left to mix for 5 min and the fat 
layer (10.3 g, Table 4.2) was added on top of the drug donor (FeSSGFsk and surfactant). 0.5 
mL samples were taken from the drug donor at defined time-points for a period of 8 hours. 







Table 4.2. Experimental conditions of drug partition to fat setups.	
Setup I II III 
	
	 	 	
FeSSGFsk volume (donor) 
(mL) 
30 500 30 
Anhydrous milk fat nominal 
quantity (g) 
10.3 172 10.3 
Anhydrous milk fat nominal 
concentration (% w/v) 
5-25 25 25 
Sampling compartment Centrifuge tube (50 mL) 
Paddle apparatus 
vessel 
Glass bottle (100 
mL) 
Sampling point Middle of FeSSGFsk layer 
Sample volume (mL) 0.5 5 0.5 
Agitation speed (rpm) 300 150 300 
Membrane length (cm) 8 cm - - 
Membrane type 
Cellulose membrane 
avg. flat width 25 
mm (1.0 in.), 
MWCO 14000 
- - 
Sampling time points (h) 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 24, 48* 
0.17, 0.33, 0.5, 1, 
1.5, 2, 3, 4, 6, 8 
0.5, 1, 1.5, 2, 2.5, 
3, 4, 6, 8 
Temperature (°C) 37 
*24 h sampling time for nifedipine, 48h sampling time for all other drugs 
4.2.5. Sample treatment and drug quantification 
Drug quantification in FeSSGFsk: 2 parts of methanol were added to 1 part of FeSSGFsk 
immediately after its sampling and the mixture was vortexed (30 sec), centrifuged (8000 rpm, 
15 min, 4 °C), filtered through a 0.45 µm RC filter and analysed with HPLC. Drug was 
quantified against a set of calibration standards in FeSSGFsk treated as described above. 












Table 4.3. HPLC methods (or modification of published methods) used for the quantification of the model compounds. 	
Drug Column Mobile phase Flow rate (ml/min) 
Temperature 
(° C) Inj. Vol. (µl) λ (nm) 
MK-C4* Phenomenex Onyx monolithic C18, 300Å, 250 x 4.6 mm, 5 µm 
ΑCN:H2O 70:30 3.5 40 100 220 
Itraconazole [49] Thermo Hypersil BDS C18, 300Å, 250 x 4.6 mm, 5 µm MeOH:H2O 80:20 1 35 100 260 
Felodipine [48] Waters XBridge Shield RP18, 130Å, 150 x 4.6, 3.5 µm ΑCN:H2O 70:30 1 25 100 238 
Indomethacin [50] Waters XBridge Shield RP18, 130Å, 150 x 4.6, 3.5 µm 
MeOH:Phosphoric acid 1.67% 
v/v 1 23 50 270 
Atorvastatin calcium [51] Thermo Hypersil BDS C18, 300Å, 250 x 4.6 mm, 5 µm 
ΑCN:Phosphate buffer  
0.025 M 
(pH 6) 40:60 
1.5 30 100 246 
Danazol [52] Thermo Hypersil BDS C18, 300Å, 250 x 4.6 mm, 5 µm MeOH:H2O 75:25 1 25 100 285 
MK-C1* Waters Symmetry Shield C18, 100Å, 50 x 4.6 mm, 5 µm 
ΑCN:Phosphate buffer 0.025 
M (pH=2.5) Gradient (0-2 min 
65:35/ 2-2.01 min 90:10/ 2.01-
3 min 90:10/ 3-3.01 min 65:35 
3 40 100 214 
Ketoconazole [39] Thermo Hypersil BDS C18, 300Å, 250 x 4.6 mm, 5 µm 
MeOH:H2O:DEA 75:25:0.1 1 25 100 260 
Propafenone hydrochloride 
[53] 
Agilent Eclipse XDB C18, 
120Å, 250 x 4.6 mm, 5 µm 
MeOH:ΑCN: 
TEA:H2O 




25 20 248 
Nifedipine [54] Thermo Hypersil BDS C18, 300Å, 250 x 4.6 mm, 5 µm 
MeOH:H2O 
60:40 1 20 50 238 
Indoprofen [55] Waters XBridge Shield RP18, 130Å, 150 x 4.6, 3.5 µm 
ΑCN:Formic acid 0.1% v/v 
40:60 1 40 50 280 
Ibuprofen [56] Agilent Eclipse XDB C18, 120Å, 150 x 4.6 mm, 5 µm 
MeOH:Acetic acid 0.2% v/v 




Phenytoin [50] Agilent Zorbax SB-C18, 150 × 4.6 mm, 3.5 µm ACN:H2O 80:20 1 20 10 210 
Griseofulvin [50] Waters XBridge Shield RP18, 130Å, 150 x 4.6, 3.5 µm MeOH:H2O 65:35 0.8 20 50 292 
Furosemide [57] Thermo Hypersil BDS C18, 300Å, 250 x 4.6 mm, 5 µm 
MeOH:Formic acid 0.1% v/v 
60:40 0.8 25 20 233 
 




4.2.6. Data analysis 
4.2.6.1. Data fitting 
In order to determine the rates of drug partition, partition data (drug % partitioned vs 
time) were fitted to a first-order model (Eq. 4.1) using GraphPad Prismâ v.7 software 
(GraphPad, US). Goodness of fits was assessed on the basis of coefficient of determination and 
normality test.  
Cpart t= C#$%&	($) 	∗ (1 − e/0part&)                                                                                                (Eq. 
4.1) 
 Cpart t is the % drug partitioned to fat at time t, Cpart max is the % maximum drug 
partitioned to fat and kpart is the first-order partition rate  
Drug partition rate constants were compared using a two-way analysis of variance 
(ANOVA) repeated measures test for the different drugs and experimental setups, with 
Bonferroni’s post-hoc test, using GraphPad Prismâ v.7 software. The effect of surfactant/lipase 
was evaluated using a two-way ANOVA for the comparison of partition rates among different 
drugs and emulsification conditions with Bonferroni’s post-hoc test. Statistical significance 
level was set at p < 0.05.  
4.2.6.2. Multivariate data analysis [Partial Least Squares (PLS) regression] 
The drug partition rate to fat was correlated to drug physicochemical properties 
[lipophilicity (log D pH 5), aqueous solubility at pH 5 (µg/mL), molecular weight (MW)] and 
food effect observed in in vivo human studies by partial least squares (PLS) regression using 
the XLSTAT software (Microsoft, US). Interactions of logD pH 5 with the above parameters 
(aqueous solubility at pH 5 (µg/mL), molecular weight (MW) and food effect) were also 
included in the model. The main advantage of PLS as a regression technique is the possibility 
to analyse data with independent variables which may be highly collinear [58]. The parameters 
were selected on the basis of the physicochemical aspects which control drug diffusion process 
between an aqueous and lipid layer. Assuming that the mechanism controlling the partition 
process is governed by the same basic principles as in lipid bylayers of biological membranes, 
drug partition is also dependent on drug diffusion coefficient and drug partition coeficient into 
the membrane barrier. Diffusion coefficient is dependent on size, shape and solvent-drug 
interaction. Therefore, even though log D is a good predictor for drug’s partition rate to fat, 




coefficient, have to be considered. Interactions of log D pH 5 with the rest of the properties were 
included in the model with an aim to elucidate possible drug partition mechanisms for which 
drug lipophilicity alone cannot account for.  
The model quality was evaluated on the square of the coefficient of determination (R2) 
and goodness of prediction (Q2). R2 and Q2 values close to 1 refer to a model of good fit and 
prediction power respectively while a difference of R2 and Q2 lower than 0.2-0.3 between them 
is indicative of a successful model [59]. A Q2 value > 0.5 was considered acceptable for good 
model predictability [60]. Full cross-validation (leave-one-out procedure) was used to develop 
and evaluate the regression model. The optimum number of calibration factors (principal 
components) for each model was selected based on the model’s optimum predictability (Q2) 
and predicted residual error sum of squares (PRESS). Lower PRESS values indicate better 
prediction [61], with the number of latent variables where PRESS starts increasing indicating 
the number of variables which to be retained in the model [62]. The importance of each 
parameter was evaluated by its variable importance in projection (VIP) value. Values above 
1.0 are considered to have a significant effect on the dependent parameter, whereas values < 
0.7-0.8 are not of statistical significance [59]. The standardised coefficients indicate the relative 
positive/negative effect of their corresponding parameter on the first-order rate of drug partition 
to fat (response value). High absolute values of standardised coefficients for variance X denote 
a big positive or negative effect on response Y. Outliers in the PLS model were evaluated on 
the basis of DMoDY (distance to model; residuals of Y), which express distance from each 
point to the PLS model with respect to the responses with high values.  
4.3. Results and Discussion 
4.3.1. Effect of fat percentage on drug rate of partition 
The rate of drug partition to fat, was highly influenced by the percentage of fat present 
in the medium, as studied with partition setup I (dialysis membrane). A two-fold increase was 
observed in the rate of partition of nifedipine (drug with the highest fat affinity of the initial 
five compounds tested) when the fat content was increased from 5 to 25% w/v in the total 
medium (lipid and milk) volume (Figure 4.1 a). The rate of nifedipine partition was doubled 
when fat concentration increased from 5 (0.05 h-1) to 25% w/v (0.1 h-1) when partition data 
were fitted to a first-order equation, which can be attributed to the larger available area for 
diffusion when higher fat volumes are used, as described by Fick’s first law of diffusion [63]. 




approximately between 0.08 and 0.1 h-1 (Figures 4.1 a, b). This signified a reduced effect of the 
fat percentage in partition rate for high fat medium content values. By increasing the amount 
of fat present in the receptor compartment, the percentage of total drug partitioned to fat in a 
period of 24 h also increased from 58% to 88% for 5% w/v and 25%w/v fat respectively. The 
pore size of the membrane (MWCO 14000), was multiple times higher than the molecular 
weight of the model drug of the study (nifedipine-346.33 g/mol), and therefore allowed the 
process to be controlled by the affinity of drug for the receptor rather than the membrane.  
	
Figure 4.1. a. Nifedipine partition profiles to fat using setup I (dialysis membrane) and 
different fat percentages. Dashed lines denote the fittings to the first-order model. b. Bars 
denote the first-order partition rates of nifedipine partition to fat in setup I. 
4.3.2. Effect of hydrodynamics on drug rate of partition 
The evaluation of the effect of agitation in the drug partition setup II, using danazol as 
model drug for the study is presented in Figure 4.2. Using increased agitation rates (200 and 
250 rpm), almost 100% of the drug was diffused in the lipid layer during the first 30 min. Such 
high agitation would be difficult to use with model drugs which partition to fat faster or equally 
fast as danazol, as it would possibly provide inadequate discrimination among them; It can be 
seen that the profiles in the two high agitation rates were very similar (Figure 4.2) and that the 
maximum portioned percentage is reached in the first 15 min. When the dissolution apparatus 
paddle was rotated at 150 rpm, a significantly slower partition profile was acquired with 
approximately 60% of the drug partitioned from the FeSSGFsk to the lipid compartment in the 




to the lipid layer is regulated by two static diffusion layers developed in the two sides of the 
oil-“aqueous” interface with drug diffused through them from the aqueous to the lipid part [64]. 
Assuming that the width of the two layers remains constant though time, the parameters 
affecting the partition behaviour are: liquid viscosity, vessel dimensions, type of agitator and 
agitation speed, with the latter being the only parameter changing in the current study, 
justifying the differences observed in the rate of drug partition [64]. 
 
Figure 4.2. Danazol partition profiles to fat using the setup II under different agitation 
conditions. 
4.3.3. Effect of experimental setup on drug rate of partition 
The 25% w/v fat percentage was the percentage selected for the evaluation of the 
different proposed setups for the discrimination of partition rates to fat between drugs, even 
though the % w/v fat in the FDA high-fat standard breakfast [65] or in fed gastric media used 
in vitro such as milk, FeSSGF (Fed State Simulated Gastric Fluid) [46] and Ensure® Plus [66] 
is lower (≈ 1.8-14% w/v). The high fat percentage provided the highest partition rate compared 
to the other fat concentrations studied (Figure 4.1), making the discrimination among the 
various drugs easier, as observed from the results of the pilot study in setup I.  
The five model drugs which were evaluated in the pilot study, using all three setups 
(Figure 4.3), all provided significantly different partition rates to fat (p < 0.05, two-way 
ANOVA) (Figure 4.4). In all setups, nifedipine showed the highest affinity for the lipid phase, 
while the whole amount of propafenone hydrochloride practically remained in the “aqueous” 
part throughout the duration of the study, possibly because of the latter’s low distribution 




Using setup I, the whole process was extremely slow for the four of the five model 
compounds of the study, with the exception of nifedipine, with the amount of drug portioned 
to the fat being < 20% in the first 8 h (Figure 4.3 a). A plateau of the percentage partitioned 
could not be reached even after 48 h for all the model compounds, while phase separation of 
the milk-based medium was observed after 2 days. The decreased rate of the drugs’ partition 
process can be attributed to the increased viscosity of the receptor (fat), which slowed down 
drug diffusion [67]. The slow reaction rates (especially for compounds other than nifedipine) 
may be considered a disadvantage for the current setup. Moreover, using above setup, no 
significant differences were observed (p < 0.05) among the rates of drug partition for the five 
model drugs used (Figure 4.4). 
Setup II resulted in the highest partition rates for the five drugs initially studied (Figure 
4.3 b). Discrimination among the partition rate of the model compounds to fat was observed 
(Figure 4.4). The drugs’ partition rates to fat ranged between 0.39 h-1 (for ketoconazole) and 
13.58 h-1 (for nifedipine). The volumes used were similar to the fed gastric volume in vivo [68, 
69], but the hydrodynamics of this set up are different from the hydrodynamics observed in the 
fed stomach, as portrayed by the differences in Reynold’s number between the fed stomach 
and the vessels in dissolution studies. USP 2 dissolution apparatus, at speeds between 50 and 
100 rpm, results in Re numbers between 5000 and 10000 [70], while the equivalent values of 







Figure 4.3.	Drug partition profiles to fat using a. setup I, b. setup II and c. setup III. The marker 
colour is representative of drug lipophilicity (log D pH 5); white colour for the five more 
hydrophilic drugs, blue colour for the five moderately lipophilic and red for the five most 
lipophilic. Dashed lines denote the fittings to the first-order model.  
	
Figure 4.4. Calculated first-order rates of drug partition studies. Stars denote statistical 
differences among setups (two-way ANOVA, Bonferroni post-hoc test, * < 0.05, ** < 0.01, 
*** < 0.001). Different letters denote statistically significant differences (p < 0.05) among 
partition rates within the same setup. 
Since the stationary level of the fluid is multiple times higher in the USP 2 dissolution 




it would be reasonable to assume that Re values in the setup III model are probably closer to 
the values resulting from the hydrodynamics developped in the fed stomach in vivo. The 
partition rates to the fat for the drugs studied in setup III were: 0.22 (± 0.06), 0.20 (± 0.07), 
0.33 (± 0.07) and 1.64 (± 0.04) h-1 for ketoconazole, atorvastatin calcium, danazol and 
nifedipine respectively, while propafenone’s transfer to fat was insignificant (Figure 4.3). 
Adequate descrimination between the drugs’ partition profiles, lower medium volume and drug 
consumption and reproducible results were obtained with this experimental set up (Figure 4.4). 
Therefore, it was selected for the investigation of partition to fat for the rest of the drugs. Setup 
III partition data were successfully fitted to the first-order equation model, with R2 values of 
0.90-1.00 and residuals randomly scattered (Figure 4.3, Table 4.4). The highest partition rates 
were observed for nifedipine (1.64 h-1) and ibuprofen (1.17 h-1), followed by indomethacin 
(0.70 h-1) and griseofulvin (0.63 h-1) (Table 4.4). It can be observed that the four drugs 
partitioned to the lipid part the fastest are of intermediate lipophilicity (log D pH 5 = 1.86-3.67). 
Our hypothesis is that the increased partition rate of drugs of moderate lipophilicity is attributed 
to a combination of adequate drug affinity to fat and also high drug amount available in soluble 
form in the aqueous donor compartment. The above hypothesis is based on the principles which 
govern the incorporation of lipophilic drugs in previously formed liposomes, where despite 
drug increased drug lipophilicity, its rate of incorporation is controlled by the amount of drug 
available in the aqueous donor phase, with drug dissolution in it being the rate limiting step, 
often leading to very slow rates if not adequate [72]. The decreased drug solubility in the 
medium may explain the absence of drug partition to fat for MK-C4, the most lipophilic drug 
in the current study (Figure 4.3 c, Table 4.4). The rate of partition of the other four drugs of 
high lipophilicity (drug represented with red markers in partition profiles, Figure 4.3 c) ranged 
from approximately 0.2 to 0.4 h-1. The absence of partition (rate @ 0 h-1) for propafenone 
hydrochloride and furosemide (Figure 4.3, Table 4.4) was attributed to decreased drug 
lipophilicity (log D < 1) in the working pH. The percentage of the total drug partitioned to the 
fat in the duration of the study (8 h) was > 78% for 9 of the 15 model drugs (Figure 4.3 c, Table 
4.4). The lower C8h percentages were observed for the least lipophilic drugs of the study 
(propafenone hydrochloride, furosemide, phenytoin, indoprofen) can be attributed to their low 
affinity for fat.  Drug transfer process between these two immiscible layers is governed by three 
steps; firstly, its diffusion towards the interface, its de- and re-solvation at the interface and, 




partition of the drug with the highest log D, MK-C4, could possibly be explained by the drug’s 
limited ability to dissolve in the “aqueous”/organic interface.  
4.3.4. Effect of drug physicochemical properties on drug rate of partition 
The relationship between drug partition rate and drug lipophilicity (log D pH 5) follows 
a bell-shaped distribution around a maxium of log D = 3-4 (Figure 4.3 a). Several moderately 
lipophilic drugs (nifedipine, ibuprofen) of the study partitioned to fat faster than others of 
higher lipophilicity (felodipine, itraconazole) indicating that lipophilicity is not the sole 
parameter affecting the process.  
Partition data (rates) showed that molecules of molecular weight higher than 500 g/mol 
partition to the lipid layer of the gastric medium at a slow rate relatively to the other model 
drugs, despite their high lipophilicity (e.g. atorvastatin calcium, ketoconazole, itraconazole, 
MK-C4) (Figure 4.5). Ionisation is also a parameter affecting drug partition into the lipid phase; 
for ionisable compounds, their un-ionised form is more easily partitioned to the lipid 
membranes [74]. It can be assumed that having the model drug in its un-ionised from in the 
aqueous donor (FeSSGFsk) would facilitate its partition to the lipid layer. Out of the 15 model 
drugs of the study, the ones being ionised at a percentage higher than 95% in the working pH 
(according to their pKa values, Table 4.2) demonstrated the lowest partition rates, regardless 
of their lipophilicity (Tables 4.1, 4.4, Figure 4.5).  
 
Figure 4.5. Drug partition rates to fat in the absence of SLS or RN lipase vs log D pH 5, MW, 
and % of un-ionised drug in the working pH. 
The impact of aqueous solubility at the working pH, lipophilicity, MW and in vivo food 
effect on drug partition behaviour was evaluated using partial least squares regression analysis. 
The initial PLS analysis for the rate of partition (1 principal component) which included all 
model drugs of the study, gave a model of moderate predictive power (Q2 = 0.35) and fit (R2 = 
0.44) to the experimental values. Of the 15 drugs, nifedipine behaved as an outlier, with 




were 2.2-2.4 times higher than the critical value given by the software for the specific PLS 
model). Reconstructing the model without including nifedipine gave a model defined by 1 
principal component of Q2 and R2 values of 0.55 and 0.64 respectively, with predictive power 
acceptable according to the set threshold (Q2 > 0.5).  
Nifedipine’s affinity to fat can be seen in the lipid percentage-dependent solubility of 
the drug in fed gastric media in vitro, as derived from its values in fed gastric media of 3.5, 
1.75 and 0.875% w/v fat, (approximately 12x, 7x and 4x solubility for early, middle and late 
FeSSGF compared to aqueous buffers of the same pH and buffer capacity) [75] Fast partition 
to fat could be one of the reasons of nifedipine being a drug which exhibits positive food effect 
when administered with high fat meals [20] with more drug being solubilised by the lipid 
content of the gastric environment after meal administration. 
Molecular weight and negative food effect were defined as negative predictors for drug 
partition to fat (negative standardised coefficients and high (> 1) VIP factors) (Figure 4.6). 
Molecular weight > 500 is considered a limiting negative factor for drug permeation to lipid 
membranes through passive diffusion [76, 77]. As observed by the negative standardised 
coefficient of the log D pH 5*MW interaction, the effect of lipophilicity is different for drugs of 
different molecular weights. Looking at the drug partition rates (Table 4.4), it can be 
demonstrated that even extremely lipophilic drugs which do not have a reasonably low 
molecular weight, cross the lipid-aqueous interface barrier at a low rate (Figure 4.5). Positive 
log D pH 5*aq sol pH 5 interaction indicates that the effect of drug lipophilicity on the rate of 
partition to fat differs according to drug aqueous solubility. Positive food effect is generally 
associated with drug lipophilicity though lipid emulsification of lipophilic drugs in the stomach 
[78] and increase in drug luminal solubility [4]. The model build failed to demonstrate any 
correlation between positive food effect and drug-fat interaction, as the statistically non-
significant negative coefficient indicates (Figure 4.6). On the contrary, the model demonstrated 
a negative correlation (Figure 4.6) between partition rate to fat with negative food effect in 
vivo. Drugs of which pharmacokinetic behaviour does not change as a result of meal 
administration (no food effect), appear to partition to fat significantly faster than the rest 
(highest positive standardised coefficient), which is another indication that partition to fat alone 
cannot be used as a sole predictor for changes in drug pharmacokinetic parameters after 





Figure 4.6. Variable importance in the projection (VIP) plot with the variables classed 
according to their importance of the response for drug partition rate (in the absence of enzymes 
or emulsifiers) to fat (left). Standardised coefficients corresponding to the variables (and their 
interactions) studied (right). Green colour denotes coefficients of VIP values > 1. 
4.3.5. Effect of emulsification conditions on drug rate of partition 
When 1% w/v of SLS was added to the drug donor, in order to simulate an extreme 
version of the emulsification of the fat taking place in the fed gastric environment, enhancement 
of the drug partition rate to fat was observed for 9/15 drugs following first-order kinetics both 
the presence and absence of surfactant). The increase in the rate of the partition process ranged 
from 11.4% (indoprofen) to 335.8% (felodipine), while a slight decrease compared to the 
partition rate in the absence of SLS was reported for three of the drugs (4.7, 10.0 and 29.5% 






Figure 4.7. Drug partition profiles to fat using the setup III in the presence of a. SLS or b. lipase. The marker colour is representative of drug 
lipophilicity (log D pH 5); white colour for the five more hydrophilic drugs, blue colour for the five moderately lipophilic and red for the five most 




The presence of SLS in the drug donor compartment had a statistically significant effect 
on the drug partition rate, compared to the profiles in the absence of surfactant (p < 0.05). The 
difference in partition rates to fat is a result of two conflicting phenomena; i. higher drug 
affinity for the donor in the presence of surfactant and ii. bigger available receptor surface area 
for partition compared to the control experiment. The addition of SLS under constant stirring 
breaks the fat into smaller droplets which increases their surface area [79]. In the fed stomach, 
where fat emulsification takes place, as a result of the agitation conditions and the presence of 
lipid digestion products, the diameter of fat droplets is significantly reduced with a the emulsion 
surface area demonstrating a three-fold increase [2], which justifies the increase in partition 
rate in this study, after the addition of SLS. The presence of surfactants (emulsifiers, proteins 
or lipolysis products) in the lipid-water interface can reduce the surface tension increasing the 
diffusion kinetics by increasing the drug interfacial permeability, compared to the large surface 
tension of the non-emulsified lipid-water interface, where partition phenomena are slow [13]. 
The partition process is drug dependent with significant difference observed among 
different drugs (p < 0.05). Higher rates of partition to fat were observed for moderately 
lipophilic drugs (logD pH 5 values 3-4) and lower rates for drugs of extreme low or high 
lipophilicity (Figure 4.8). A bell-shaped curve is observed for the correlation of partition rate 
with log D pH 5 (Figure 4.8). 
	
Figure 4.8. Drug partition rates to fat a. in the presence of SLS or b. RN lipase, vs log D pH 5, 




The PLS analysis for the rate of partition (1 principal component) which included all 
model drugs of the study except for nifedipine, gave a model of good predictive power (Q2 = 
0.54) and fit (R2 = 0.60) to the experimental values. Absence of food effect and interactions of 
log D pH 5 with negative food effect and absence of food effect were defined as positive 
predictors for drug partition to fat (positive standardised coefficients and high (> 1) VIP 
factors) (Figure 4.9). Faster partition rates to fat both the presence and absence of the surfactant, 
in drugs of similar bioavailability in fasted and fed conditions, is another indication that drug 
rate partition to fat is not directly associated with in vivo positive food effect. On the contrary, 
a negative correlation with positive in vivo food effect can only be observed in the negative 
standardised coefficients in all three conditions (absence and presence of SLS or lipase) in the 
medium, which is only statistically significant in the presence of the ionic surfactant (Figure 
4.9). In the fed stomach, during gastric emptying, aqueous content is transferred to the 
duodenum significantly faster than fat, which is held by the angular notch [2]. Therefore, if the 
drug is adequately soluble in the watery portion of the gastric content, aided by the natural 
surfactants present (a role played by the surfactant in the developed in vitro partition setup), 
slower partition to the lipid layer would mean increased drug quantity available for transfer to 
the intestinal environment. A slower partition to fat therefore, provided that the drug is 
adequately soluble and does not precipitate in the aqueous part of the stomach, may be 
associated with positive food effect. Negative effect of drug aqueous solubility is attributed to 
the high affinity or highly soluble drugs for the “aqueous” compartment.  
  
Figure 4.9. Variable importance in the projection (VIP) plot with the variables classed 
according to their importance of the response for drug partition rate (in the presence of SLS) 
to fat (left). Standardised coefficients corresponding to the variables (and their interactions) 




In the presence of the lipase, the differences in partition behaviour among drugs of 
different lipophilicity were subtler (Figure 4.8) than in the presence of SLS. Rates of partition 
ranged from 0.207 h-1 (atorvastatin calcium) to 1.354 h-1 (nifedipine) (Table 4.4). Although 
partition rates for all drugs were equally high or slightly higher than in the absence of the 
enzyme (Table 4.4, Figures 4.3 c, 4.7 b), the differences were not statistically significant, which 
implied that the partition rates to fat were not affected by the presence of the lypolytic enzyme. 
MK-C1 and nifedipine demonstrated slightly slower rates than in the absence of lipase by 1.11 
and 1.21 times respectively. Similarly to the other two conditions (absence of 
surfactant/enzyme and presence of SLS), drugs of intermediate lipophilicity (blue markers in 
Figure 4.7 b) partition to fat faster and to a higher percentage than extremely lipophilic (red 
markers) and hydrophilic (white markers) drugs. Except for the three most hydrophilic drugs 
(propafenone hydrochloride, furosemide, indoprofen) and the extremely lipophilic MK-C4, a 
percentage higher than 80% of all drugs partitioned to the fat layer in a period of 8 hours except 
for itraconazole (Figure 4,7 b, Table 4.4). Interestingly, in the presence of lipase, itraconazole 
started diffusing to fat only after 3 hours and only 32.4% of the initial drug concentration 
partitioned to fat in 8 hours.   
 The bell-shaped distribution around log D values of 3-4, (Figure 4.8) indicates that in 
the presence of lipase, drug partition behaviour is not only governed by the drug lipophilicity, 
but it can be also controlled by other physicochemical parameters, an effect confirmed by the 
multivariate analysis of data. Looking at the partition rates against MW and un-ionised drug 
fraction plots (Figure 4.8), the rate of partition seems to be affected by MW and drug ionisation 
to a smaller extent.  
The PLS analysis for the rate of partition (1 principal component) which included all 
model drugs of the study except for nifedipine, gave a model of good predictive power (Q2 = 
0.53) and fit (R2 = 0.65) to the experimental values. Regression analysis demonstrated that the 
variables affecting drug partition behaviour remained almost unchanged in the presence or 
absence of gastric lipase. In both cases, the main variables with a negative effect on drug rate 
of partition were drug MW, logD pH 5*MW interaction and drug aqueous solubility (Figure 
4.10). The negative effect of the former is attributed to the negative correlation of molecular 
weight on drug diffusion coefficient [80]. The effect of logD pH 5 differs with MW, as negative 
log D*MW interaction indicates. Drug aqueous solubility is negatively correlated with drug 
partition rate due to higher affinity for water-soluble compounds for the donor compartment. 




correlation of drug partition rate with its lipophilicity is dependent on drug aqueous solubility. 
This positive coefficient, could be an indication that lipophilicity is a parameter favourably 
affecting the partition process, provided that the drug is adequately soluble in the donor 
compartment. 
 
Figure 4.10 Variable importance in the projection (VIP) plot with the variables classed 
according to their importance of the response for drug partition rate (in the presence of lipase) 
to fat (left). Standardised coefficients corresponding to the variables (and their interactions) 






Table 4.4. Drug first-order partition rates to fat in the absence and presence of SLS and lipase. 
Drug No emulsifier SLS Lipase 
 kpart (h-1) C8h kpart (h-1) C8h kpart (h-1) C8h 
propafenone hydrochloride 0 (0)* - 0 (0) - 0 (0)* - 
furosemide 0 (0)* - 0 (0) - 0 (0)* - 
indoprofen 0.429 (0.049) 19.4 (7.1) 0.477 (0.087) 25.0 (0.6) N/A 30.8 (1.9) 
ketoconazole 0.223 (0.037) 80.0 (1.2) Ν/Α 18.4 (1.8) 0.825 (0.002) 97.2 (0.8) 
griseofulvin 0.628 (0.059) 84.1 (3.6) 0.565 (0.045) 41.7 (2.4) 1.036 (0.058) 95.5 (3.3) 
phenytoin 0.364 (0.039) 59.7 (3.3) 0.592 (0.103) 48.0 (2.4) 0.617 (0.155) 90.1 (2.4) 
ibuprofen 1.165 (0.073) 95.8 (0.5) 1.111 (0.163) 86.0 (1.0) 1.228 (0.065) 95.9 (0.46) 
danazol 0.330 (0.043) 93.5 (0.9) 1.033 (0.213) 86.7 (1.8) 0.673 (0.036) 100 (0) 
nifedipine 1.642 (0.022) 100 (0) 3.748 (0.134) 82.3 (1.2) 1.354 (0.018) 100 (0) 
indomethacin 0.697 (0.095) 90.4 (1.7) 2.344 (0.760) 75.6 (3.2) 1.109 (0.240) 95.4 (2.1) 
atorvastatin calcium 0.198 (0.043) 41.6 (11.5) 1.122 (0.211) 23.2 (6.6) 0.207 (0.087) 82.1 (4.3) 
MK-C1 0.404 (0.036) 88.5 (14.1) 1.212 (0.513) 90.4 (1.0) 0.365 (0.044) 88.5 (1.7) 
felodipine 0.390 (0.005) 88.4 (0.8) 1.699 (0.406) 87.9 (2.7) 0.673 (0.036) 98.9 (2.0) 
itraconazole 0.335(0.020) 78.6 (2.8) 0.236 (0.044) 100 (0) N/A 32.4 (2.5) 
MK-C4 0 (0)* - 0.703 (0.066) 93.0 (2.8) 0 (0)* - 
*partition was insignificant; partition rates were considered zero 





Drug interaction with fat has been closely related to possible in vivo food effect after 
drug administration with meals of high lipid content. The current study strove to depict the 
drug partition process to the lipid phase of the fed stomach content by developing an in vitro 
discriminating method, able to assess the differences in rates of partition to fat, of drugs of 
different physicochemical characteristics. Using model drugs of a wide range of lipophilicity, 
ionisation and food effect, the in vitro setup developed provided discrimination of drug 
partition rates. The study revealed that percentage of fat, lipid and aqueous compartment 
volumes and agitation conditions affect the rate of partition significantly. Simulations using a 
biorelevant gastric medium as a surrogate of the fed stomach content, reflected the dependence 
of the rate of partition not only to drug lipophilicity but also to other physicochemical properties 
such as its MW and aqueous solubility. Furthermore, the current investigation revealed a 
correlation between drugs demonstrating negative food effect and slow partition to fat. 
However, it is important to highlight that food effect on bioavailability depends on a number 
of complex mechanisms and cannot be predicted solely based on the elucidation of lipid-drug 
interactions in the fed stomach. Moreover, conclusions on drug partition rates must not only be 
based on API properties but the effect of drug formulation must also be considered. The effect 
of food texture (homogeneous meal vs meal with solid food components) is an aspect which 
can potentially affect the time available for drug to partition to the indigested fat and needs to 
be investigated in future studies. After administration of solid meals, fluids can be emptied 
from the fundus to the pyloric antrum and into the intestine with rates as fast as in the fasted 
state, around the caloric gastric contents along the stomach walls [81]. Therefore, the time for 
which drug is available to partition to the undigested lipid layer before being emptied with the 
watery phase in the small intestine needs to be taken into consideration. Conclusions on drug 
partition rates must not only be based on API properties but the effect of drug formulation must 
also be considered. The effect of drug surface activity on partition behaviour was not assessed 
in this work and should be considered in future studies. Several drugs of different 
physicochemical properties have been found to be surface active. Cases of drugs such as 
phenothiazines, antihistamines and local anaesthetics have been extensively reported in the 
literature [82-84]. Surface activity of several compounds has been associated with their affinity 
to lipid membranes [85, 86]. Demonstrating a detergent-like behaviour, drugs have the ability 
to self-associate and bind, disrupt and solubilize lipid bilayers [87]. Further studies, 




intestinal environment combining the partition principles of developed setup with simulated 
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Chapter 5: Towards the development of a biorelevant medium to 
simulate the gastric conditions in the fed state  
Abstract 
Fed state simulated gastric fluid (FeSSGF), a milk-based medium, has been used in biorelevant 
dissolution studies, simulating the fed state gastric environment. For drug quantification in 
heterogeneous media like FeSSGF, a laborious extraction technique prior to drug analysis is 
usually required. The aim of the current study was to develop a novel biorelevant medium with 
similar physicochemical properties to FeSSGF which would require a less time/labour 
consuming extraction protocol. A stepwise development approach was followed, gradually 
incorporating casein and a mixture of lecithin/triolein in the medium, to simulate drug 
solubilisation in casein micelles and polar/non-polar lipids of milk respectively. pH, 
osmolality, buffer capacity and surface tension of the non-milk-based developed medium 
(FeSSGFnm) (were similar to the reference medium (FeSSGF). To evaluate its similarity to 
FeSSGF in terms of drug solubilisation and determine the effect of protein and lipid content in 
drug solubility, 24 h-solubility studies for 5 drugs of a range of lipophilicity (log P = 0.74-6.2) 
and ionisation (two weak bases, one weak acid and two neutral compounds) were performed 
in fed gastric biorelevant media of different lipid and protein content. FeSSGFnm overestimated 
drug solubility from 1.38 to 142 times, an effect more profound for the drugs of higher 
lipophilicity. Excluding the lipid part from the medium resulted in solubility values down to 
20 times lower than in FeSSGF and inversely proportional to drug lipophilicity (log P). The 
study demonstrated that changes in lipid and protein content in the medium can be critical for 
drug solubility. To develop a FeSSGF-like biorelevant medium, further insight is required in 
simulation of drug solubilisation in casein micelles and its distribution to lipid components in 
terms of control of the size and composition of the lipid-protein aggregates. 





It has been widely reported that meal intake can affect the pharmacokinetic parameters 
of multiple drugs through changes in the physiology of the gastrointestinal environment [1] 
and the physicochemical properties of its contents, such as the pH, osmolality, buffer capacity 
and surface tension [2-4]. Presence of bile salts [5], gastric secretions [2, 6] and fat content [7] 
are also parameters affecting drug bioavailability and can potentially be included to dissolution 
media designed to simulate the in vivo conditions in this state.  
To date, several media have been proposed for the simulation of the gastric environment 
after administration of a meal, taking the above aspects into consideration [8]. The development 
of these more “biorelevant” media in the last two decades is the response to the need of 
mimicking the GI tract conditions with dissolution media able to be used for predictive 
dissolution testing, which is not often feasible with conventional compendial buffers. The long-
term purpose of the development of such media is the correlation of in vivo drug release with 
the drugs’ in vivo pharmacokinetic profiles (IVIVC) towards the reduction of the number of 
bioequivalent studies needed prior to their approval [9]. 
For the simulation of fed gastric content most in vitro developed media use versions of 
the FDA high-fat standard breakfast as points of reference for medium development, as food 
effect is more likely to be observed after administration of meals of high fat content compared 
to meals of lower fat percentage [10]. In general, such meals would have a 800-1000 kcal 
energy content, with approximately 500-600, 250 and 150 kcal deriving from fat, carbohydrates 
and proteins respectively [10]. Milk was one of the first fed state environment-surrogates used 
in dissolution studies, due to its simplicity and stability, despite being of lower energy content 
compared to a standardised meal administered in food effect studies [11, 12]. Dissolution 
studies in milk demonstrated significant differences in drug dissolution profiles compared to 
simple buffers [13]. It has been shown though, that milk osmolality and buffer capacity values 
are significantly lower compared to the equivalent values of homogenised high (62% kcal 
derived from fat) and low fat (37% kcal derived from fat) standard breakfasts [14], which 
indicates its limited biorelevance. Further studies suggested the presence of combinations of 
HCl, pepsin and lipolysis enzymes in the medium in order to account for lipid and protein 
digestion processes taking place in vivo [15, 16]). Other approaches included the use of more 
biolelevant media of high lipid content (up to 30% w/v), such as lipid emulsions normally used 




One of the media lately suggested to simulate the gastric fed state environment is the 
Fed State Simulated Gastric Fluid (FeSSGF), developed by Jantratid et al. [19] approximately 
ten years ago. The three versions of the medium developed (FeSSGFearly, FeFFGFmiddle and 
FeSSGFlate) are composed of different ratios of full fat milk and acetate or phosphate buffers 
and simulate the gastric contents at the early (0-75 min), middle (75-165 min) and late (after 
165 min) phases of the postprandial stomach. FeSSGFmiddle has been extensively used as a 
compromise for the simulation of the sum of the conditions of the gastric environment after 
meal administration. It has been successfully implemented in biorelevant dissolution for tablets 
and capsules of poorly soluble drugs (cinarrizine, nelfinavir, BCS IV weak base) achieving 
good predictions of plasma profiles in the fed state in combination with biorelevant intestinal 
media and coupled with pharmacokinetic simulation modelling [20-22] and revealing the 
advantages in dissolution using biorelevant media compared to compendial ones.  
The challenge of the use of FeSSGF is its treatment, which due to its protein content 
requires  techniques like protein precipitation prior to drug analysis [8]. To address the above 
issue, alternative versions of the three FeSSGF (early, middle and late) “snapshot” media were 
developed (FeSSGFEm) [23, 24], containing the equivalent amount of fat, deriving from a lipid 
emulsion (Lipofundin® MCT 20%) which did not contain any proteins. Analysis with simple 
filtration was possible for the above medium, but its resemblance in terms of drug solubilisation 
with the original version of FeSSGF remains in question, as lipophilic drugs are solubilised in 
milk via two mechanisms; i. solubilisation in the lipid part of the emulsion and ii. solubilisation 
in the casein micelles [25-27]. Milk is a not a typical oil-in-water emulsion and lipids in milk 
are organised in assembles in the form of fat globules, each constituting of a triglyceride-, 
cholesterol- and retinol ester core, emulsified by a tri-layered amphiphilic membrane (milk fat 
globule membrane, MFGM) of phospholipids, proteins and cholesterol [28, 29]. The most 
abundant proteins in bovine milk are caseins (approximately 80% of total milk proteins). 
Casein micelles are clusters of protein (50-600 nm) formed in milk and consist of four different 
casein types, αs1, αs2, β, and κ in the form of phosphate and calcium ions, which are in 
equilibrium state with their equivalent monomers [30, 31].  
The aim of the current study was to develop a novel non-milk-based fed state gastric 
biorelevant dissolution medium with similar physicochemical properties and drug 
solubility/dissolution characteristics to FeSSGF, which would require an easier and less 
laborious sample treatment prior to analysis. Drug solubilisation in milky part of FeSSGF, in 




development of the new fed gastric medium. Triolein and egg lecithin were used to simulate 
the triglyceride core and membrane of the milk’s fat globule respectively, whereas sodium 
caseinate (NaCas) was added in order to reproduce drug solubilisation in milk’s casein 
micelles. A stepwise development of the final medium was performed with the goal to assess 
the role of the buffer, casein content and triolein in the medium’s physicochemical properties 
and solubilisation power in drugs of a broad range of lipophilicity (log P = 0.74-6.20) and 
ionisation (two weak bases, one weak acid, two neutral compounds). 
5.2. Materials and Methods 
5.2.1. Materials 
Furosemide (> 98% (HPLC), danazol (≥ 98%), itraconazole (≥ 98% (TLC)) and casein 
sodium salt from bovine milk (C8654) were all purchased from Sigma-Aldrich, UK. Nifedipine 
98-102% (on dried substance)), glycerol (≥ 99%), sodium chloride, sodium hydroxide, sodium 
acetate trihydrate, hydrochloric acid 37% and glacial acetic acid ≥ 99% were all purchased 
from Fisher Scientific, UK and griseofulvin (> 97%) from Alfa Aesar, UK. Egg-lecithin 
(Lipoid E PCS, Phosphatidylcholine from egg) was acquired from Lipoid GmbH 
(Ludwigshafen, Germany) and 3.6% fat UHT-treated milk was commercially purchased 
(Sainsbury’s, UK). All organic solvents used in protein precipitation and drug analysis were 
HPLC-grade and were purchased from VWR, UK. 
Cronus 13 mm regenerated cellulose (RC) syringe filters 0.45 µm were purchased from 
LabHut Ltd, UK and Whatman 13 mm glass microfiber syringe filters 2.7 µm (GF/D) from 
Fisher Scientific, UK.  
5.2.2. Instrumentation  
All samples were analysed in an HPLC system consisting of an Agilent 1200 series 
binary pump (G1312A), an Agilent 1200 series DAD detector (G1315D), an Agilent 1200 
series autosampler (G1329A), an Agilent 1200 series controller (G1316A) and a Chemstation 
software (Agilent Technologies, Santa Clara, United States).  
A pH meter Mettler-Toledo AG (model SevenCompact pH/Ion S220, Schwerzenbach, 
Switzerland), a centrifuge Hereus Biofuge Primo R (Thermo Scientific, Hanau, Germany) and 
a vortex mixer Rotamixer (HTZ, Cheshire, UK) were used. A ring tensiometer (Sigma 700 
Force tensiometer, Attension, UK) and an Advance Instruments Inc. microosmometer 




Organic solvent was evaporated using a rotary evaporator consisting of a Büchi Waterbath B-
480 and a Büchi Rotovapor R-114 (Büchi Labotechnik, Flawil, Switzerland) was used for 
organic solvent evaporation.  
5.2.3. Media composition  
FeSSGF was developed according to the in vivo physicochemical properties measured 
in the fed gastric environment during the middle phase of the gastric digestion and has been 
fully characterized in terms of its physicochemical properties [19]. Medium pH, buffer 
capacity, osmolality, surface tension and lipid/protein content were used as the basis of the new 
medium development [19] and were selected on the basis of physicochemical properties 
measured in vivo, from samples taken from the stomach antrum of healthy volunteers after 
administration of Ensure® Plus [2]. Both FeSSGF and FeSSGFnm were designed to simulate the 
“middle” postprandial conditions (75-165 min after food administration).	
5.2.3.1. Fed State Simulated Gastric Fluid (FeSSGF) composition  
Fed State Simulated Gastric Fluid (FeSSGF) was prepared according to Jantratid et al. 
[19] by mixing 3.6% fat milk and acetate buffer pH = 5 at a 1:1 volume ratio. For the 
preparation of 1 L of medium, 500 mL milk and 480 mL buffer were mixed under constant 
stirring using a magnetic stirrer. pH was adjusted to 5 with 1 N HCl and the volume was 
adjusted to 1 L with the buffer. Medium composition is described in Table 5.1. 
5.2.3.2. Non-milk-based Fed State Simulated Gastric Fluid (FeSSGFnm) composition  
Sodium caseinate concentration in the medium was set at 12.5 mg/mL, based on casein 
content experimental values reported for cow milk in the literature. Concentration of casein in 
milk lies between 24 and 32 mg/mL, depending on the bovine species, area and diet [32-34]; 
therefore a 25 mg/mL solution simulated the “milky” half part of the medium. Sodium 
caseinate was selected due to its high solubility (approximately 50 mg/mL in water according 
to the supplier) and on the basis that at pH 5, in the presence of 100 mM NaCl, sodium caseinate 
concentrations of 5% w/w  form aggregates of approximately 150 nm size [35], similar to the 
casein micelle size formed in milk. 
 Milk fat consists mainly of triglycerides (98% w/w) of more than 400 different 
saturated and unsaturated fatty acids, with tripalmitin (16:0) and triolein (18:1), being the most 
prevalent [36]. Milk fat globules have the form of a triglyceride core, surrounded by a tri-layer 




phospholipids and secondarily of cerebrosides and cholesterol [36]. Approximately 60-70% of 
the membrane’s polar lipids consists of glycerophospholipids and sphingolipids [(mainly 
phosphatidylcholine (PC) and phosphatidylethanolamine (PE) [37]], which represent 0.5%–
1% of milk fat [38]. 1.8% w/v total amount of fat was used for the simulation of the lipid part 
of FeSSGF, with 99% of the total fat comprising of triolein and 1% of lecithin (egg 
phosphatidylcholine, E-PC). 	
FeSSGFnm was developed in steps with its physiochemical characteristics measured in 
each level of development. The rationale behind this design was the assessment of the role of 
proteins and lipids in drug solubility. The composition of each level is described in Table 5.1.  
To prepare 1 L medium the following procedure was used: The same procedure was 
used for all development levels of the novel medium, with the gradual incorporation of ions 
(Level 1), various protein concentrations (Levels 2a-d), and lipid concentrations (Levels 3a-b) 
(Table 5.1). Level 3b represents the final developed medium (FeSSGFnm). 
Approximately 480 mL of “blank” buffer (Level 1) was prepared adding the amounts 
of NaCl, CH3COOH, CH3COONa and glycerine calculated for 1 L and transferred to a 1 L 
round-bottom flask. Glycerol was added as a co-solvent so as to achieve a more effective 
emulsification of the non-polar lipids added. Its concentration was selected on the basis of 
lipid/glycerol ratio of Lipofundin® MCT 20 (a lipid emulsion which has been used as a lipid 
part surrogate in biorelevant fed gastric media [23]). Appropriate volume of a lecithin solution 
(100 mg/mL in CH2Cl2) was added, with the organic solvent being evaporated under vacuum. 
The pressure was decreased from 650 mbar to 100 mbar in 2 min steps for a 15 minute-period 
and was subsequently maintained at 100 mbar for another 15 min (40 °C). Appropriate volume 
of a triolein solution (50 mg/mL in CH2Cl2) was added under the same conditions as lecithin. 
500 mL of a second solution of NaCas in water (25 mg/mL) was prepared by continuous 
stirring. The two solutions were combined by vigorous stirring for approximately 2 h and the 






















 Buffer Buffer + proteins 
Buffer + proteins + 
lipids 




17.12 17.12 17.12 17.12 17.12 17.12 17.12 17.12 
Acetic acid 
(mM) 
29.75 29.75 29.75 29.75 29.75 29.75 29.75 29.75 




- - 0.1 1 5 12.5 1 12.5 
Lecithin 
(mM) 
- - - - - - 0.46 0.46 
Glycerol 
(mg/mL) 
      2 2 
Triolein 
(mM) 
- - - - - - 40.25 40.25 
 pH adjusted to 5 (1 N HCl/NaOH) 
5.2.4. Physicochemical characterisation of the media 
All physicochemical properties’ measurements were performed in triplicate (n=3) with 
the results being expressed as mean ± SD. 
5.2.4.1. pH 
To maintain the pH required, the salt/acid ratio of selected buffer was calculated using 
the Henderson-Hasselbalch equation (Eq. 5.1) [39], 




where pKa is the acid dissociation constant and A-, HA are its unprotonated and 
protonated forms.  
A daily calibrated pH meter was used for the measurement of the pH of the media. The 
pH of milk is approximately 6.7, therefore pH was adjusted to using 1 N HCl in the final 
medium. Similarly, when NaCas solutions were used in the developed media, pH had to be 
adjusted. More concentrated NaCas solutions required higher HCl consumption for pH 
adjustment.  
5.2.4.2. Osmolality 
The desired osmolality values were achieved by adjustment with NaCl, according to 
Raoult’s law relation (Eq. 5.2) [40],  
ΔTf = i · Kf · m                                                                                                      (Eq. 5.2) 
where ΔTf represents the freezing-point depression, i the Van’t Hoff factor, accounting 
for the number of individual ions formed by a compound in solution, Kf the cryoscopic constant 
(-1.858 K · kg ·mol-1 and m the concentration in moles of solute per kilogram of solvent (mol 
kg-1) or molality of the solution. 
Osmolality was measured by determination of the freezing-point of the media using a 
micro-osmometer. 20 µl of medium was inserted into the instrument’s operating cradle and 
then lowered to the freezing chamber, supercooling the sample. Following a solenoid-induced 
pulse and subsequent sample freezing, the liberated heat of fusion was related by a 
microprocessor to the sample’s freezing point and osmolality is shown on a digital display [41].  
5.2.4.3. Buffer capacity 
The concentrations of the un-protonated/protonated forms were selected on the basis of 
having a solution of pH = 5 and of the desired buffer capacity. The Van Slyke equation (Eq. 
5.3) was used to calculate the buffer concentration needed [19], 
β = 2.3C %&	[$)*],(%&-[$)*],)/                                                                                                   (Eq. 
5.3) 
where β stands for buffer capacity, C for the total buffer molar concentration (un-
protonated and protonated form molar concentrations) and [H3O]+ for the hydronium ions’ 




Buffer capacity was measured with dropwise addition of 0.1 N HCl or 0.1 N NaOH, 
measuring the volume the volume required to change the pH by one unit, under constant 
stirring. It was calculated according to the following equation (Eq. 5.4) [42]; 
 0102$ = 	 	 44.&460	78	9&:;	&00;0<7	4&=:;	2$	4>&?@; ?78A&B6<C	D&4<78	7D	&460	78	9&:;&E;8&@;	E7B=A;	7D	:&A2B;	7E;8	8&?@;	6?E7BE;0 2$	4>&?@;2870=4;0                                                          (Eq. 5.4) 
5.2.4.4. Surface tension 
Surface tension (25 °C) was measured with the Du Nouy ring method [43]. 
Approximately 10 mL of sample was placed into a glass vessel (Ø 46mm). The ring was 
submerged below the interface of the sample and help horizontal. After immersion, the ring 
was pulled up through the surface. The force required to raise the ring from the liquid's 
meniscus was measured and related to the liquid's surface tension.  
5.2.5. Model drug selection and drug solubility studies  
Five compounds were selected on the basis of covering a range of lipophilicity values 
(log P = 0.74-6.2). The compounds studied were: furosemide (log P = 0.74, weak acid), 
griseofulvin (log P = 2.18, neutral), nifedipine (log P = 2.91, weak base), danazol (log P = 4.2, 
neutral) and itraconazole (log P = 6.2, weak base). 
24 h-solubility values in FeSSGF and Level 2d, 3a and 3b (FeSSGFnm) media were 
determined by using the shake-flask method in FeSSGF [22]. The solubility of the model 
compounds was determined by weighing excess amounts of the drug into 5 mL Eppendorf 
tubes, followed by the addition of 4 mL of medium. The samples were left to equilibrate in a 
shaking water bath at 37 °C for 24 hours. An aliquot of the medium was filtered through a 
GF/D filter of 2.7 µm pore size to remove undissolved drug particles. To remove the medium’s 
proteins, 1 mL of ΑCN was added to 0.5 mL of the filtered sample, vortexed at full speed (30 
sec). For FeSSGF, the vortexing step was followed by a centrifugation step (15 min, 8000 rpm, 
4 °C), while for the other media the sample was filtered immediately through a 0.45 µm RC 
filter, then diluted 2-200 times (according to the drug solubility) with medium and analysed 
using HPLC. Drug was quantified against calibration standards in the same media, with the 






5.2.6. Drug quantification and HPLC analysis 
Modified versions of chromatographic methods depicted in the literature were used for 
drug quantification and are presented in Table 5.2. 
Table 5.2. HPLC-UV analytical methods for drug quantification.	
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Filter adsorption studies were performed for all drugs. No significant drug adsorption 
was observed for both RC (0.45 µm) and GF/D (2.7 µm) filters. 
5.2.7. Statistical Analysis  
Differences in drug solubility in FeSSGF and Level 2d, 3a and 3b (FeSSGFnm) media 
were evaluated with a two-way Analysis of Variance (ANOVA) (Statgraphics v. XVI, 
StatPoint Technologies Inc., United States) with a post-hoc Bonferroni test. Effect of different 
protein content and lipid content on drug solubility was assessed with log P as a covariate in 




5.3. Results and Discussion 
5.3.1.  Physicochemical characterisation of FeSSGFnm levels  
The physicochemical properties of FeSSGFnm and intermediate development media 
(Table 5.1) are presented in Figure 5.1. 
The pH value of the medium was mainly controlled by the buffer selected for the 
medium preparation (acetate buffer pH = 5) and by the milk or casein solution used.  
The buffer capacity of the medium is particularly important as it can affect dissolution 
of ionisable drugs [49]. Buffer capacity was mainly governed by the “blank” buffer (Figure 
5.1). A slight increase was observed with increasing the sodium caseinate concentration due to 
the buffering potential of sodium caseinate solutions, the buffer capacity of which is 
concentration dependent (Level 2a-2d media) [50]. The buffer capacity of the final medium 
was 27.12 ± 0.31 mEq/L/ΔpH when the sample was titrated with 0.1 N HCl, which was similar 
to the value measured for FeSSGF (24.12 ± 0.90 mEq/L/ΔpH). Similar differences between 
the two media (FeSSGF and FeSSGFnm) were also observed with 0.1 N NaOH titration (Figure 
5.1).  
Osmolality can have an effect on dissolution rate of drugs due to the difference in 
osmotic pressure created between the inner part of the formulation and the dissolution medium. 
Big differences in osmotic pressure are associated with higher water penetration and swelling 
of the formulation [8]. The required osmolality values in FeSSGF and the new medium were 
adjusted with NaCl, according to the in vivo values measured in gastric juice [2]. The mean 
values of all media were between 390 and 406 mOsm/kg (Figure 5.1). 
Surface tension values measured at each level of the novel medium are presented in 
Figure 1. Surface tension of FeSSGF was measured at 52.3 ± 0.3 mN/m [19], a value 
significantly higher than the equivalent measured in vivo (30-31 mM/m) [2]. It was observed 
that casein was the main factor responsible for lowering surface tension. The surface tension 
of the “blank” acetate buffer was 57.8 ± 3 mN/m. The addition of sodium caseinate decreased 
the medium’s surface tension to values of approximately 45 mN/m (media Levels 2a-2d) 
(Figure 5.1). The surface tension of the medium was not affected by sodium caseinate 
concentration in the range studied (0.1 to 12.5 mg/mL), possibly because the working 
concentration range is close or above casein’s critical micelle concentration value (0.1 mg/mL) 




decrease by 1-2 mN/m, probably attributed to the small amount of lecithin added (0.46 mM) in 
Levels 3a, 3b of the medium, which acts as surfactant and has been shown to reduce surface 
tension in biorelevant media [52]. 
 
Figure 5.1. Physicochemical properties of FeSSGF and levels of FeSSGFnm*.  
* Surface tension in FeSSGF as reported in Jantratid et al. [19] 
5.3.2. Drug solubility in FeSSGFnm levels  
Drug solubility data in FeSSGF and in the last three levels of FeSSGFnm development 
are presented in Figure 5.2. A log P-dependent solubility was observed for all the media except 
for level 3b with solubility values ranging from approximately 1 to 8500 µg/mL for the 5 model 
drugs in the 4 media. 
It can be observed that despite the presence of fat in some of the medium levels which 
facilitates solubilisation of lipophilic compounds, high lipophilicity and solubility in the 
developed media were still negatively correlated in FeSSGF and level 2d and 3a media (Figure 
5.3). Level 2d and level 3a media differ in composition with level 2d medium being a solution 
of sodium caseinate, not containing any phospholipids or triolein (Table 5.1). Despite the 
lipids’ well-studied positive effect in enhancing the solubilisation of lipophilic drugs in vivo 
and in vitro [7], solubility values in these two media were similar (399.4 ± 168.8, 41.51 ±15.24, 
17.19 ± 3.87, 4.20 ± 0.41, 1.62 ± 0.37 µg/mL in level 2d and 294.3 ± 18.5, 17.36 ± 0.28, 11.09 




danazol and itraconazole respectively) (Figure 5.2). The similarity in drug solubility values, 
despite the absence of fat in level 2d medium, may be attributed to the increased amount of 
casein in medium 3a (12.5 mg/mL vs 1 mg/mL). The physiological role of casein micelles is 
the distribution of phosphate salts and amino acids to neonates [55], but due to their 
solubilisation capacity, casein micelles have also shown promising potential as basis of drug 
delivery systems for poorly soluble drugs like flutamide [56] and celecoxib [57]. Therefore, 
drugs may be forming complexes with the casein micelles increasing their solubility in the 
medium. The formation of hydrophobic interactions between non polar regions of drugs and 
casein micelles, excluding the possibility of electrostatic bond formation has been suggested 
with the use of fluorescence spectroscopy [53]. Another study for vitamin D, a lipophilic 
compound, has also reported binding via formation of hydrophobic interactions between the 
compound of interest and caseinates. [54].  
 
Figure 5.2. 24 h-solubility values in FeSSGF and levels of FeSSGFnm (n=3). 
	




FeSSGFnm overpredicted the solubility of all five drugs in FeSSGF, with only solubility 
values of furosemide and nifedipine being within reasonably comparable limits (1.38 and 4.94 
times higher respectively), while solubility of griseofulvin, danazol and itraconazole was 142.3, 
100.2 and 46.9 times higher than in FeSSGF (Figure 5.4). The observed differences in the 
solubility between FeSSGF and the developed medium could be attributed to the difficulty to 
replicate the sum of the micelles’ characteristics formed in FeSSGF. Changes in the size and 
nature of the surfactant’s polar head and length of its non-polar part as well the presence of 
other solutes in the solution, can alter the aggregation characteristics, shape and size of the 
micelles formed, affecting thus the medium’s solubilisation capacity [58]. Moreover, addition 
of lipid material has been found to produce aggregates and also increase the variability of 
micelles regarding their shape and size [52]. In the current study, only one type of polar (E-
PC) and non-polar (triolein) lipids was used in order to simulate the lipid membrane and the 
non-polar core of the medium’s fat globules, respectively. The triglyceride core of bovine milk 
fat globules comprises of triglycerides of more than 400 saturated and unsaturated fatty acids 
[36]. 29 of the fatty acids have been quantified, with each accounting for more than 1 mg/g of 
the total fatty acid content [59]. Similarly, substituting the milk fat globule membrane which 
keeps the lipids emulsified in milk with egg lecithin could be a reason for achieving higher 
drug solubility values than expected. Except for phosphatidylcholine which represents 
approximately 35% of the polar lipids of the fat globule, MFGM contains a significant amount 
of other types of phospholipids (phoshatidylserine, phosphatidylinositol and 
phoshatidylethanolamine) [37]. It also contains glycolipids, glycoproteins, total and partial 
glycerides, cholesterol and free fatty acids [37], which for reasons of simplicity were not taken 
into consideration in the final medium (FeSSGFnm) development.  
Medium 2d, which did not contain any lipids, underpredicted drug solubility (Figure 
5.4) with the developed medium/FeSSGF solubility ratios decreasing with drug lipophilicity. 
The ratio calculated for furosemide (log P = 0.74) was 0.65 and it progressively decreased, 
reaching a value of 0.05 in the case of the extremely lipophilic itraconazole (log P = 6.2) (Figure 
5.4). Low solubility results of drugs of high partition coefficient values (log P > 4) in the lipid-
free medium can be justified by their decreased aqueous solubility and their high affinity in 
oils [60]. Despite its similar lipid content to FeSSGF and level 3b medium (FeSSGFnm), 
medium 3a demonstrated similar solubility values to the lipid-free medium (Level 2d) (Figure 
5.4). A possible reason for the similar solubility values of the lipid-free and level 3a media 




lipid part in drug solubilisation. It is possible that the reduced amount of casein (1 mg/ mL), 
compared to FeSSGFnm (12.5 mg/ mL) was not adequate for the emulsification of triolein. 
Level 3a medium demonstrated phase separation within minutes, with the shaking conditions 
in solubility studies not sufficing for the homogeneous distribution. Increased casein content 
acted as a surfactant [61], helping the non-polar lipids suspend in the medium. Protein and lipid 
contents of medium were deemed to affect drug solubility significantly (p < 0.05), showing 
increased solubility values for the higher levels of lipid and protein contents. Drug lipophilicity 
(log P) did not affect significantly the above dependence on lipid and protein contents (p = 
0.34). 
 
Figure 5.4. Difference in solubility obtained in the FeSSGFnm levels compared to FeSSGF. 
5.4. Conclusion 
In the last years, several media simulating the fed state gastric environment have been 
developed and used in biorelevant solubility and dissolution studies, with the role of fat content 
as a factor affecting drug pharmacokinetics after meal administration being extensively studied 
and included in vitro medium development. In the current study, a medium of physicochemical 
properties similar to FeSSGFmiddle was developed, which required a simpler extraction 
treatment, saving time and effort in drug analysis. FeSSGFnm was developed on the basis of 
simulating drug solubilisation in the casein micelles and lipid components of milk contained in 
FeSSGFmiddle. In the range of drugs selected, the new medium overestimated drug solubility, 
an effect which was more profound for lipophilic drugs. Taking fat content into consideration 
for drugs of moderate to high lipophilicity though was essential, as pointed by the lower 
solubility values observed when triolein was not a part of the medium’s composition. Both 




focus on the deeper understanding of the drug solubilisation mechanism in milk’s casein 
micelles and lipid components. Additionally, simulation of the lipid core and tri-layer 
membrane of milk fat globules could be proven valuable towards the development of a medium 
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Conclusions and Future Directions 
Conclusions 
The assessment of food effect in drugs’ pharmacokinetic behaviour has been 
extensively investigated over the last decades. Both EU and US regulatory agencies have 
mandated food effect studies in orally administered medicinal products for both immediate and 
modified-release oral formulations. Versions of a high-fat standardised breakfast are proposed 
by both EMA and FDA as reference meals administered in in vivo studies. The need for 
simulation of the above meals in the gastric compartment, with the aim to predict food effect 
in vitro, was addressed by use/development of biorelevant media which would take into 
consideration the composition and physicochemical characteristics of the GI tract. The effect 
of meal fat content has been characterised as of great importance for the prediction of the drugs’ 
pharmacokinetic behaviour and has been included in the majority of the media developed so 
fat. Despite the successful employment of such media, two main drawbacks associated with 
the media’s heterogeneous nature arose; complexity in sample treatment prior to its analysis 
and lack of a unified analytical guideline deriving from the drug’s physiochemical 
characteristics and interaction with medium components. The current project gave an insight 
on three main aspects considered important towards the understanding of drug’s distribution in 
the simulated gastric media (i. API-medium interactions, ii. excipients-medium interactions 
and iii. API-fat interactions). The ultimate goal of the project was to use the above observations 
so as to set the basis for a predictive protocol which uses drug/formulation properties as input 
variables towards the selection of an optimal analytical protocol in fed state gastric biorelevant 
media. 
The current status and recent developments towards the in vitro simulation of the fed 
gastric environment were presented in Chapter 1. The effect of the gastric environment on the 
drug’s pharmacokinetic behaviour is governed by a number of parameters, the most important 
of which are: i. API’s physicochemical properties, ii. formulation characteristics, iii. type of 
meal administered, iv. presence of lipolysis enzymes and v. in vivo hydrodynamics. Most of 
the different media currently used were developed on the basis of reflecting the gastric 
properties (pH, osmolality, surface tension, buffer capacity) measured after administration of 
solid or liquid meals. So far, the use of lipolysis enzymes in gastric media has been relatively 
limited in such media. A number of techniques has been used as pre-treatment steps for the 




extraction. In all relevant studies cited in Chapter 1, a pattern was observed; lack of a commonly 
accepted medium for gastric fed-state studies in vitro, lack of reasonably simple and time 
efficient extraction techniques and a case-by-case approach for the analysis of each drug 
according only to its own unique physicochemical characteristics. 
Protein precipitation and solid phase extraction are two sample clean-up techniques 
very commonly used prior to analysis of compounds dissolved in biological fluids or 
heterogeneous media, for which simple filtration cannot provide a “clean” sample. Protein 
precipitation was proven to be effective for the extraction of compounds of a wide range of 
lipophilicity, with the selection of appropriate reagents added to an adequate amount (at least 
1:2 medium:reagent ratio). A dependence between the amount of drug recovered and specific 
physicochemical characteristics of the compounds of interest (lipophilicity, ionisation, aqueous 
solubility, protein affinity) was demonstrated, which can potentially serve as the basis of 
selection of a compound’s extraction conditions based on the above properties. The equivalent 
predictive potential of solid phase extraction is significantly more limited. Despite 
demonstrating an improved efficiency for compounds of intermediate lipophilicity, the most 
commonly used C18 cartridges could discriminate among drugs of different physicochemical 
characteristics. While HLB cartridges can potentially be used for drugs of higher lipophilicity 
which are adequately soluble in water (according to the PLS regression analysis), the higher 
cost/time consumed and the lower amount of drug recovered make solid phase extraction a 
secondary choice in biorelevant media analysis. 
Protein precipitation was proven effective for drugs of a wide range of lipophilicity and 
ionisation, but the presence of certain excipients can affect the extraction potential of the 
protocols for the analysis of active substances developed in Chapter 2. Certain excipients 
(magnesium stearate, HPMC) decreased the amount of the extracted drug when mixed with 
APIs, an effect more profound for lipophilic drugs (according to the MLR analysis). 
Interactions between excipients with the APIs and medium components affect the efficiency of 
the protocols developed; the above extent though was much smaller in solid dosage forms and 
was only observed in physical mixtures. Therefore, the effect of excipients in drug analysis 
should be mainly investigated in cases of drugs administered in the form of powders or liquid 
formulations.  
Drug partition behaviour to the lipid portion of the gastric content may be a potential 




meals. The work in Chapter 4 revealed a possible correlation between the drugs’ rate of 
partition to fat and lipophilicity, a behaviour which is also controlled by other physicochemical 
properties. Regression analysis showed that high drug lipophilicity, low molecular weight and 
high aqueous solubility in the working pH, are the parameters to which the rate of partition is 
most positively correlated. Moreover, drugs of negative food effect experience low partition 
rates, which is in accordance to the initial hypothesis associating the rate of drug distribution 
to fat with food effect observed in vivo. The inclusion of lipolytic enzymes in biorelevant 
concentrations does not appear to change the partition behaviour observed.  
The need for a gastric fed biorelevant medium, which would be easier to analyse than 
the lipid emulsions and milk-based media currently used, has not been yet fully met. In this 
thesis, a stepwise approach produced a medium with similar physicochemical properties to 
FeSSGF, requiring a simpler sample clean-up process. The effect of the casein micelles and 
lipid content on drug solubilisation were clearly observed, but the simulation of the emulsified 
fat globules in milk was revealed to be more complicated than expected as drug solubility 
values can change significantly by small alterations in content of polar/non-polar lipids and 
casein.  
Future Directions 
The research portrayed within the project was an attempt to build a predictive model on 
the analysis of a wide range of drugs in fed state media and assess relationships among drug 
physicochemical properties, analytical aspects and food effect observed in vivo. With the focus 
of the current study on gastric fed state, it is evident that for the development of a generally 
applicable predictive model, other parameters responsible for a potential food effect must be 
incorporated. The roles of gastric residence and in vivo hydrodynamics should also be 
considered in the final model in regard to the simulation of the gastric compartment, while 
variations of the type of meal administered may need to be considered too. The inclusion of an 
equivalent model built for the fasted intestinal state, to be used in conjunction with the gastric, 
may report different findings and lead to clearer correlations with food effect. 
In terms of drug analysis in fed gastric media, expansion of the work performed in the 
analysis of milk-based media should be expanded to lipid emulsions, which are widely used in 
in vitro simulation of the fed stomach content. The development of a roadmap for selection of 
optimum working conditions in both types of media can be a determinant step towards an 




With regards to excipients, the matrix-excipient interaction hypothesis stated in chapter 3 
should be confirmed experimentally, using a microscopy technique. Moreover, evaluation of 
the effect of the manufacturing process (in terms on how the API and excipients are mixed) on 
the extraction process could be beneficial; evaluation of each excipient type separately or in 
combination with others can give more definitive answers on drug-excipient interactions in 
both solid and liquid oral dosage forms.  
To evaluate the full extent of the effect of drug-fat interactions to possible food effect, 
research is still required for the full understanding of both partition and release processes to 
and from gastric content’s lipid portion if the fed state. As mentioned in Chapter 4, food effect 
on bioavailability depends on a number of complex mechanisms and therefore, light must be 
shed to several aspects of drug-lipid interactions in order to develop a food effect-predictive 
assay. It is possible that the different types of dietary fats and oils demonstrate a different 
behaviour in regard to their interaction with fat. Therefore, future work in developing in vitro 
setups with lipids more representative to the high-fat standardised meals administered in fed 
state BE studies may be able to elucidate lipid induced-food effect mechanisms due to better 
biorelevance. Further studies should also investigate parameters such as the role of the meal 
composition, compound’s surface activity and excipients present in the formulations affecting 
the rate of drug partition to the lipid portion of the gastric content. Future work should 
investigate the rate of drug “release” from the lipid part of the gastric fed content to the 
intestinal environment. A drug release setup using FeSSIF (Fed State Simulated Intestinal 
Fluid), a biorelevant medium representative of the fed intestinal environment, as dissolution 
medium is proposed as a first step for future consideration. The combination of the above 
partition and release processes in a single experimental setup and the assessment of their 
cumulative effect can potentially lead to a better understanding of the mechanisms of fat-
induced food effect in the GI tract. Knowledge of these interactions must be incorporated to 
the development of new media, more biorelevant and preferably simple in analysis. The 
development of fed gastric media requiring simpler sample clean-up prior to drug analysis, as 
opposed to the existing milk-based ones or lipid emulsions, will help pharmaceutical scientists 
overcome analytical issues related to sample treatment and save significant time. As 
demonstrated in the last chapter, the biorelevant simulation of the fat globules is a prerequisite 
for the design of the desired alternative medium similar to FeSSGF (or in the development of 




of which has only relatively recently been taken into consideration in biorelevant dissolution, 
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